Substituted pyrazole compounds and methods of treating hyperproliferative diseases using same

By providing compounds with structural formula (Ia)-(Ie), inhibiting their cell cycle and inducing apoptosis against cancer cells with KRAS gene mutations, the problem of insufficient effectiveness of existing treatment methods on these cancers is solved, and the problem of achieving the problem of poor results of existing treatments is achieved. Effective treatment of specific cancers.

CN118930533APending Publication Date: 2024-11-12BANTAM PHARMACEUTICAL LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410345199.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2016-11-30
Filing Date
2017-11-29
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

Existing cancer treatment methods are not effective for certain types of cancer, such as cancers with KRAS gene mutations, and the metabolic characteristics of cancer cells are different from those of normal cells, making it difficult for traditional therapies to effectively inhibit the growth and division of cancer cells.

Method used

A novel compound with the structural formula (Ia)-(Ie) is provided for the preparation of agents for the treatment of cancer by inhibiting the cell cycle of cancer cells, inducing apoptosis of cancer cells or inhibiting glutathione synthesis, Cancer cells with KRAS gene mutations are targeted for treatment.

Benefits of technology

This compound can effectively inhibit the growth and division of cancer cells, especially for cancer cells with KRAS gene mutations, providing a new therapeutic strategy and improving the therapeutic effect of specific types of cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118930533A_ABST
    Figure CN118930533A_ABST
Patent Text Reader

Abstract

Disclosed are compounds useful, for example, in methods of treating hyperproliferative disorders such as cancer, methods of arresting cell cycle in cancer cells, methods of inhibiting glutathione synthesis in cancer cells, as well as related compounds for use and their use in medicaments. In certain embodiments, the methods, uses, and compounds are provided with reference to compounds having the structural formulae (Ia), (Ib), (Ic), (Id), and (Ie) wherein R1, L1, L2, Q, L3, R3, L4, R4, L5, and R5 are as described herein. In certain embodiments, the compounds disclosed herein are particularly effective against cancers having a mutant KRAS gene. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of a Chinese invention patent application (filing date: November 29, 2017; application number: 201780084999.4 (International application number: PCT / US2017 / 063774); invention name: Substituted pyrazole compounds and methods for treating hyperproliferative diseases using the same).

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims priority to U.S. Provisional Patent Application No. 62 / 428,271, filed on November 30, 2016, which is hereby incorporated by reference in its entirety. Technical Field

[0004] The present disclosure relates to the field of compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions. More particularly, the present disclosure relates to methods of using certain compounds to treat hyperproliferative disorders such as cancer. Background Art

[0005] Cancer is an uncontrolled cell proliferation, a multifactorial disease characterized by the formation, growth, and in some cases, metastasis of tumors. In the United States, more than 1.5 million people will be diagnosed with cancer this year, and more than 500,000 people will die from cancer. Overall, it is estimated that at least one in three people will develop some form of cancer in their lifetime. There are more than 200 different histopathological types of cancer, and in the United States, breast cancer, lung cancer, colorectal cancer, and prostate cancer account for more than half of all new cases. Current cancer therapies vary depending on the location and stage of the cancer, but generally include a combination of surgery, systemic therapy, radiation therapy, and chemotherapy. Although considerable effort has been put into developing anti-cancer strategies, many of them remain ineffective for specific cancers.

[0006] The uncontrolled cell proliferation that characterizes cancer involves not only a dysregulated control of cell proliferation but also a corresponding adjustment of energy metabolism to promote cell growth and division. Cellular metabolic reprogramming is emerging as a key molecular hallmark of cancer cells. Under aerobic conditions, normal cells process glucose, first converting it to pyruvate via glycolysis in the cytosol and then to carbon dioxide in the mitochondria. Under anaerobic conditions, glycolysis is favored, and relatively little pyruvate is allocated to oxygen-consuming mitochondria. When growth factors and nutrients are abundant, oncogenic signaling pathways direct enhanced metabolism, leading to increased synthesis of macromolecules such as lipids, proteins, and nucleic acids. The net effect is support for cell growth and proliferation. However, during tumor formation, the harsh, hypoxic, and nutrient-deficient environment presents challenges cells and their ability to maintain metabolic homeostasis. Cancer cells can reprogram their glucose metabolism by restricting the majority of their energy metabolism to glycolysis, thereby reprogramming their energy production, a reprogramming that early biochemists considered primitive and inefficient. Despite these early beliefs, the metabolic signature of cancer cells is not a passive response to damaged mitochondria but rather the result of oncogene-directed metabolic reprogramming required to support anabolic growth. Oncogene mutations that allow for increased and more efficient utilization of scarce nutrients are unique targets for cancer therapy. Summary of the Invention

[0007] In one aspect, the present disclosure provides compounds having any one of structural formulas (Ia)-(Ie):

[0008]

[0009]

[0010] The compound is optionally in the form of a pharmaceutically acceptable salt or N-oxide, and / or solvate or hydrate, wherein

[0011] L 1 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6-and-NR 6 S(O) 1-2 -;

[0012] R 1 Selected from the group consisting of:

[0013] hydrogen,

[0014] C1-C8 alkyl, C1-C8 alkenyl and C1-C8 alkynyl, each of which is unsubstituted or fluorinated,

[0015] Cycloalkyl and heterocycloalkyl, each of which is optionally substituted by 1-2 R 1E Replace, and

[0016] Phenyl and monocyclic heteroaryl, each of which is optionally substituted by 1-5 R 1E replace,

[0017] in

[0018] Each R 1E Independently selected from oxo; optionally substituted C1-C4 alkyl; C1-C4 fluoroalkyl; halogen; -CN; SF5; -N3; ​​-C(O)R 1F ;-SR 1F ;-S(O) 1-2 R 1F ;-OR 1F ;-(OCH2CH2O) n -R 1G , wherein n is 1-4; -N(R 1G )C(O)CH2-O-(CH2CH2O) n R 1G , wherein n is 0-3; -C(O)NR 1G (CH2CH2O) n R 1G ;-NR 1G R 1F ; and -C(O)R 1F ;

[0019] Each R 1F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[0020] Each R 1G Independently selected from H and C1-C3 alkyl;

[0021] L 2 selected from the group consisting of: a chemical bond, -CH2-, -CH(CH3)-, or -CH2CH2-;

[0022] Q is selected from the group consisting of: H, -CH2OH, -C(O)OH, -C(O)OR2A 、-C(O)NR 2B R 2A 、-C(O)NR 2B S(O)2R 2A 、-C(O)NR 2B S(O)2NR 2B R 2A 、-C(O)R 2A , -S(O)2OH, -P(O)(OH)2, -C(OH)(CF3)2, S(O)2R 2A 、-N(R 2B )S(O)2R 2A 、-S(O)2NR 2B R 2A , -C(O)NHOH, -C(O)NH-O(C1-C3 alkyl) and -CO(NH)CN, wherein

[0023] Each R 2A are independently selected from H and C1-C3 alkyl, and

[0024] Each R 2B Independently selected from H and C1-C3 alkyl;

[0025] L 3 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2-, -CH(CH3)(OH)- or -CH(OH)-;

[0026] R 3 is aryl or heteroaryl, each of which (i) is optionally substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace,

[0027] in

[0028] Each L 3C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O-, or -NR 3G -;

[0029] Each R 3D independently selected from oxo optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and -NR 3G S(O) 1-2 R 3F ;

[0030] Each R 3E independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F 、-NR 3G S(O) 1-2 R 3F ;

[0031] Each R 3F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[0032] Each R 3G Independently selected from H and C1-C3 alkyl, C1-C3 fluoroalkyl;

[0033] L 4 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6 -and-NR 6 S(O) 1-2 -;

[0034] R 4 selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkenyl, and optionally substituted C1-C8 alkynyl;

[0035] L 5 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2CH2-, -CH=CH-, -C≡C-, -CH2-, -CH(CH3)(OH)-, or -CH(OH)-; and

[0036] R 5 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each of which (i) is optionally substituted with a single substituent selected from: -L 5C -(optionally replaced by 1-5 R 5D substituted phenyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) and -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic cycloalkyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 5E replace,

[0037] in

[0038] Each L 5C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O-, or -NR 3G -;

[0039] Each R 5D independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and -NR 3G S(O) 1-2 R 3F ;

[0040] Each R 5E independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, -SF5, -N3, -C(O)R 5F 、-SR 5F 、-S(O) 1-2 R 5F 、-OR 5F 、-NR 5G R 5F 、-C(O)R 5F 、-C(O)NR 5G R 5F 、-NR 5G C(O)R 5F 、-C(S)NR 5G R 5F 、-NR 1G C(S)R 5F 、-C(O)OR 5F 、-OC(O)R 5F 、-C(O)SR 5F 、-SC(O)R 5F 、-C(S)OR 5F 、-OC(S)R 5F 、-C(S)SR 5F 、-SC(S)R 5F 、-S(O) 1-2 OR 5F 、-OS(O) 1-2 R 5F 、-S(O) 1-2 NR 5G R 5F and -NR 5G S(O) 1-2 R 5F ;

[0041] Each R 5F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[0042] Each R 5G Independently selected from H and C1-C3 alkyl;

[0043] in

[0044] Each R 6 Selected from the group consisting of: hydrogen, C1-C3 alkyl and -C(O)(C1-C3 alkyl);

[0045] Each optionally substituted alkyl, alkenyl, and alkynyl group is unsubstituted, fluorinated, or substituted with one or two hydroxy groups;

[0046] Each cycloalkyl group has 3-10 ring carbons and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each fused ring having 3-8 ring members;

[0047] each heterocycloalkyl group has 3-10 ring members and 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each having 3-8 ring members;

[0048] each aryl is phenyl or naphthyl, and optionally comprises one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members;

[0049] Each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, and optionally contains one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members.

[0050] In some such embodiments, each optionally substituted alkyl, alkylene, alkenyl, alkenylene, alkynyl, and alkynylene is unsubstituted or fluorinated. For example, in some such embodiments, each optionally substituted alkyl, alkylene, alkenyl, alkenylene, alkynyl, and alkynylene is unsubstituted.

[0051] In another aspect, the present disclosure provides pharmaceutical compositions comprising a compound as described herein.

[0052] In another aspect, the present disclosure provides a method for treating a hyperproliferative disorder, such as cancer, in a subject in need thereof, comprising administering to the subject an effective amount of a compound as described herein.

[0053] In another aspect, the present disclosure provides a compound as described herein for use in treating a hyperproliferative disorder, such as cancer.

[0054] In another aspect, the disclosure provides the use of a compound as described herein for the preparation of a medicament for the treatment of a hyperproliferative disorder such as cancer.

[0055] In certain embodiments of the various aspects of the present disclosure, the hyperproliferative disorder is a hematopoietic cancer. In certain alternative embodiments of the present disclosure, the hyperproliferative disorder is a solid tumor.

[0056] In certain embodiments of the various aspects of the present disclosure, the hyperproliferative disorder is a cancer (eg, a solid tumor such as colorectal cancer, lung cancer, or pancreatic cancer) having a mutant KRAS gene, eg, a heterozygous mutant KRAS gene.

[0057] Another aspect of the present disclosure provides a method for inhibiting cell cycle progression in cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein. In certain such embodiments, the cancer cells are hematopoietic cancer cells. In other such embodiments, the cancer cells are cancer cells of solid tumors (e.g., pancreatic cancer, lung cancer, or colorectal cancer). In certain such embodiments, the cancer cells have a heterozygous mutant KRAS gene. Cell cycle progression can be inhibited, for example, in the G0 / G1 phase.

[0058] Another aspect of the present disclosure provides a method for inducing apoptosis in cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein. In certain such embodiments, the cancer cells are hematopoietic cancer cells.

[0059] Another aspect of the present disclosure provides a method for inducing a cytotoxic effect on cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein. In certain such embodiments, the cancer cells are hematopoietic cancer cells. In other such embodiments, the cancer cells are cancer cells of a solid tumor (e.g., pancreatic cancer, lung cancer, or colorectal cancer). In certain such embodiments, the cancer cells have a heterozygous mutant KRAS gene.

[0060] Another aspect of the present disclosure provides a method for inhibiting glutathione synthesis in cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein. In certain such embodiments, the cancer cells are hematopoietic cancer cells. In other such embodiments, the cancer cells are cancer cells of a solid tumor (e.g., pancreatic cancer, lung cancer, or colorectal cancer). In certain such embodiments, the cancer cells have a heterozygous mutant KRAS gene.

[0061] In certain embodiments, the compound used in the methods, compounds, and uses described herein is a compound having any one of the following structural formulas (I):

[0062] Other aspects and embodiments of the disclosure will be apparent from the detailed description provided herein.

[0063] All publications mentioned herein are hereby incorporated by reference in their entirety to the extent not inconsistent with the specific disclosure provided herein. BRIEF DESCRIPTION OF THE DRAWINGS

[0064] Figure 1 is a bar graph showing the responsiveness of cell lines to treatment with broadly disclosed test compounds as a function of the KRAS genotype and KRAS zygosity of the cell lines.

[0065] Figure 2 is a graph showing glutathione levels in three cell lines (BJAB, HCT116, and NHFL) after treatment with test compounds. BJAB is represented by the dark grey (bottom) line, HCT116 is represented by the black (middle) line, and NHFL is represented by the light grey (top) line.

[0066] Figure 3 is a pair of bar graphs demonstrating decreased glutathione levels in HCT-116 cells following treatment with a test compound (top graph) and menadione (bottom graph), both treatments being performed in the presence and absence of N-acetylcysteine ​​(NAC).

[0067] Figure 4A is a set of graphs presenting flow cytometry data collected from a representative cell cycle experiment performed in HCT116 cells following test compound treatment. Figure 4B It is expressed as the percentage of cells in each stage of the cell cycle Figure 4A A bar chart of the data in . DETAILED DESCRIPTION

[0068] In one aspect, the present disclosure provides methods, compounds, and uses for treating various hyperproliferative disorders using the compounds described herein. The compounds can be generally defined with respect to any one or various subgeneric compounds of formula (Ia), (Ib), (Ic), and (Id) above, wherein R 1 , L 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5Optionally independently selected from Groups (Ia) et seq., (Ia) et seq., (2a) et seq., (3a) et seq., (4a) et seq., (5a) et seq., (6a) et seq., (7a) et seq., (8a) et seq., (9a) et seq., and (10a) et seq. as defined below (e.g., wherein the compound has a structural formula as defined in any combination of the following embodiments):

[0069] In certain embodiments of the compounds as otherwise described herein, the compound has one of the following structural formulas:

[0070] (Ia);

[0071] (Ib);

[0072] (Ic);

[0073] (Id);

[0074] (Ie).

[0075] In certain embodiments of the compounds as otherwise described herein, R 1 Selected from one of the following groups (1a)-(1k):

[0076] (1a)R 1 Selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl and cycloalkyl, which are optionally substituted with 1-5 R 1E replace;

[0077] (1b)R 1 It is hydrogen;

[0078] (1c)R 1 is an optionally substituted C1-C8 alkyl group;

[0079] (1d)R 1 is an unsubstituted C1-C8 alkyl group or a fluorinated C1-C8 alkyl group, such as propyl or butyl;

[0080] (1e)R 1 is an unsubstituted cycloalkyl group;

[0081] (1f)R 1 is an optionally substituted C1-C8 alkenyl group;

[0082] (1g)R 1 is optionally replaced by 1-5 R E substituted phenyl;

[0083] (1h)R 1 is propyl, butyl or butenyl;

[0084] (1i)R 1 It is a trifluoromethyl-substituted phenyl group, a methoxy-substituted phenyl group or a fluorine-substituted phenyl group.

[0085] (1j)R1 is a phenyl group substituted with: -(OCH2CH2O) n -R 1G , wherein n is 1-4; -N(R 1G )C(O)CH2-O-(CH2CH2O) n R 1G , wherein n is 0-3; or -C(O)NR 1G (CH2CH2O) n R 1G ;(1k)R 1 It is hydroxymethyl, methoxymethyl, hydroxyethyl or methoxyethyl.

[0086] In certain such embodiments, R 1 Each optionally substituted alkyl group (including R 1E These groups) are unsubstituted or fluorinated. For example, in certain such embodiments, R 1 Each optionally substituted alkyl, alkenyl and alkynyl group (including R 1E of these groups) are unsubstituted.

[0087] In certain embodiments of the compounds as otherwise described herein, L 1 One selected from the following groups (2a)-(2e) (2a)L 1 is a chemical bond, -S-, -S(O)-, or -S(O)2-;

[0088] (2b)L 1 Selected from chemical bonds, -CH2-, -CH(CH3)-, -CH2CH2-, -C(O)-, -S-, -S(O) 1-2 -, -O-, and -NR 6 -;

[0089] (2c)L 1 It is -O- or -S-.

[0090] (2d)L 1 is a chemical bond (for example, when R 1 (1d), (1f), (1g), (1i), (1j) or (1k) above);

[0091] (2e)L 1 Yes-NR 6 -.

[0092] In certain embodiments of the compounds as otherwise described herein, L 2 Selected from one of the following groups (3a)-(3c) (3a)L 2 is -CH2-, -CH(CH3)- or -CH2CH2-;

[0093] (3b)L 2 It is a chemical bond;

[0094] (3c)L2 It is a chemical bond or -CH2-.

[0095] In certain embodiments of the compounds as otherwise described herein, Q is selected from one of the following groups (4a)-(4d): (4a) Q is selected from the group consisting of: -CH2OH, -C(O)OH, -C(O)OR 2A 、-C(O)NR 2B R 2A 、-C(O)NR 2B S(O)2R 2A 、-C(O)NR 2B S(O)2NR 2B R 2A 、-C(O)R 2A , -S(O)2OH, -P(O)(OH)2, -C(OH)(CF3)2, S(O)2R 2A 、-N(R 2B )S(O)2R 2A 、-S(O)2NR 2B R 2A , -C(O)NH-O(C1-C3 alkyl), -C(O)NHOH, and -CO(NH)CN;

[0096] (4b) Q is selected from the group consisting of: -CH2OH, -C(O)OH, -C(O)OR 2A 、-C(O)NR 2B R 2A 、-C(O)NR 2B S(O)2R 2A 、-C(O)NR 2B S(O)2NR 2B R 2A 、-C(O)R 2A , -S(O)2OH, -P(O)(OH)2.

[0097] (4c) Q is -CH2OH, -C(O)OH or -C(O)OR 2A ;

[0098] (4d) Q is -COOH.

[0099] In certain embodiments of the compounds as otherwise described herein, L 3 One selected from the following groups (5a)-(5c) (5a)L 3 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2-, -CH(CH3)(OH)- or -CH(OH)-;

[0100] (5b)L 3 It is a chemical bond;

[0101] (5c)L 3 It is a chemical bond, -CH2-, -CH(CH3)(OH)- or -CH(OH)-.

[0102] In certain embodiments of the compounds as otherwise described herein, R 3 One selected from the following groups (6a)-(6k)

[0103] (6a)R 3 is aryl (eg, phenyl) or heteroaryl (eg, monocyclic heteroaryl), each of which (i) is optionally substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace;

[0104] (6b)R 3 is optionally replaced by 1-5 R 3E substituted aryl (e.g., phenyl, benzodioxole, or dihydro-1H-isoquinoline);

[0105] (6c)R 3 is aryl (eg, phenyl, benzodioxole, or dihydro-1H-isoquinoline), which (i) is substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace;

[0106] (6d)R 3 is aryl (eg, phenyl, benzodioxole, or dihydro-1H-isoquinoline), which (i) is substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D Substituted phenyl), -L 3C -(optionally replaced by 1-5 R 3D substituted monocyclic heteroaryl), -L3C -(optionally replaced by 1-5 R 3D substituted monocyclic cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace;

[0107] (6e)R 3 As defined in (6a)-(6d), wherein the aryl group is not separated by any R 3E replace;

[0108] (6f)R 3 is optionally replaced by 1-5 R 3E substituted heteroaryl (e.g., isothiazole, pyridone, thiadiazole, pyrazine, pyrazolopyrimidine, pyrazolopyridine, imidazole, benzofuran, indole, imidazopyridine, pyridine, pyrazole, isoxazole, triazolopyridine, benzimidazole, thiophene, benzothiophene, furan, or pyrimidine);

[0109] (6g)R 3 is a heteroaryl group (e.g., an isothiazole, a pyridone, a thiadiazole, a pyrazine, a pyrazolopyrimidine, a pyrazolopyridine, an imidazole, a benzofuran, an indole, an imidazopyridine, a pyridine, a pyrazole, an isoxazole, a triazolopyridine, a benzimidazole, a thiophene, a benzothiophene, a furan, or a pyrimidine), which (i) is substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace;

[0110] (6h)R 3 is a heteroaryl group (e.g., an isothiazole, a pyridone, a thiadiazole, a pyrazine, a pyrazolopyrimidine, a pyrazolopyridine, an imidazole, a benzofuran, an indole, an imidazopyridine, a pyridine, a pyrazole, an isoxazole, a triazolopyridine, a benzimidazole, a thiophene, a benzothiophene, a furan, or a pyrimidine), which (i) is substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted phenyl), -L 3C -(optionally replaced by 1-5 R 3D substituted monocyclic heteroaryl), -L 3C-(optionally replaced by 1-5 R 3D substituted monocyclic cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace;

[0111] (6i)R 3 As defined in (6f)-(6h), wherein the heteroaryl group is not separated by any R 3E replace;

[0112] (6j)R 3 selected from the group consisting of phenyl, benzodioxolyl, dihydro-1H-isoquinolinyl, imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, thiazolyl, pyridyl and pyrazinyl, pyridonyl, thiadiazolyl, pyrazolopyrimidinyl, pyrazolopyridinyl, benzofuranyl, indolyl, imidazopyridinyl, pyrazolyl, triazolopyridinyl, benzimidazolyl, benzimidazolyl, thienyl, benzothienyl, furanyl and pyrimidinyl, each of which (i) is optionally substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace.

[0113] (6k)R 3 is selected from the group consisting of phenyl and monocyclic heteroaryl (e.g. pyridyl, pyrazolyl), optionally substituted by 1-5 R 3E replace.

[0114] In certain such embodiments, R 3 Each optionally substituted alkyl, alkenyl and alkynyl group (including R 3D and R 3E These groups) are unsubstituted or fluorinated. For example, in certain such embodiments, R 3 Each optionally substituted alkyl, alkenyl and alkynyl group (including R 3D and R 3E In certain embodiments, L 3C is methylene or -O-. In certain such embodiments, the optional number of R3E substituents is 1-3 or 1-2.

[0115] In certain embodiments of the compounds as otherwise described herein, R 4 Selected from one of the following groups (7a) (7d)

[0116] (7a)R 4 It is hydrogen;

[0117] (7b)R 4 is an optionally substituted C1-C8 alkyl, an optionally substituted C1-C8 alkenyl or an optionally substituted C1-C8 alkynyl;

[0118] (7c)R 4 is hydrogen or unsubstituted C1-C6 alkyl;

[0119] (7d)R 4 It is an unsubstituted C1-C3 alkyl group.

[0120] In certain such embodiments, R 4 Each optionally substituted alkyl, alkenyl, and alkynyl group of is unsubstituted or fluorinated. For example, in certain such embodiments, R 4 Each optionally substituted alkyl, alkenyl, and alkynyl group of is unsubstituted.

[0121] In certain embodiments of the compounds as otherwise described herein, L 4 One selected from the following groups (8a)-(8c) (8a)L 4 Selected from chemical bonds, -C(O)-, -S-, -S(O) 1-2 -, -O-, and -NR 6 -;

[0122] (8b)L 4 It is a chemical bond;

[0123] (8c)L 4 Is -O- (for example, when R 4 is any one of (7a), (7b), (7c) or (7d) above).

[0124] In certain embodiments of the compounds as otherwise described herein, L 5 One selected from the following groups (9a)-(9c)

[0125] (9a)L 5 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2CH2-, -CH2-, -CH(CH3)(OH)- or -CH(OH)-;

[0126] (9b)L 5 It is a chemical bond;

[0127] (9c)L 5 Is a chemical bond, -O-, -S-, -C(O)-, or -S(O) 1-2 -.

[0128] In certain embodiments of the compounds as otherwise described herein, R 5 One selected from the following groups (21o)-(21q)

[0129] (10a)R 5 is aryl (eg phenyl) or heteroaryl (eg isoxazolyl, pyridyl, imidazopyridyl, pyrazolyl), each of which is optionally substituted by 1-5 R 5E replace;

[0130] (10b)R 5 is optionally replaced by 1-5 R 5E substituted phenyl;

[0131] (10c)R 5 is selected from the group consisting of phenyl, isoxazolyl, pyridinyl, imidazopyridinyl and pyrazolyl, each of which is optionally substituted by 1-5 R 5E replace.

[0132] (10d)R 5 is phenyl substituted with a single substituent selected from: -L 5C -(optionally replaced by 1-5 R 5D Substituted phenyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) and -L 5C -(optionally replaced by 1-5 R 5D Substituted monocyclic cycloalkyl)-L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 5E replace;

[0133] (10e)R 5 is a phenyl group, which is replaced by a single -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) substituent and (ii) optionally substituted with 1-5 R 5E replace;

[0134] (10f)R 5 is a phenyl group, which is replaced by a single -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heterocycloalkyl) substituent and (ii) optionally substituted with 1-5 R 5E replace;

[0135] (10g) (10d), (10e) or (10f) above, wherein L 5C It is a chemical bond;

[0136] (10h) above (10d), (10e) or (10f), wherein L 5C is -O- or -C(O)-;

[0137] (10h)R 5 is optionally replaced by 1-5 R 5E substituted heterocycloalkyl;

[0138] (10i)R 5 is a heterocycloalkyl group, which is replaced by a single -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic cycloalkyl) substituent and (ii) optionally substituted with 1-5 R 5E replace;

[0139] (10j) (10h) or (10i) above, wherein the heterocycloalkyl group is connected to -L via a nitrogen atom. 5 - a nitrogen-containing heterocycloalkyl group;

[0140] (10k) (10h), (10i) or (10j) above, wherein the heterocycloalkyl group is monocyclic;

[0141] (101) (10h), (10i) or (10j) above, wherein the heterocycloalkyl group is bicyclic;

[0142] (10m) Any of (10h) to (101) above, wherein the heterocycloalkyl group is saturated;

[0143] (10n)R 5 is optionally replaced by 1-5 R 5E substituted cycloalkyl;

[0144] (10o) or above (10n), wherein the cycloalkyl group is replaced by 1 to 5 R 5E replace;

[0145] (10p) (10n) or (10o) above, wherein the cycloalkyl group is monocyclic;

[0146] (10q) Any of the above (10n), (10o) or (10p), wherein the cycloalkyl group is saturated;

[0147] In certain such embodiments, R 5 Each optionally substituted alkyl, alkenyl and alkynyl group (including R 5D and R 5E These groups) are unsubstituted or fluorinated. For example, in certain such embodiments, R 5 Each optionally substituted alkyl, alkenyl and alkynyl group (including R 5D and R5E of these groups) are unsubstituted.

[0148] Various specific embodiments Nos. 1-1024 of compounds for use in the methods, compounds, and uses of the present disclosure comprise compounds of formula (I), each as defined in the following rows (or a pharmaceutically acceptable salt or N-oxide thereof, or a solvate or hydrate thereof), wherein each entry is a group number as defined above:

[0149]

[0150]

[0151]

[0152]

[0153]

[0154]

[0155]

[0156]

[0157]

[0158]

[0159]

[0160]

[0161]

[0162]

[0163]

[0164]

[0165]

[0166]

[0167]

[0168]

[0169]

[0170]

[0171]

[0172]

[0173] Certain specific embodiments of the compounds of the present disclosure are the compounds of Examples 1-512 in the above table, wherein the structural formula is (Ia).

[0174] For example, certain embodiments of compounds otherwise described herein have any of the above structural formulae (Ia)-(Ie), e.g., structural formula (Ia) or (Ie), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5 and, where applicable, as described with respect to any of the above table Examples 1-1024) and wherein R 1 L is unsubstituted or fluorinated C1-C8 alkenyl. 1 It's a chemical bond.

[0175] For example, certain embodiments of compounds otherwise described herein have any of the above structural formulae (Ia)-(Ie), e.g., structural formula (Ia) or (Ie), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5 and, where applicable, as described with respect to any of the above table Examples 1-1024) and wherein R 1 is optionally replaced by 1-5 R E In certain such embodiments, L 1 It's a chemical bond.

[0176] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3, L 4 、R 4 , L 5 and R 5 and, where applicable, as described with respect to any of the above table Examples 1-1024) and wherein R 1 is phenyl substituted with one, two or three substituents each independently selected from fluoro, chloro, nitro, methyl, methoxy, ethyl, ethoxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxy, pentafluoroethyl and 2,2,2-trifluoroethoxy. In certain such embodiments, L 1 It's a chemical bond.

[0177] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5 and, where applicable, as described with respect to any of the above table Examples 1-1024) and wherein R 1 L is trifluoromethyl-substituted phenyl, methoxymethyl, hydroxymethyl, methoxy-substituted phenyl, or fluoro-substituted phenyl. In certain such embodiments, L 1 It's a chemical bond.

[0178] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5 and, where applicable, as described with respect to any of the above table Examples 1-1024) and wherein R 1 is a phenyl group substituted with: -(OCH2CH2O) n -R 1G , wherein n is 1-4; -N(R 1G )C(O)CH2-O-(CH2CH2O) n R 1G , wherein n is 0-3; or -C(O)NR1G (CH2CH2O) n R 1G In certain such embodiments, L 1 It's a chemical bond.

[0179] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 , L 2 ,Q,L 3 、R 3 , L 4 、R 4 , L 5 and R 5 any alternative definition of , and where applicable with respect to any of the above table Examples 1-1024) and wherein R 1 is hydroxymethyl, methoxymethyl, hydroxyethyl or methoxyethyl. In certain such embodiments, L 1 It's a chemical bond.

[0180] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 5 and R 5 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 4 -R 4 It is -OH or -O-(unsubstituted or fluorinated C1-C8 alkyl), for example, methoxy.

[0181] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5is phenyl substituted with a single substituent selected from: -L 5C -(optionally replaced by 1-5 R 5D substituted phenyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) and -L 5C -(optionally replaced by 1-5 R 5E Substituted monocyclic cycloalkyl)-L 5C -(optionally replaced by 1-5 R 5E substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 5E replace.

[0182] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 It is R 5 is a phenyl group, which is replaced by a single -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) substituent and (ii) optionally substituted with 1-5 R 5E The monocyclic heteroaryl group may be, for example, oxadiazole.

[0183] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 It is R 5 is a phenyl group, which is replaced by a single -L 5C -(optionally replaced by 1-5 R 5Esubstituted monocyclic heterocycloalkyl) substituent and (ii) optionally substituted with 1-5 R 5E The monocyclic heterocycloalkyl group may be, for example, morpholinyl, such as morpholin-1-yl, or oxetanyl, such as oxetan-3-yl.

[0184] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 is optionally replaced by 1-5 R 5E Substituted heterocycloalkyl. The heterocycloalkyl may be, for example, connected to -L via a nitrogen atom. 5 -nitrogen-containing heterocycloalkyl. In some such embodiments, the heterocycloalkyl is monocyclic. In other such embodiments, the heterocycloalkyl is bicyclic. In some such embodiments, the heterocycloalkyl is saturated. In various embodiments as further described herein, the heterocycloalkyl is morpholinyl (e.g., morpholin-1-yl), 1,4-dioxaspiro[4,5]dec-enyl (e.g., 1,4-dioxaspiro[4,5]dec-en-8-yl), piperidinyl (e.g., piperidin-1-yl), azabicyclo[3.2.1]octyl (e.g., azabicyclo[3.2.1]octyl-8-yl), piperazinyl (e.g., piperazin-1-yl), pyrrolidinyl (e.g., pyrrolidin-1-yl), or azaspiro[2.5]octyl (e.g., azaspiro[2.5]octyl-6-yl).

[0185] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 is a heterocycloalkyl group, which is replaced by a single -L 5C-(optionally replaced by 1-5 R 5E substituted monocyclic cycloalkyl) substituent and (ii) optionally substituted with 1-5 R 5E The heterocycloalkyl group may be connected to -L, for example, via a nitrogen atom. 5 -nitrogen-containing heterocycloalkyl. In some such embodiments, the heterocycloalkyl is monocyclic. In other such embodiments, the heterocycloalkyl is bicyclic. In some such embodiments, the heterocycloalkyl is saturated. In various embodiments as further described herein, the heterocycloalkyl is morpholinyl (e.g., morpholin-1-yl), 1,4-dioxaspiro[4,5]dec-enyl (e.g., 1,4-dioxaspiro[4,5]dec-en-8-yl), piperidinyl (e.g., piperidin-1-yl), azabicyclo[3.2.1]octyl (e.g., azabicyclo[3.2.1]octyl-8-yl), piperazinyl (e.g., piperazin-1-yl), pyrrolidinyl (e.g., pyrrolidin-1-yl) or azaspiro[2.5]octyl (e.g., azaspiro[2.5]octyl-6-yl). The cycloalkyl can be, for example, a saturated cycloalkyl, such as a saturated C3-C5 cycloalkyl, such as a cyclopropyl.

[0186] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R 3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 is optionally replaced by 1-5 R 5E In some embodiments, the cycloalkyl group is a cyclohexenyl group (e.g., a cyclohexen-1-yl group, e.g., a 4-trifluoromethylcyclohexen-1-yl group) or a cyclohexyl group.

[0187] Other embodiments of compounds further described herein have any of the above structural formulas (Ia)-(Ie), such as structural formula (Ia), wherein the variables are as otherwise described in any of the embodiments herein (e.g., with respect to the variable L as described herein). 1 、R 1 , L 2 ,Q,L 3 、R3 , L 4 and R 4 any alternative definition of , and as applicable, described with respect to any of Examples 1-1024 in the above table) and wherein -L 5 -R 5 is phenyl substituted with one, two or three substituents each independently selected from fluoro, chloro, nitro, methyl, methoxy, ethyl, ethoxy, trifluoromethyl, difluoromethyl, fluoromethyl, trifluoromethoxy, pentafluoroethyl and 2,2,2-trifluoroethoxy. In certain such embodiments, L 5 It's a chemical bond.

[0188] In certain other embodiments, including those described with reference to Formula (I) and (Ia)-(If) and any of the above Embodiments 1-1024, each optionally substituted alkylene, alkenylene, and alkynylene recited in any of the foregoing embodiments is unsubstituted. In alternative other embodiments, including those described with reference to Formula (I)-(Io) and any of the above Embodiments 1-1024, each optionally substituted alkylene, alkenylene, and alkynylene recited in any of the foregoing embodiments is unsubstituted or fluorinated.

[0189] In certain other embodiments, including those described with reference to Formula (I) and (Ia)-(If), and any of Embodiments 1-1024 above, as well as any of the embodiments described in the preceding paragraph, each optionally substituted alkyl, alkenyl, and alkynyl group recited in any of the preceding embodiments is unsubstituted. In alternative other embodiments, including those described with reference to Formula (I)-(Io), and any of Embodiments 1-1024 above, as well as any of the embodiments described in the preceding paragraph, each optionally substituted alkyl, alkenyl, and alkynyl group recited in any of the preceding embodiments is unsubstituted.

[0190] In certain other embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of the embodiments 1-1024 above, as well as any of the embodiments described in the preceding two paragraphs, each cycloalkyl recited in any of the preceding embodiments is a 3-7 membered monocyclic cycloalkyl. For example, in certain specific embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of the embodiments 1-1024 above, as well as any of the embodiments described in the preceding two paragraphs, each cycloalkyl recited in any of the preceding embodiments is cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, or cyclohexenyl.

[0191] In certain other embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of Embodiments 1-1024 above, as well as any of the embodiments described in the first three paragraphs, each heterocycloalkyl recited in any of the preceding embodiments is a 4-7 membered monocyclic heterocycloalkyl having 1-2 heteroatoms selected from O, S, and N. For example, in certain specific embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of Embodiments 1-1024 above, as well as any of the embodiments described in the first three paragraphs, each heterocycloalkyl recited in any of the preceding embodiments is pyrrolidinyl, tetrahydrofuranyl, tetrahydrothiophenyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, tetrahydro-2H-pyranyl, or tetrahydro-2H-thiopyranyl.

[0192] In certain other embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of Embodiments 1-1024 above, and any of the embodiments described in the first four paragraphs, each heteroaryl is a 5-6 membered monocyclic heteroaryl having 1-3 heteroatoms selected from O, S, and N. For example, in certain specific embodiments, including those described with reference to formula (I) and (Ia)-(If), and any of Embodiments 1-1024 above, and any of the embodiments described in the first four paragraphs, each heteroaryl is furanyl, thienyl, pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, or thiazolyl.

[0193] In certain other embodiments, including those described with reference to Formula (I) and (Ia)-(If) and any one of Embodiments 1-1024 above and any one of the embodiments described in the preceding four paragraphs, each aryl group is phenyl.

[0194] In certain other embodiments as described above, including those described with reference to Formulas (I) and (Ia)-(If) and any of the above Embodiments 1-1024 and any of the embodiments described in the preceding five paragraphs, R 5 is substituted with 1, 2 or 3 substituents selected from halogen (e.g., chloro- or fluoro-) and fluorinated C1-C3 alkyl (e.g., trifluoromethyl, difluoromethyl, fluoromethyl, pentafluoroethyl, trifluoroethyl). For example, in one embodiment as described above, R 5 is phenyl substituted with one or two substituents selected from trifluoromethyl, fluorine and chlorine (e.g., 3-substituted, 4-substituted, 3,4-disubstituted, 2,4-disubstituted or 2,5-disubstituted). For example, in certain embodiments, R 5 It may be a dichlorophenyl group, such as 3,4-dichlorophenyl, or a trifluoromethylphenyl group, such as 4-trifluoromethylphenyl.

[0195] In certain embodiments, the compound is one of the compounds in the following table, which is optionally provided in the form of a pharmaceutically acceptable salt or N-oxide, and / or solvate or hydrate. BJAB cell proliferation data are provided in the table: "A" indicates EC 50 Measured values ​​less than or equal to 1 μM; "B" indicates EC 50 Measured values ​​greater than 1 μM and less than or equal to 5 μM; "C" indicates EC 50 Measured values ​​greater than 5 μM and less than or equal to 10 μM; "D" indicates EC 50 Measured values ​​greater than 10 μM and less than or equal to 25 μM; "E" indicates EC 50 Measured values ​​greater than 25 μM and less than or equal to 50 μM; "F" indicates EC 50 Measured values ​​greater than 50 μM and less than or equal to 100 μM; "G" indicates that in the experiments performed, no EC less than or equal to 80 μM was present. 50 Measured values; "H" indicates that in the experiments performed, there were no EC values ​​less than or equal to 50 μM. 50 Measured values; "I" indicates that there were no EC values ​​less than or equal to 40 μM in the experiments performed. 50 Measured values; "J" indicates that there were no EC values ​​less than or equal to 25 μM in the experiments performed. 50 Measured values; "K" indicates that in the experiments performed, there were no EC values ​​less than or equal to 20 μM. 50 and "L" indicates that in the experiments performed, there were no EC values ​​less than or equal to 5 μM. 50 Measurement value.

[0196]

[0197]

[0198]

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207] In certain embodiments, the compounds described herein may contain one or more asymmetric carbon atoms, whereby the compounds may exist in different stereoisomer forms. These compounds may be, for example, racemates, chiral non-racemic or diastereomers. In these cases, a single enantiomer, i.e., an optically active form, may be obtained by asymmetric synthesis methods or by splitting the racemate. The splitting of the racemate may be achieved, for example, by conventional methods, such as crystallization in the presence of a splitting agent; chromatography using, for example, a chiral hPLC column; or derivatizing the racemic mixture with a splitting agent to produce diastereomers, separating the diastereomers by chromatography and removing the splitting agent to produce the original compound in an enantiomeric enriched form. Any of the above procedures may be repeated to increase the enantiomeric purity of the compound.

[0208] When the compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, and unless otherwise specified, it is intended that the compounds encompass cis, trans, Z, and E. Likewise, all tautomeric forms are also intended to be encompassed.

[0209] In certain embodiments of the methods, compounds, and uses as otherwise described herein, the compound is not one of the compounds listed below:

[0210] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0211] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0212] 1-(4-(3,4-dichlorophenyl)-5-(ethylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0213] 1-(4-(3,4-dichlorophenyl)-5-(ethylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0214] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0215] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0216] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-(methylsulfonamido)benzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0217] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-(methylsulfonamido)benzyl)-1H-pyrazole-5-carboxylic acid;

[0218] 1-(4-(3,4-dichlorophenyl)-5-(propylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0219] 1-(4-(3,4-dichlorophenyl)-5-(propylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0220] 1-(5-(butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid methyl ester;

[0221] 1-(5-(Butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0222] 1-(4-(3,4-dichlorophenyl)-5-(propylthio)thiazol-2-yl)-3-methyl-4-(2-(methylsulfonamido)benzyl)-1H-pyrazole-5-carboxylic acid;

[0223] N-(2-((5-(4-(aminomethyl)piperidine-1-carbonyl)-1-(4-(3,4-dichlorophenyl)-5-(propylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-4-yl)methyl)phenyl)methanesulfonamide;

[0224] 4-Bromo-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0225] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0226] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(imidazo[1,2-a]pyridin-6-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0227] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-phenyl-1H-pyrazole-5-carboxylic acid;

[0228] 1-(5-(cyclohexylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0229] 4-(Benzofuran-2-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0230] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-fluoropyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0231] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2',5,5'-trimethyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0232] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0233] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3,5-difluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0234] 1-(4-(5-chloro-2-fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3,5-dichlorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0235] 1-(4-(5-chloro-2-fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0236] 4-(3,5-dichlorophenyl)-1-(4-(3,5-dimethylisoxazol-4-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0237] 4-(3,5-dichlorophenyl)-1-(5-(isopropylthio)-4-(1-methyl-1H-pyrazol-4-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0238] 4-(3,5-dichlorophenyl)-1-(5-(isopropylthio)-4-(pyridin-4-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0239] 4-(3,5-dichlorophenyl)-1-(5-(isopropylthio)-4-(pyridin-3-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0240] 4-(3,5-dichlorophenyl)-1-(4-(imidazo[1,2-a]pyridin-6-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0241] Methyl 1-(5-(sec-butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-4-(3,5-dichlorophenyl)-3-methyl-1H-pyrazole-5-carboxylate;

[0242] 1-(5-(sec-butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-4-(3,5-dichlorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0243] 1-(5-(sec-butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester;

[0244] 1-(5-(sec-butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0245] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(2-methoxyphenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0246] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(3-methoxyphenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0247] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(4-methoxyphenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0248] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-phenylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0249] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-(hydroxymethyl)-5-methylisoxazol-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0250] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-(methoxymethyl)-5-methylisoxazol-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0251] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(p-tolylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0252] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-m-tolylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0253] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-o-tolylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0254] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(phenylethynyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0255] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyridin-3-yl)-1H-pyrazole-5-carboxylic acid;

[0256] 1-(4-(3,4-dichlorophenyl)-5-(methylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0257] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-(hydroxymethyl)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0258] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0259] 4-(3-(Aminomethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0260] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(4-(hydroxymethyl)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0261] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylic acid;

[0262] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylic acid;

[0263] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(4-(trifluoromethyl)phenyl)-1H-pyrazole-5-carboxylic acid;

[0264] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(hydroxy(phenyl)methyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0265] 1-(4-(3,4-dichlorophenyl)-5-(isopropylsulfinyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0266] 1-(4-(3,4-dichlorophenyl)-5-(isopropylsulfonyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0267] 4-([1,2,4]triazolo[4,3-a]pyridin-3-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0268] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3,5-dimethylisoxazol-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0269] 4-(1H-benzo[d]imidazol-2-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0270] 4-(3-chloro-2-methylphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0271] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0272] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-isopropylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0273] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-methoxy-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0274] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1H-imidazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0275] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyrazolo[1,5-a]pyridin-3-yl)-1H-pyrazole-5-carboxylic acid;

[0276] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyrazolo[1,5-a]pyrimidin-3-yl)-1H-pyrazole-5-carboxylic acid;

[0277] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2',5-dimethyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0278] 2-(4-(3,4-dichlorophenyl)-5-(isopropylsulfonyl)thiazol-2-yl)-2',5-dimethyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0279] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(1-methyl-1H-benzo[d]imidazol-2-yl)-1H-pyrazole-5-carboxylic acid;

[0280] 4-(5-cyanopyridin-3-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0281] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-ethoxypyridin-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0282] 2'-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2,5,5'-trimethyl-3,4'-bi(2H-pyrazole)-3'-carboxylic acid;

[0283] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyrimidin-5-yl)-1H-pyrazole-5-carboxylic acid;

[0284] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxamide;

[0285] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(4,6-dimethylpyrimidin-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0286] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-N-(pyridin-2-ylmethyl)-1H-pyrazole-5-carboxamide;

[0287] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-N-(2-hydroxyethyl)-N,3-dimethyl-1H-pyrazole-5-carboxamide;

[0288] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-N,3-dimethyl-N-(5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxamide;

[0289] (4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-5-yl)(3-(diethylamino)pyrrolidin-1-yl)methanone;

[0290] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(pyrazin-2-yl)-1H-pyrazole-5-carboxylic acid;

[0291] 4-(3-cyano-5-methylphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0292] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-N-(1H-tetrazol-5-yl)-1H-pyrazole-5-carboxamide;

[0293] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(5-methyl-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylic acid;

[0294] 4-(3-cyano-5-methoxyphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0295] 4-(3-cyano-5-(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0296] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-(methoxymethyl)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0297] 4-(3-Benzyl-5-methylisoxazol-4-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0298] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-((dimethylamino)methyl)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0299] (1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-phenyl-1H-pyrazol-5-yl)MeOH;

[0300] 4-(Benzo[d][1,3]dioxol-5-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0301] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(4-methoxypyrimidin-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0302] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(isothiazol-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0303] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-methylisothiazol-5-yl)-1H-pyrazole-5-carboxylic acid;

[0304] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0305] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0306] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluoro-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0307] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-hydroxy-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0308] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-isopropoxy-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0309] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-methyl-5-(oxetan-3-yloxy)phenyl)-1H-pyrazole-5-carboxylic acid;

[0310] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-(dimethylamino)-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0311] 4-(3-(1H-imidazol-1-yl)-5-methylphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0312] 4-(2-(azetidin-1-yl)-6-methylpyridin-4-yl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0313] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-methyl-6-morpholinopyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0314] 1-(5-(Isopropylthio)-4-(3-methoxyphenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0315] 1-(4-(3,4-dichlorophenyl)-5-(isopentylthio)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0316] 1-(5-(Isopropylthio)-4-(3-methoxyphenyl)thiazol-2-yl)-3-methyl-4-(2-(methylsulfonamido)benzyl)-1H-pyrazole-5-carboxylic acid;

[0317] 1-(5-(sec-butylthio)-4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-4-(2-nitrobenzyl)-1H-pyrazole-5-carboxylic acid;

[0318] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1H-indol-6-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0319] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-nitrophenyl)-1H-pyrazole-5-carboxylic acid;

[0320] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-5-methyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0321] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1H-indol-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0322] 4-(2-chlorophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0323] 4-(3-chlorophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0324] 4-(4-chlorophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0325] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0326] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0327] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(4-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0328] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-o-tolyl-1H-pyrazole-5-carboxylic acid;

[0329] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-m-tolyl-1H-pyrazole-5-carboxylic acid;

[0330] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-p-tolyl-1H-pyrazole-5-carboxylic acid;

[0331] 4-(4-acetamidophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0332] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-(methylsulfonamido)benzyl)-1H-pyrazole-5-carboxylic acid;

[0333] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-(N,N-dimethylsulfamoylamino)benzyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0334] 4-(4-aminophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0335] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(4-(methylsulfonamido)phenyl)-1H-pyrazole-5-carboxylic acid;

[0336] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-(methylsulfonamido)phenyl)-1H-pyrazole-5-carboxylic acid;

[0337] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2'-(2-methoxyethyl)-5-methyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0338] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1H-indol-7-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0339] 2-(4-(1H-indol-7-yl)-3-methyl-1H-pyrazol-1-yl)-4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazole;

[0340] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2'-ethyl-5-methyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0341] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-N-(2-methoxyethyl)-3-methyl-4-m-tolyl-1H-pyrazole-5-carboxamide;

[0342] (4-(aminomethyl)piperidin-1-yl)(1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-o-tolyl-1H-pyrazol-5-yl)methanone;

[0343] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(5-methoxypyridin-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0344] 2-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-2'-isobutyl-5-methyl-4,4'-bi(2H-pyrazole)-3-carboxylic acid;

[0345] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-(methylamino)pyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0346] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-1'-(dimethylcarbamoyl)-3-methyl-1H,1'H-[4,4'-bipyrazole]-5-carboxylic acid;

[0347] (4-(aminomethyl)piperidin-1-yl)(4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-5-yl)methanone;

[0348] N-(2-aminoethyl)-4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-N,3-dimethyl-1H-pyrazole-5-carboxamide;

[0349] (3-aminoazetidin-1-yl)(4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-5-yl)methanone;

[0350] (4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-5-yl)(morpholino)methanone;

[0351] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-N,N,3-trimethyl-1H-pyrazole-5-carboxamide;

[0352] (4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazol-5-yl)(4-(hydroxymethyl)piperidin-1-yl)methanone;

[0353] 1-(4-(3,4-dichlorophenyl)-5-isobutylthiazol-2-yl)-1',3-dimethyl-1H,1'H-[4,4'-bipyrazole]-5-carboxylic acid;

[0354] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3,5-dimethylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0355] 4-(3,5-dichlorophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0356] 4-(3-chloro-5-methoxyphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0357] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-methoxy-5-(trifluoromethyl)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0358] 4-(3-chloro-5-methylphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0359] 4-(3,5-bis(trifluoromethyl)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-N-(methylsulfonyl)-1H-pyrazole-5-carboxamide;

[0360] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(imidazo[1,2-a]pyridin-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0361] 4-(3,5-dichlorophenyl)-1-(4-(3,5-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0362] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0363] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluoro-5-hydroxyphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0364] 4-(3-amino-5-methylphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0365] 4-(3-chloro-5-hydroxyphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0366] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(1-methyl-1H-indol-7-yl)-1H-pyrazole-5-carboxylic acid;

[0367] 4-(3,4-dichlorophenyl)-5-(isopropylthio)-2-(1H-pyrazol-1-yl)thiazole;

[0368] 1-(4-(2-chlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0369] 1-(4-(3-chlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0370] 1-(4-(4-chlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0371] 1-(4-(2,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0372] 1-(4-(2,5-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0373] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(phenylethynyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0374] 1-(4-Benzyl-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0375] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluoro-5-methoxyphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0376] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-methoxy-5-methylphenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0377] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-methoxypyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0378] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-methylpyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0379] 1-(4-(1H-indol-4-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0380] 1-(4-(3-Fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(1H-indol-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0381] 1-(4-(1H-indol-5-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0382] 1-(4-(cyclopropylethynyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0383] 4-cyclopropyl-1-(4-cyclopropyl-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0384] 4-cyclopropyl-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0385] 4-(3-chloro-5-isopropoxyphenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0386] 4-(3-chloro-5-(2-methoxyethoxy)phenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0387] 1-(4-(3-chlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0388] 1-(4-(4-chlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0389] 1-(4-(2,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0390] 4-Bromo-1-(4-(6-(3-fluorophenyl)pyridin-3-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0391] (R)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-methyl-6-((tetrahydrofuran-3-yl)oxy)pyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0392] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-(2-methoxyethoxy)-6-methylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0393] (S)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(2-methyl-6-((tetrahydrofuran-3-yl)oxy)pyridin-4-yl)-1H-pyrazole-5-carboxylic acid;

[0394] 1-(4-(cyclohex-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0395] 1-(4-(cyclopent-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0396] 4-(3-chloro-5-methoxyphenyl)-1-(5-(isopropylthio)-4-phenylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0397] 4-(3-Fluorophenyl)-1-(4-(4-fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0398] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methoxyphenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0399] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(methylsulfonyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0400] 1-(4-(4-fluoro-3-methoxyphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0401] 1-(4-(4-chloro-3-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0402] 1-(4-(4-chloro-3-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0403] 1-(4-(4-chloro-3,5-difluorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0404] 1-(4-(4-chloro-3,5-difluorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0405] 1-(4-(4-chloro-3-methoxyphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0406] 1-(4-(4-chloro-3-methoxyphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0407] 4-(2,6-dimethylpyridin-4-yl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0408] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0409] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-4-(3-methyl-5-(oxetan-3-yloxy)phenyl)-1H-pyrazole-5-carboxylic acid;

[0410] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2-methoxy-6-methylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0411] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluoro-5-(oxetan-3-yloxy)phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0412] 4-(3-fluorophenyl)-1-(4-(3-fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0413] 1-(4-(Benzofuran-2-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0414] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-phenylthiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0415] 1-(5-(Isopropylthio)-4-phenylthiazol-2-yl)-1',3-dimethyl-1H,1'H-[4,4'-bipyrazole]-5-carboxylic acid;

[0416] 4-(2,6-dimethylpyridin-4-yl)-1-(4-(4-fluorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0417] 1-(4-(4-chloro-2-methoxyphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0418] 1-(4-(4-chloro-2-methoxyphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0419] 1-(4-(3-chloro-4-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0420] 1-(4-(1,5-dimethyl-6-oxo-1,6-dihydropyridin-3-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0421] 1-(4-(2-chloro-5-(trifluoromethoxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0422] 1-(4-(5-cyanopyridin-3-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0423] 1-(4-(1,3-dimethyl-1H-pyrazol-5-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0424] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(pyrimidin-5-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0425] 1-(4-(4-cyanophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0426] 1-(4-(3-fluoro-4-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0427] 1-(4-(2-cyanophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0428] 1-(4-(4-chloro-2-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0429] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(2-methyl-4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0430] 1-(4-(4-chloro-3-cyanophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0431] 4-(3,5-dichlorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0432] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-((2-methoxyethyl)carbamoyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0433] 1-(4-(4-(dimethylcarbamoyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0434] 4-(3-chloro-5-methoxyphenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0435] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethoxy)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0436] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(2-methyl-4-(trifluoromethoxy)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0437] 4-(3-chloro-5-fluorophenyl)-1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0438] 1-(4-(4-cyano-3-methylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0439] 1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0440] 1-(4-(3,4-dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-isopropyl-1H-pyrazole-5-carboxylic acid;

[0441] 1-(4-(4-(difluoromethyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0442] 1-(4-(3,4-dichlorophenyl)-5-isopropoxythiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0443] 1-(4-(4-ethylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0444] 2-(4-(2,6-dimethylpyridin-4-yl)-3,5-dimethyl-1H-pyrazol-1-yl)-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole;

[0445] 4-(3-Fluorophenyl)-1-(4-(5-fluoropyridin-3-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0446] 1-(4-(Benzofuran-3-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0447] 4-(3,4-difluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0448] 4-(4-fluoro-3-methylphenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0449] 4-(4-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0450] 4-(4-fluoro-3-methoxyphenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0451] 1-(4-(4-chloro-2,6-dimethylphenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0452] 1-(4-(4-(1,1-difluoroethyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0453] 4-(4-fluoro-3,5-dimethylphenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0454] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(2-(trifluoromethyl)pyrimidin-5-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0455] 1-(4-(4-chloro-3-(ethylcarbamoyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0456] 1-(4-(2-amino-4-(trifluoromethyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0457] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-((4-(trifluoromethyl)phenyl)ethynyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0458] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(5-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0459] 4-(3-Fluorophenyl)-3-methyl-1-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid;

[0460] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-N-(2-methoxyethyl)-N,3-dimethyl-1H-pyrazole-5-carboxamide;

[0461] N-(2-(2-(2-(2-azidoethoxy)ethoxy)ethoxy)ethyl)-4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxamide;

[0462] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-N-(2-methoxyethyl)-3-methyl-1H-pyrazole-5-carboxamide;

[0463] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-N-(propylsulfonyl)-1H-pyrazole-5-carboxamide;

[0464] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(2-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0465] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(3-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0466] 4-(3-Fluorophenyl)-1-(5-(isopropylamino)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0467] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(pentafluoro-λ 6 -thio)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0468] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-N-methoxy-3-methyl-1H-pyrazole-5-carboxamide;

[0469] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid;

[0470] 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(6-(trifluoromethyl)pyridin-3-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid; and

[0471] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid. [Paragraph A61]

[0472] In certain embodiments of the compounds as otherwise described herein, the compounds are in the form of N-oxides. However, in certain embodiments as described above, the compounds are not in the form of N-oxides.

[0473] In certain embodiments of the compounds as otherwise described herein, the compounds are in the form of pharmaceutically acceptable salts of the compounds or N-oxides as described herein. One of ordinary skill in the art will appreciate that a variety of pharmaceutically acceptable salts can be provided, as described in further detail below. One of ordinary skill in the art will appreciate that the phrase "optionally in the form of a pharmaceutically acceptable salt or N-oxide, or solvate or hydrate" includes compounds in the form of pharmaceutically acceptable salts of N-oxides. However, in certain embodiments as described above, the compounds are not in the form of pharmaceutically acceptable salts.

[0474] In certain embodiments of compounds as otherwise described herein, the compound is in the form of a solvate (e.g., hydrate) of a compound, N-oxide, or salt as described herein. One of ordinary skill in the art will appreciate that a variety of solvates and / or hydrates can be formed. One of ordinary skill in the art will appreciate that the phrase "optionally in the form of a pharmaceutically acceptable salt or N-oxide, or solvate or hydrate" includes compounds in the form of solvates and hydrates of the base compound, pharmaceutically acceptable salt, and N-oxide as described above. However, in certain embodiments as described above, the compound is not in the form of a solvate or hydrate.

[0475] The compounds described herein can be effectively provided in the form of a pharmaceutical composition comprising a compound according to any of the aforementioned aspects or embodiments described herein, an N-oxide, a salt, a solvate or a hydrate and a pharmaceutically acceptable excipient, a diluent or a carrier. The pharmaceutical composition can be, for example, in the form of a tablet, a capsule or a parenteral formulation, but one of ordinary skill in the art will appreciate that the compound can be provided in a variety of pharmaceutical compositions.

[0476] As mentioned above, mutations that allow for increased and more efficient utilization of scarce nutrients are advantageous during tumor formation. Oncogenic Ras stimulates glucose uptake by enhancing the expression of GLUT1, and stimulates anabolic pathways that utilize glucose and convert it to glutathione, a key cellular antioxidant. Ras also regulates glutamine metabolism, specifically directing glucose and glutamine carbons into pathways that support biosynthesis, redox homeostasis, and ultimately, cell survival and growth.

[0477] In addition to these effects on cellular metabolism, Ras has also been described as having an impact on the progression of cells through the cell cycle. Specifically, Ras is thought to play a role in early G1 and propagation across the restriction point in G2. Ras activity at the G1 restriction point is particularly important because this event is a key integration point for growth factor signaling that allows cells to further divide or enter G0 or dormancy. Ras coordinates growth factor signaling to regulate the levels of cell cycle proteins, cyclin-dependent kinases, and antagonistic cyclin-dependent kinase inhibitors.

[0478] For more information, see generally Hanahan D, Weinberg RA (2011), Hallmarks of cancer: the next generation. Cell 144(5):646–674; Ward PS, Thompson CB (2012), Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell 21(3):297–308; Prabakaran S (2016), Kras rewires metabolic networks. Sci Signal 9(418):ec56–ec56; Kerr EM, Gaude E, Turrell FK, Frezza C, Martins CP (2016), Mutant Kras copy number defines metabolic reprogramming and therapeutic sensitivity. Susceptibilities.), Nature 531(7592):110-113; Flier JS, Mueckler MM, Usher P, Lodish HF (1987), Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes., Science 235(4795):1492-1495; Yun J et al. (2009), Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells.), Science 325(5947):1555-1559; Son J et al. (2013), Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway., Nature 496(7443):101-105; Kim MH, Kim H (2013), Oncogenes and tumor suppressors regulate glutamine metabolism in cancer cells., J Cancer Prev 18(3):221-226; Gaglio D et al. (2011), Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth., Mol Syst Biol 7:523; Hitomi M, Stacey DW (1999), Cellular ras and cyclin D1 are required during different cell cycle periods in cycling NIH 3T3 cells. Mol Cell Biol 19(7):4623-4632; Hitomi M, Stacey DW (2001), Ras-dependent cell cycle commitment during G2 phase.), FEBS Lett 490(3):123-131; Foster DA, Yellen P, Xu L, Saqcena M (2010), Regulation of G1 Cell Cycle Progression: Distinguishing the Restriction Point from a Nutrient-Sensing Cell Growth Checkpoint(s)., Genes Cancer 1(11):1124-1131; Massagué J (2004), G1 cell-cycle control and cancer., Nature 432(7015):298-306; Pardee AB (1974), A restriction point for control of normal animal cell proliferation., Proc Natl Acad Sci USA, 71(4):1286-1290; Martinsson HS, Starborg M, Erlandsson F, Zetterberg A (2005), Single cell analysis of G1 check points-the relationship between the restriction point and phosphorylation of pRb., Exp Cell Res, 305(2):383-391; Larsson O, Zetterberg A (1995), Existence of a commitment program for mitosis in early G1 in tumor cells.), Cell Prolif 28(1):33-43; Yen A, Pardee AB (1978), Exponential 3T3 cells escape in mid-G1 from their high serum requirement., Exp Cell Res 116(1):103-113; Novák B, Tyson JJ (2004), A model for restriction point control of the mammalian cell cycle., J Theor Biol 230(4):563-579; Weber JD, Hu W, Jefcoat SC, Raben DM, Baldassare JJ (1997), Ras-stimulated Extracellular Signal-related Kinase 1and RhoA Activities Coordinate Platelet-derived Growth Factor-induced G1 Progressionthrough the Independent Regulation of Cyclin D1 and p27KIP1. J Biol Chem 272(52):32966-32971; Kawada M et al. (1997), Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway.), Oncogene 15(6):629-637; Deng X, Mercer SE, Shah S, Ewton DZ, Friedman E (2004), The cyclin-dependent kinase inhibitor p27Kip1 is stabilized in G(0) by Mirk / dyrk1B kinase. J Biol Chem 279(21):22498-22504; Ladha MH, Lee KY, Upton TM, Reed MF, Ewen ME (1998), Regulation of exit from quiescence by p27 and cyclin D1-CDK4. Mol Cell Biol Biol 27(2):22498-22504. Biol) 18(11):6605-6615; Fan J, Bertino JR (1997), K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 14(21):2595-2607.

[0479] Specifically, the Ras-related oncogene, KRAS (also known as k-Ras or V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog), has been shown to have a direct impact on cellular metabolism. The result is a global rearrangement of metabolic circuits. KRAS has been noted to have pleiotropic effects on glucose utilization, glutathione synthesis, redox balance, and glutamine metabolism. Glutathione is a ubiquitous intracellular peptide with multiple functions, including regulation of cell proliferation, detoxification, and antioxidant defense (Lu, Shelly C., Mol Aspects Med. 2009; 30(1-2): 42-59). Increased glutathione levels have been associated with early proliferative responses (e.g., stimulating cells to shift from the G0 to the G1 phase of the cell cycle) and are crucial for cells to enter the S phase (ibid.). Glutathione is also involved in the regulation of cell death, potentially regulating apoptosis and necrosis (ibid.). Furthermore, increased glutathione levels have also been reported in many tumors and have been implicated in conferring drug and / or radioresistance and hindering chemotherapy (supra).Thus, glutathione synthesis inhibitors offer a unique chemotherapeutic target.

[0480] Without intending to be bound by theory, the inventors believe that the compounds described herein exert their effects against cancer cells by arresting the cell cycle in the G0 / G1 phase. Therefore, as described above, the compounds described herein can be used in a variety of methods and uses. For example, in certain embodiments of the present disclosure, a method for treating a hyperproliferative disorder in a subject in need thereof comprises administering to the subject an effective amount of a compound as described herein. In other embodiments of the present disclosure, compounds as described herein for use in treating hyperproliferative disorders are provided. Other embodiments of the present disclosure provide compounds as described herein for use in the preparation of a medicament for treating a hyperproliferative disorder. In each of these embodiments, the hyperproliferative disorder can be, for example, cancer.

[0481] The present inventors have determined that, in certain embodiments, the compounds described herein inhibit cell cycle progression in cancer cells. Accordingly, another embodiment of the present disclosure provides a method for inhibiting cell cycle progression in cancer cells, comprising contacting the cancer cells with an effective amount of a compound as described herein. In certain such embodiments, cell cycle progression is inhibited in the G0 / G1 phase.

[0482] In certain embodiments, inhibiting cell cycle progression in the G0 / G1 phase induces apoptosis in cancer cells. Thus, another embodiment of the present disclosure provides a method for inducing apoptosis in cancer cells, such as hematopoietic cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein. However, in other embodiments, such as in certain solid tumors, apoptosis may not be required to achieve a significant therapeutic effect.

[0483] The present inventors have determined that, in certain embodiments, the compounds described herein can induce cytotoxic effects against cancer cells (e.g., through the apoptotic mechanism described above or through alternative mechanisms). Accordingly, another embodiment of the present disclosure provides a method for inducing cytotoxic effects against cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein.

[0484] The present inventors have determined that, in certain embodiments, the compounds described herein can inhibit glutathione synthesis in cancer cells. Accordingly, another embodiment of the present disclosure provides a method for inhibiting glutathione synthesis in cancer cells. The method comprises contacting the cancer cells with an effective amount of a compound as described herein.

[0485] The methods, compounds, and uses described herein can be used for cells of a variety of different cancers or a variety of different types of cancers. For example, in certain embodiments of the methods, compounds, and uses as otherwise described herein, the cancer is a hematopoietic cancer. In other embodiments, the cancer is a solid tumor.

[0486] In certain embodiments of the methods, compounds, and uses as otherwise described herein, the cancer is a lymphoma (e.g., Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, mantle cell lymphoma, T-cell lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma, double hit lymphoma, Waldenstrom macroglobulinemia, primary central nervous system (CNS) lymphoma, and intravascular large B-cell lymphoma (ILBCL)). In other such embodiments, the cancer is a leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute myeloblastic leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), chronic myelomonocytic leukemia (CMML), aggressive NK cell leukemia, acute biphenotypic leukemia, and polycythemia vera), acute and chronic T-cell and B-cell leukemias. In other such embodiments, the cancer is a plasma cell neoplasm (e.g., multiple myeloma).

[0487] However, one of ordinary skill in the art will appreciate from the disclosure provided herein that the methods, compounds, and uses described herein can be used for a variety of other types of cancer. For example, in certain embodiments of the methods, compounds, and uses as otherwise described herein, the cancer is selected from appendix cancer, bone cancer (e.g., Ewing sarcoma, osteosarcoma, and malignant fibrous histiocytoma), bronchial tumors, carcinoma of unknown primary focus, chronic myeloproliferative neoplasms, colon and rectal cancer, head and neck cancer (including head and neck squamous cell carcinoma (HNSCC)), leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute myeloblastic leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), chronic myelomonocytic leukemia (CMML), aggressive NK cell leukemia, acute biphenotypic leukemia, and polycythemia vera), acute and chronic T cell and B The present invention relates to a group of cancers that are primarily caused by the development of melanomas (e.g., primary myeloma, leukemia, myelosuppressive disorder, myeloproliferative disorder, myelosuppressive disorder, and chronic myeloproliferative disorder), including hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, hematopoietic stem cell carcinoma, and hematopoietic stem cell carcinoma.

[0488] And in other embodiments of the methods, compounds, and uses as otherwise described herein, the cancer is selected from adrenocortical carcinoma, adrenocortical carcinoma, AIDS-related cancers (e.g., Kaposi sarcoma, AIDS-related lymphoma, Burkitt's lymphoma, and primary CNS lymphoma), anal cancer, appendiceal cancer, astrocytoma (e.g., cerebellar or cerebral astrocytoma in children), bile duct cancer (e.g., cholangiocarcinoma), bladder cancer, bone cancer (e.g., Ewing's sarcoma, osteosarcoma, and malignant fibrous histiocytoma), brain tumors (e.g., glioblastoma multiforme, cerebellar astrocytoma, cerebral astrocytoma / malignant glioma, ependymoma, medulloblastoma, oligodendroglioma, supratentorial primitive neuroectodermal tumor, and optic pathway and hypothalamic glioma), brainstem glioma, breast cancer, bronchial tumor, gastrointestinal carcinoid tumor, carcinoid tumor, primary lesion not Cancers of the central nervous system (e.g., atypical teratoid / rhabdoid tumors, embryonal tumors, and germ cell tumors), cervical cancer, childhood cancers, chondrosarcoma, chronic myeloproliferative neoplasms, colon and rectal cancer, craniopharyngioma, desmoplastic small round cell tumors, ductal carcinoma in situ (DCIS), endometrial cancer, ependymoma, epithelioid hemangioendothelioma (EHE), esophageal cancer, olfactory neuroblastoma, extracranial germ cell tumors, extragonadal germ cell tumors, eye cancers (e.g., intraocular melanoma and retinoblastoma), fallopian tube cancer, gallbladder cancer, stomach cancer, gastrointestinal stromal tumors (GIST), gestational trophoblastic disease (GTD), Glioma, hairy cell leukemia, head and neck cancer (e.g., head and neck squamous cell carcinoma (HNSCC)), hepatocellular (liver) cancer, histiocytosis, Langerhans cell, hypopharyngeal cancer, renal cancer, Langerhans cell histiocytosis, laryngeal cancer, laryngeal cancer and papillomatosis, leukemia (e.g., acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), acute myeloblastic leukemia, chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), chronic neutrophilic leukemia (CNL), chronic myelomonocytic leukemia (CMML), aggressive NK cells leukemias, acute biphenotypic leukemia, and polycythemia vera), acute and chronic T-cell and B-cell leukemias), cancers of the lip and oral cavity, liver cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer (NSCLC), lung adenocarcinoma, lung carcinoma, and lung squamous cell carcinoma), lung carcinoid tumors, lymphomas (e.g., Burkitt's lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma, mantle cell lymphoma, T-cell lymphoma, cutaneous T-cell lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma, double-hit lymphoma, Waldenstrom's macroglobulinemia, primary central nervous system (CNS) lymphoma, and intravascular large B-cell lymphoma (ILBCL)),Male breast cancer, meningioma, mesothelioma, midline carcinoma involving the NUT gene, oral cancer, multiple endocrine neoplasia syndrome, plasma cell neoplasms (e.g., multiple myeloma), mycosis fungoides, myelodysplastic syndrome, myelodysplastic / myeloproliferative neoplasms and chronic myeloproliferative neoplasms, nasal cavity and paranasal sinus cancer, nasopharyngeal carcinoma (NPC), neuroblastoma, oral cancer, lip and oral cavity cancer, and oropharyngeal cancer, ovarian cancer, pancreatic cancer and pancreatic neuroendocrine tumors (e.g., islet cell tumor), paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary peritoneal cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Sézary syndrome, skin cancer (e.g., basal and squamous cell carcinoma, Merkel cell carcinoma), ovarian cancer, pancreatic cancer and pancreatic neuroendocrine tumors (e.g., islet cell tumor), paraganglioma, parathyroid cancer, penile cancer, pharyngeal cancer, pheochromocytoma, pituitary tumor, pleuropulmonary blastoma, primary peritoneal cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, salivary gland cancer, Sézary syndrome, skin cancer (e.g., basal and squamous cell carcinoma, Merkel cell carcinoma), carcinoma and melanoma), small intestine cancer, soft tissue sarcoma, squamous cell carcinoma, stomach cancer, testicular cancer, pharyngeal cancer, thymoma and thymic carcinoma, thyroid cancer, transitional cell carcinoma of the renal pelvis and ureter, urethral cancer, uterine cancer and uterine sarcoma, vaginal cancer, vascular tumors, vulvar cancer, and Wilms tumor.

[0489] For example, in several specific embodiments of the methods, compounds, and uses as otherwise described herein, the cancer is a solid tumor. In various embodiments, the solid tumor can be, for example, lung cancer, colorectal cancer, or pancreatic cancer.

[0490] In a specific embodiment of the methods, compounds, and uses as otherwise described herein, the cancer is diffuse large B-cell lymphoma.

[0491] The data provided herein show that the compounds are particularly effective against cancers with heterozygous mutant KRAS genes. KRAS mutations are found in >90% of pancreatic cancers, 50% of colon cancers, and 25% of lung adenocarcinomas. Therefore, in certain embodiments of the methods, compounds, and uses as further described herein, the cancer has a mutant KRAS gene, such as a heterozygous mutant KRAS gene.

[0492] However, in certain embodiments of the methods, compounds, and uses as otherwise described herein, the cancer or hyperproliferative disorder is not Burkitt's lymphoma.

[0493] In view of the prior art, one of ordinary skill in the art, based on this disclosure, will be able to determine the effective amounts and dosages of the compounds described herein.

[0494] definition

[0495] As used herein, a single dash "-" or a double dash "=" may be used before and / or after a term to indicate the bond order of the chemical bond between the substituent and its parent moiety; a single dash indicates a single bond and a double dash indicates a double bond or, in the case of a spirocyclic substituent, a pair of single bonds. In the absence of a single or double dash, a single bond is understood to be formed between a substituent and its parent moiety; furthermore, unless a dash indicates otherwise, substituents are intended to be read "left to right" with reference to the referenced chemical structure. For example, arylalkyl, arylalkyl-, and -alkylaryl indicate the same functional group.

[0496] For simplicity, chemical moieties are primarily defined and referred to as monovalent chemical moieties (e.g., alkyl, aryl, etc.) throughout the text. However, in the case where the appropriate structure is clear to those skilled in the art, these terms are also used to convey the corresponding multivalent moieties. For example, although the "alkyl" moiety can refer to a monovalent group (e.g., CH3-CH2-), in some cases, a divalent linking moiety can be an "alkyl," in which case it will be understood by those skilled in the art that an alkyl group is a divalent group (e.g., -CH2-CH2-), equivalent to the term "alkylene." (Similarly, where a divalent moiety is required and is stated as "aryl," it will be understood by those skilled in the art that the term "aryl" refers to the corresponding divalent moiety, i.e., arylene). All atoms should be understood to have their normal valences for forming chemical bonds (i.e., carbon is 4, N is 3, O is 2, and S is 2, 4, or 6, depending on the oxidation state of S). The nitrogen in the compounds disclosed herein can be high-valent, such as N-oxides or tetrasubstituted ammonium salts. Sometimes a moiety can be defined, for example, as -B-(A) a, wherein a is 0 or 1. In such examples, when a is 0, the moiety is -B, and when a is 1, the moiety is -BA.

[0497] As used herein, the term "alkyl" encompasses saturated hydrocarbons having a designated number of carbon atoms, such as 1 to 10 carbons (i.e., inclusive), 1 to 8 carbons, 1 to 6 carbons, 1 to 3 carbons, or 1, 2, 3, 4, 5, or 6 carbons. Alkyl groups can be straight or branched and, depending on the circumstances, can be monovalent or divalent groups (i.e., alkylene groups). For example, the moiety "-(C1-C6 alkyl)-O-" represents an oxygen connected through an alkylene bridge having 1 to 6 carbons and C1-C3 alkyl represents methyl, ethyl, and propyl moieties. Examples of "alkyl" include, for example, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, and tert-butyl, pentyl, and hexyl.

[0498] The term "alkoxy" represents an alkyl group having the specified number of carbon atoms attached to the parent molecular moiety through an oxygen bridge. Examples of "alkoxy" include, for example, methoxy, ethoxy, propoxy, and isopropoxy.

[0499] Unless otherwise indicated, as used herein, the term "alkenyl" is an unsaturated hydrocarbon containing 2 to 10 carbons (i.e., inclusive), 2 to 8 carbons, 2 to 6 carbons, or 2, 3, 4, 5, or 6 carbons and containing at least one carbon-carbon double bond. Alkenyl groups can be straight or branched and, depending on the context, can be monovalent or divalent groups (i.e., alkenylene). For example, the moiety "-(C2-C6 alkenyl)-O-" represents that the oxygen is connected through an alkenylene bridge having 2 to 6 carbons. Representative examples of alkenyl groups include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-heptenyl, 3-decenyl, and 3,7-dimethylocta-2,6-dienyl.

[0500] Unless otherwise indicated, as used herein, the term "alkynyl" is an unsaturated hydrocarbon containing 2 to 10 carbons (i.e., inclusive), 2 to 8 carbons, 2 to 6 carbons, or 2, 3, 4, 5, or 6 carbons and containing at least one carbon-carbon triple bond. Alkynyl groups can be straight or branched and, depending on the context, can be monovalent or divalent groups (i.e., alkynylene). For example, the moiety "-(C2-C6 alkynyl)-O-" represents an oxygen attached through an alkynylene bridge having 2 to 6 carbons. Representative examples of alkynyl groups include, but are not limited to, ethynyl, 1-propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.

[0501] The term "aryl" refers to an aromatic ring system having a monocyclic ring (e.g., phenyl) that is optionally fused to other aromatic hydrocarbon rings or non-aromatic hydrocarbon rings or heterocycles. "Aryl" includes ring systems having multiple condensed rings, at least one of which is a carbocyclic ring and an aromatic ring (e.g., 1,2,3,4-tetrahydronaphthyl, naphthyl). Examples of aryl include phenyl, 1-naphthyl, 2-naphthyl, indanyl, indenyl, dihydronaphthyl, fluorenyl, tetrahydronaphthyl, and 6,7,8,9-tetrahydro-5H-benzo[a]cycloheptenyl. "Aryl" also includes ring systems having a first carbocyclic ring, an aromatic ring fused to a non-aromatic heterocycle, such as 1H-2,3-dihydrobenzofuranyl and tetrahydroisoquinolinyl. Aryl herein is unsubstituted or, when designated as "optionally substituted," unless otherwise indicated, may be substituted in one or more substitutable positions by various groups as indicated.

[0502] The term "halogen" or "halo" indicates fluorine, chlorine, bromine and iodine. In certain embodiments of each embodiment as described herein, the term "halogen" or "halo" refers to fluorine or chlorine. In certain embodiments of each embodiment described herein, the term "halogen" or "halo" refers to fluorine. The term "fluoroalkyl" indicates an alkyl group substituted with at least one fluorine (i.e., as described herein). "Fluoroalkyl" includes alkyl groups substituted with multiple fluorines, such as perfluoroalkyl. Examples of fluoroalkyl groups include fluoromethyl, difluoromethyl, trifluoromethyl, pentafluoroethyl, 2,2,2-trifluoroethyl, 1,1,1,3,3,3-hexafluoroprop-2-yl and 2,2,3,3,3-pentafluoroprop-1-yl.

[0503] The term "heteroaryl" refers to an aromatic ring system containing at least one aromatic heteroatom selected from nitrogen, oxygen, and sulfur in the aromatic ring. Most commonly, a heteroaryl group will have 1, 2, 3, or 4 heteroatoms. A heteroaryl group may be fused to one or more non-aromatic rings, such as a cycloalkyl or heterocycloalkyl ring, wherein the cycloalkyl and heterocycloalkyl rings are as described herein. In one embodiment of the compounds of the invention, the heteroaryl group is bonded to the remainder of the structure through an atom in the heteroaryl aromatic ring. In another embodiment, the heteroaryl group is bonded to the remainder of the structure through a non-aromatic ring atom. Examples of heteroaryl groups include, for example, pyridyl, pyrimidinyl, quinolyl, benzothiophenyl, indolyl, indolinyl, pyridazinyl, pyrazinyl, isoindolyl, isoquinolyl, quinazolinyl, quinoxalinyl, phthalazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, indolizinyl, indazolyl, benzothiazolyl, benzimidazolyl, benzofuranyl, furanyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, benzo[ 1,4]oxazinyl, triazolyl, tetrazolyl, isothiazolyl, naphthyridinyl, isochromanyl, chromanyl, isoindolyl, isobenzothiophenyl, benzoxazolyl, pyridopyridinyl, purinyl, benzodioxolyl, triazinyl, pteridinyl, benzothiazolyl, imidazopyridinyl, imidazothiazolyl, benzisoxazinyl, benzoxazinyl, benzopyranyl, benzothiopyranyl, chromonyl, chromanonyl, pyridinyl- N-oxide, isoindolinonyl, benzodioxanyl, benzoxazolinonyl, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, quinolyl N-oxide, indolyl N-oxide, indolyl N-oxide, isoquinolyl N-oxide, quinazolinyl N-oxide, quinoxalinyl N-oxide, phthalazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, indolizinyl N-oxide, indazolyl N-oxide, benzothiazolyl N-oxide, benzimidazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide, tetrazolyl N-oxide, benzothiopyranyl S-oxide, benzothiopyranyl S,S-dioxide. Preferred heteroaryl groups include pyridyl, pyrimidinyl, quinolinyl, indolyl, pyrrolyl, furanyl, thienyl, and imidazolyl, pyrazolyl, indazolyl, thiazolyl, and benzothiazolyl.In certain embodiments, each heteroaryl is selected from pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, imidazolyl, isoxazolyl, pyrazolyl, oxazolyl, thiazolyl, furyl, thienyl, pyrrolyl, oxadiazolyl, thiadiazolyl, triazolyl, tetrazolyl, isothiazolyl, pyridyl-N-oxide, pyrrolyl N-oxide, pyrimidinyl N-oxide, pyridazinyl N-oxide, pyrazinyl N-oxide, imidazolyl N-oxide, isoxazolyl N-oxide, oxazolyl N-oxide, thiazolyl N-oxide, pyrrolyl N-oxide, oxadiazolyl N-oxide, thiadiazolyl N-oxide, triazolyl N-oxide and tetrazolyl N-oxide. Preferred heteroaryl groups include pyridyl, pyrimidinyl, quinolyl, indolyl, pyrrolyl, furyl, thienyl, imidazolyl, pyrazolyl, indazolyl, thiazolyl and benzothiazolyl. Heteroaryl groups herein are unsubstituted or, when designated as "optionally substituted," unless otherwise indicated, can be substituted in one or more substitutable positions with various groups as indicated.

[0504] The term "heterocycloalkyl" refers to a non-aromatic ring or ring system containing at least one heteroatom, preferably selected from nitrogen, oxygen and sulfur, wherein the heteroatom is in a non-aromatic ring. Heterocycloalkyl can have 1, 2, 3 or 4 heteroatoms. Heterocycloalkyl can be saturated (i.e., heterocycloalkyl) or partially unsaturated (i.e., heterocycloalkenyl). Heterocycloalkyl includes monocyclic groups with three to eight ring atoms, as well as bicyclic and polycyclic ring systems, including bridged and fused systems, wherein each ring contains three to eight ring atoms. The heterocycloalkyl ring is optionally fused to other heterocycloalkyl rings and / or non-aromatic hydrocarbon rings. In certain embodiments, heterocycloalkyl has 3 to 7 members in a single ring. In other embodiments, heterocycloalkyl has 5 or 6 members in a single ring. In some embodiments, heterocycloalkyl has 3, 4, 5, 6 or 7 members in a single ring. Examples of heterocycloalkyl include, for example, azabicyclo[2.2.2]octyl (in each case also including "quinuclidine" or quinuclidine derivatives), azabicyclo[3.2.1]octyl, 2,5-diazabicyclo[2.2.1]heptyl, morpholinyl, thiomorpholinyl, thiomorpholinyl S-oxide, thiomorpholinyl S,S-dioxide, 2-oxazolidinone, piperazinyl, homopiperazinyl, piperazinone, pyrrolidinyl, azepanyl, azetidinyl, pyrrolinyl, tetrahydropyranyl, 1H)-1, 1H-1, 2-dihydro-1, 2-dihydro-2, 2-dihydro-3, 4-dihydro-isoquinolin-2(1H)-yl, 1H-1 ... Particularly desirable heterocycloalkyl groups include morpholinyl, 3,4-dihydroisoquinolin-2(1H)-yl, tetrahydropyranyl, piperidinyl, azabicyclo[2.2.2]octyl, γ-butyrolactonyl (i.e., oxo-substituted tetrahydrofuranyl), γ-butyrolactamyl (i.e., oxo-substituted pyrrolidine), pyrrolidinyl, piperazinyl, azepanyl, azetidinyl, thiomorpholinyl, thiomorpholinyl S,S-dioxide, 2-oxazolidinone, imidazolidinone, isoindolindione, piperazinone. Heterocycloalkyl groups herein are unsubstituted or, when designated as "optionally substituted," may be substituted in one or more substitutable positions with various groups as indicated, unless otherwise stated.

[0505] The term "cycloalkyl" refers to a non-aromatic carbocyclic ring or ring system that is saturated (i.e., cycloalkyl) or partially unsaturated (i.e., cycloalkenyl). The cycloalkyl ring is optionally fused to other cycloalkyl rings or otherwise connected (e.g., a bridged system). Some examples of the cycloalkyl present in the disclosed compounds have 3 to 7 members in a single ring, such as 5 or 6 members in a single ring. In certain embodiments, the cycloalkyl has 3, 4, 5, 6, or 7 members in a single ring. Examples of cycloalkyl include, for example, cyclohexyl, cyclopentyl, cyclobutyl, cyclopropyl, tetrahydronaphthyl, and bicyclo [2.2.1] heptane. Cycloalkyl herein is unsubstituted or, when designated as "optionally substituted," can be substituted in one or more substitutable positions by various groups as indicated.

[0506] The term "ring system" encompasses single rings, as well as fused and / or bridged polycyclic rings.

[0507] The term "oxo" means a double-bonded oxygen and is sometimes represented as =0 or, for example, in describing a carbonyl group "C(O)", can be used to indicate the carbon substituted with an oxo group.

[0508] Unless specifically stated otherwise, the term "substituted" when used to modify a specified group or radical means that one or more hydrogen atoms of the specified group or radical are each independently replaced by the same or different substituents as defined below.

[0509] As used herein, the phrase "pharmaceutically acceptable salt" refers to pharmaceutically acceptable acid and base addition salts and solvates. Such pharmaceutically acceptable salts include salts of acids such as hydrochloric acid, phosphoric acid, hydrobromic acid, sulfuric acid, sulfinic acid, formic acid, toluenesulfonic acid, methanesulfonic acid, nitric acid, benzoic acid, citric acid, tartaric acid, maleic acid, hydroiodic acid, alkanoic acids such as acetic acid, HOOC-(CH2) n -COOH, wherein n is 0-4, etc. Non-toxic pharmaceutical base addition salts include salts of bases such as sodium, potassium, calcium, ammonium, etc. Those skilled in the art will recognize a variety of non-toxic pharmaceutically acceptable addition salts.

[0510] It will also be understood by those skilled in the art of medicinal chemistry that the disclosed structures are intended to encompass isotopically enriched forms of the compounds of the invention. As used herein, "isotopes" include atoms having the same atomic number but different mass numbers. As known to those skilled in the art, certain atoms, such as hydrogen, exist in different isotopic forms. For example, hydrogen comprises three isotopic forms, namely protium, deuterium, and tritium. Considering the compounds of the invention, it will be apparent to those skilled in the art that certain compounds may be enriched at a given position in a particular isotope of the atom at that position. For example, a compound having a fluorine atom may be enriched in a radioactive fluorine isotope. 18F form. Similarly, the compound can be enriched with heavy isotopes of hydrogen: deuterium and tritium; and similarly, can be enriched with radioactive isotopes of carbon, such as 13 C. Such isotopic variant compounds undergo different metabolic pathways and can be used, for example, to study ubiquitination pathways and their role in disease. Of course, in certain embodiments, the compound has substantially the same isotopic profile as the naturally occurring material.

[0511] As used herein, the term "cell" is intended to refer to a cell in vitro, ex vivo, or in vivo. In some embodiments, an ex vivo cell can be a portion of a tissue sample removed from an organism, such as a mammal. In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism, such as a mammal.

[0512] As used herein, the terms "individual," "patient," or "subject" are used interchangeably to refer to any animal, including mammals, preferably mice, rats, other rodents, rabbits, dogs, cats, pigs, cows, sheep, horses, or primates, and most preferably humans.

[0513] As used herein, the phrase "therapeutically effective amount" or "effective amount" refers to that amount of an active compound or agent that elicits the biological or medicinal response that is being sought by a researcher, veterinarian, medical doctor or other clinician in a tissue, system, animal, individual or human.

[0514] In certain embodiments, an effective amount may be an amount suitable for the following purposes:

[0515] (i) inhibiting disease progression;

[0516] (ii) prophylactic uses, e.g., preventing or limiting the development of a disease, condition, or disorder in an individual who may be susceptible to or otherwise at risk of developing the disease, condition, or disorder but who does not yet experience or display the pathology or symptoms of the disease;

[0517] (iii) inhibiting a disease; e.g., inhibiting a disease, condition, or disorder in a subject who is experiencing or exhibiting the pathology or symptoms of the disease, condition, or disorder;

[0518] (iv) ameliorating the disease state referred to, e.g., ameliorating the disease, condition or disorder in a subject experiencing or displaying the pathology or symptoms of the disease, disorder or condition (i.e., reversing or ameliorating the pathology and / or symptoms) such as reducing the severity of the disease; or

[0519] (v) induce the biological effects mentioned.

[0520] As used herein, the terms "treatment" or "treating" mean (i) ameliorating a referenced disease state, condition or disorder (or symptoms thereof), e.g., ameliorating the disease, condition or disorder in a subject experiencing or displaying the pathology or symptoms of the disease, condition or disorder (i.e., reversing or ameliorating the pathology and / or symptoms), such as reducing the severity of the disease or its symptoms, or inhibiting the progression of the disease; or (ii) causing a referenced biological effect (e.g., inducing apoptosis or inhibiting glutathione synthesis).

[0521] Pharmaceutical formulations and dosage forms

[0522] The compounds of the present disclosure can be in the form of dosage unit formulations containing one or more pharmaceutically acceptable carriers, diluents or excipients, for example, orally, topically, parenterally, by inhalation or spray or rectally administered. As used herein, the term parenteral includes transdermal, subcutaneous, intravascular (e.g., intravenous), intramuscular or intrathecal injection or infusion techniques, etc. The medicaments comprising the compounds of the present disclosure can be provided in any suitable formulation and dosage form as described herein.

[0523] Pharmaceutical compositions can be prepared using the compounds disclosed herein. For example, in one embodiment, a pharmaceutical composition comprises a pharmaceutically acceptable carrier, diluent, or excipient and a compound as described above with reference to any one of the structural formulas.

[0524] In the pharmaceutical compositions disclosed herein, one or more compounds of the present disclosure may be present in combination with one or more pharmaceutically acceptable carriers, diluents or excipients and, if necessary, other active ingredients. Pharmaceutical compositions containing compounds of the present disclosure may be in a form suitable for oral use, such as tablets, sugar-coated tablets, buccal tablets, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.

[0525] Compositions intended for oral use can be prepared according to any suitable method for manufacturing pharmaceutical compositions, and these compositions may contain one or more agents selected from the group consisting of sweeteners, flavorings, colorants, and preservatives to provide pharmaceutically optimal and palatable formulations. Tablets contain a mixture of the active ingredient and non-toxic pharmaceutically acceptable excipients suitable for making tablets. These excipients can be, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating agents and disintegrants such as corn starch or alginic acid; binders such as starch, gelatin, or gum arabic; and lubricants such as magnesium stearate, stearic acid, or talc. Tablets can be uncoated, or they can be coated by known techniques. In some cases, these coatings can be prepared by suitable techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained effect over a longer period of time. For example, time-delay materials such as glyceryl monostearate or glyceryl distearate can be used.

[0526] Formulations for oral use may also be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate or kaolin; or in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, such as peanut oil, liquid paraffin or olive oil.

[0527] Formulations for oral use may also be in the form of buccal tablets.

[0528] Aqueous suspensions contain a mixture of the active substance and excipients suitable for the manufacture of aqueous suspensions. Such excipients may include suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth, and gum arabic; dispersants or wetting agents, such as naturally occurring phospholipids, such as lecithin, or condensation products of alkylene oxides with fatty acids, such as polyoxyethylene stearate, or condensation products of ethylene oxide with long-chain fatty alcohols, such as heptadecaethyleneoxyhexadecanoate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as polyoxyethylene sorbitol monooleate, or condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as polyethylene sorbitan monooleate. Aqueous suspensions may also contain one or more preservatives, such as ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweeteners, such as sucrose or saccharin.

[0529] Oily suspensions can be prepared by suspending the active ingredient in a vegetable oil, such as peanut oil, olive oil, sesame oil, or coconut oil, or a mineral oil such as liquid paraffin. Oily suspensions may contain thickeners, such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners and flavorings may be added to provide a palatable oral formulation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.

[0530] Dispersible powders and granules suitable for preparing aqueous suspensions by adding water provide a mixture of the active ingredient with a dispersant or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersants, wetting agents, or suspending agents are exemplified by those mentioned above. Other excipients, such as sweeteners, flavorings, and coloring agents, may also be present.

[0531] Pharmaceutical compositions may also be in the form of oil-in-water emulsions. The oil phase may be a vegetable oil, a mineral oil, or a mixture thereof. Suitable emulsifiers include naturally occurring gums such as gum arabic or gum tragacanth; naturally occurring phospholipids such as soy or lecithin; esters or partial esters derived from fatty acids and hexyl alcohols or anhydrides, such as sorbitan monooleate; and condensation products of such partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. The emulsion may also contain sweeteners and flavorings.

[0532] In some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is not water. In other embodiments, water comprises less than 50% of the composition. In some embodiments, the composition comprising less than 50% water has at least 1%, 2%, 3%, 4%, or 5% water. In other embodiments, trace amounts of water are present in the composition.

[0533] In some embodiments, the pharmaceutically acceptable carrier, diluent, or excipient is not an alcohol. In other embodiments, alcohol comprises less than 50% of the composition. In some embodiments, compositions comprising less than 50% alcohol have at least 1%, 2%, 3%, 4%, or 5% alcohol. In other embodiments, trace amounts of alcohol are present in the composition.

[0534] Syrups and elixirs can be formulated with sweeteners such as glycerol, propylene glycol, sorbitol, glucose, or sucrose. These formulations may also contain demulcents, preservatives, flavorings, and coloring agents. Pharmaceutical compositions may be in the form of sterile injectable aqueous or oily suspensions. This suspension may be formulated according to known techniques using the suitable dispersants or wetting agents and suspending agents mentioned above. Sterile injectable preparations may also be in the form of sterile injectable solutions or suspensions in non-toxic parenterally acceptable diluents or solvents, such as solutions in 1,3-butanediol. Acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile fixed oils may be used as solvents or suspending media. For this purpose, any mild fixed oil may be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids such as oleic acid may also be used to prepare injectables.

[0535] For example, for rectal administration of drugs, the compounds of the present disclosure can also be administered in the form of suppositories. These compositions can be prepared by mixing the compound with a suitable non-irritating excipient, which is solid at normal temperature but liquid at rectal temperature and will therefore melt in the rectum to release the drug. These materials include cocoa butter and polyethylene glycol.

[0536] The compounds of the present disclosure can also be administered parenterally via a sterile medium. Depending on the vehicle and concentration used, the drug can be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives, and buffers can be dissolved in the vehicle.

[0537] The compositions can be formulated in unit dosage form of the active ingredient. The term "unit dosage form" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect in association with a suitable pharmaceutical excipient.

[0538] The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. However, it will be appreciated that the actual amount of compound administered will generally be determined by the physician based on the relevant circumstances, including the condition to be treated, the route of administration selected, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.

[0539] To prepare solid compositions, such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of the compounds described herein. When these preformulation compositions are referred to as homogeneous compositions, the active ingredient is typically evenly dispersed throughout the composition, allowing the composition to be readily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing, for example, 0.1 to about 500 mg of the active ingredient of the compound described herein.

[0540] Tablet or pill can be coated or otherwise mixed to provide the dosage form realizing long-term effect advantage.For example, tablet or pill can comprise inner dosage and outer dosage component, and the latter is in the form of film coating on the former.These two components can be separated by enteric layer, and described enteric layer is in order to resist disintegration in stomach and allows inner component to be delivered to duodenum intact or delay release.Multiple materials can be used for this type of enteric layer or coating, and these materials comprise multiple polymeric acid and polymeric acid and the mixture of materials such as shellac, cetyl alcohol and cellulose acetate.

[0541] The amount of compound or composition administered to a patient will vary depending on the drug being administered, the purpose of administration, such as prophylaxis or treatment, the patient's condition, the mode of administration, and the like. In therapeutic applications, the composition can be administered to a patient already suffering from a disease in an amount sufficient to cure or at least partially arrest the symptoms of the disease and its complications. The effective dose will depend on the disease condition being treated and will be determined by the attending physician based on factors such as the severity of the disease, the patient's age, weight, and general condition.

[0542] The composition administered to the patient can be in the form of the pharmaceutical composition described above. These compositions can be sterilized by conventional sterilization techniques or can be aseptically filtered. The aqueous solution can be packaged for use as is, or lyophilized, and the lyophilized formulation is combined with a sterile aqueous carrier before administration. The pH value of the compound formulation will typically be between 3 and 11, more preferably 5 to 9 and most preferably 7 to 8. It should be understood that the use of some of the aforementioned excipients, carriers or stabilizers can result in the formation of pharmaceutical salts.

[0543] The therapeutic dose of the compound can vary according to, for example, the specific use for which the treatment is directed, the mode of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The ratio or concentration of the compound described herein in the pharmaceutical composition can vary depending on a variety of factors, including dosage, chemical characteristics (e.g., hydrophobicity), and route of administration. For example, for parenteral administration, the compound described herein can be provided in the form of an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound. Some typical dosage ranges are about 1 μg to about 1 g per kilogram of body weight per day. In some embodiments, the dosage range is about 0.01 mg to about 100 mg per kilogram of body weight per day. The dosage is likely to depend on the following variables: the type and degree of progression of the disease or condition, the overall health of the particular patient, the relative biological efficacy of the selected compound, the formulation of the excipient, and its route of administration. The effective dose can be extrapolated from a dose-response curve obtained by an in vitro or animal model test system.

[0544] The compounds described herein may also be formulated in combination with one or more additional active ingredients, which may include any pharmaceutical agent, such as an antiviral agent, a vaccine, an antibody, an immunopotentiator, an immunosuppressant, an anti-inflammatory agent, and the like.

[0545] One of ordinary skill in the art will formulate the compounds into pharmaceutical formulations herein based on, for example, the physicochemical properties of the described compounds, the amount of compound required to achieve a pharmaceutically effective amount, and the desired route of administration.

[0546] Examples

[0547] General synthetic method

[0548] There are many general references available that provide commonly known chemical synthesis schemes and conditions that can be used to synthesize the disclosed compounds (see, for example, Smith and March, March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th ed., Wiley-Interscience, 2001; or Vogel, A Textbook of Practical Organic Chemistry, Including Qualitative Organic Analysis, 4th ed., New York: Longman, 1978).

[0549] The compounds described herein can be purified by any means known in the art, including chromatography, such as HPLC, preparative thin layer chromatography, flash column chromatography, and ion exchange chromatography. Any suitable stationary phase can be used, including normal phase and reverse phase and ionic resins. Most typically, the disclosed compounds are purified by silica gel and / or alumina chromatography. See, for example, Introduction to Modern Liquid Chromatography, 2nd edition, LRSnyder and JJKirkland, eds., John Wiley and Sons, 1979; and Thin Layer Chromatography, E.Stahl, ed., Springer-Verlag, New York, 1969.

[0550] During any of the processes for preparing the subject compounds, it may be necessary and / or desirable to protect sensitive or reactive groups on any molecule of interest. This can be achieved by means of conventional protecting groups as described in standard works such as J.F.W. McOmie, "Protective Groups in Organic Chemistry", Plenum Press, London and New York 1973; T.W. Greene and P.G. Wuts, "Protective Groups in Organic Synthesis", 3rd ed., Wiley, New York 1999; "The Peptides", Vol. 3 (Editors: E. Gross and J. Meienhofer), Academic Press, London and New York 1981; "Methoden der organischen Chemie", Houben-Weyl, 4th Supplementary Edition, Vol. 15 / 1, Georg Thieme Verlag, Stuttgart 1974; H.-D. Jakubke and H. Jescheit, “Amino Acids, Peptides, Proteins”, Verlag Chemie, Weinheim, Deerfield Beach and Basel 1982; and / or Jochen Lehmann, “Chemistry of Carbohydrates: Monosaccharides and Derivates”, Georg Thieme Verlag, Stuttgart 1974. These protecting groups can be removed at a suitable subsequent stage using methods known in the art.

[0551] Taking into account the specific preparation procedures described herein, the compounds disclosed herein can be prepared using procedures familiar to those of ordinary skill in the art. Those skilled in the art can adopt the reaction procedures described in the following examples to conform to the desired target molecule. Of course, in some cases, those skilled in the art will use different reagents to achieve one or more independent steps or use protected forms of certain substituents. In addition, those skilled in the art will recognize that the compounds of the present disclosure can be synthesized using completely different pathways.

[0552] Compounds suitable for use in the pharmaceutical compositions disclosed herein include the compounds in the above table. A variety of exemplary synthetic methods are provided below; those of ordinary skill in the art will use the procedures described herein and / or other procedures familiar to those of ordinary skill in the art to prepare the compounds described herein.

[0553] The following synthetic examples and biochemical data are intended to further illustrate certain embodiments and are not intended to limit the scope of the compounds disclosed herein.

[0554] Compound 1: 1-(4-(4-chloro-2-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0555] 3-(2-bromo-5-chlorophenoxy)oxetane

[0556] Diisopropyl diazoformate (292 mg, 1.45 mmol) was added to a solution of 2-bromo-5-chlorophenol (200 mg, 0.964 mmol), oxetane-3-ol (89 mg, 1.2 mmol) and triphenylphosphine (379 mg, 1.45 mmol) in THF (4.2 mL). The reaction mixture was stirred at room temperature for 18 hours. Ethyl acetate was added and the mixture was washed with 1N NaOH (3 ×). The organic layer was dehydrated with sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using a solution of ethyl acetate in hexane (10%) to give the title compound (208 mg, 0.789 mmol, 82%).

[0557] 2-(4-chloro-2-(oxetan-3-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Cyclopentane

[0558] Degassed dioxane was added to a mixture of 3-(2-bromo-5-chlorophenoxy)oxetane (100 mg, 0.379 mmol), pinacol diborane (116 mg, 0.455 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium(II) dichloride (28 mg, 0.038 mmol) and potassium acetate (112 mg, 1.14 mmol). The reaction mixture was heated at 85°C for 18 hours. The mixture was filtered over celite and the pad was washed with dioxane. The filtrate was evaporated to give the title compound (219 mg, 186%, 50% w / w as determined by NMR analysis) which was used as is.

[0559] 2-Chloro-5-(isopropylthio)thiazole

[0560] At -78 ° C, a 2.5M solution of n-BuLi in hexane (20.5mL, 51.2mmol) was added to a THF solution (117mL) of 2-chlorothiazole (4.9g, 41.0mmol). The reaction mixture was stirred at the same temperature for 30 minutes. Diisopropyl disulfide (13.1mL, 82.0mmol) was added to the reactant and stirred at the same temperature for 1.5 hours. Water was added to quench the reaction and then Et2O was added. The reaction mixture was transferred to a separatory funnel and the aqueous layer was extracted with Et2O (3×). The combined organic layers were dehydrated with Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry filling) using a solution of EtOAc in hexane (0 to 5% gradient) to obtain the title compound (2.31g, 11.9mmol, 29%) as a yellow liquid.

[0561] 4-Bromo-2-chloro-5-(isopropylthio)thiazole

[0562] A 2M solution of bromine (72.7 μL, 1.42 mmol) in dichloromethane ("DCM") was added dropwise to a solution of 2-chloro-5-(isopropylthio)thiazole (250 mg, 1.29 mmol) in DCM. The reaction was stirred at room temperature for 3 hours. A solution of NaSO was added and the aqueous layer was extracted with DCM (3×). The combined organic layers were washed with brine, dried over NaSO, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a solution of DCM in hexanes (50 to 100% gradient) to give the title compound (271 mg, 0.99 mmol, 77%) as a colorless liquid.

[0563] 4-Bromo-2-hydrazino-5-(isopropylthio)thiazole

[0564] In a glass microwave vial, DIPEA (64 μ L, 0.37 mmol) is added to a solution of hydrazine hydrochloride (13.0 mg, 0.18 mmol) and 4- bromo-2- chloro- 5- (isopropylsulfanyl) thiazole (50.0 mg, 0.18 mmol) in NMP (2 mL). The vial is sealed and heated to 150 ° C under microwave irradiation for 1 hour. The crude product is purified by reverse phase flash chromatography (C18, using 0 to 40 to 70% gradient of MeCN / containing 10 mM NH4CO2H buffer H2O) and extracted with Et2O and dried in vacuo to give the title compound (29.0 mg, 0.11 mmol, 59%) as a yellow solid.

[0565] Methyl 2-(methoxyimino)-3-(2-nitrobenzyl)-4-oxopentanoate

[0566] Methyl acetylacetonate (1.0g, 6.94mmol), methoxyhydroxylamine hydrochloride (0.58g, 6.94mmol) and molecular sieve (2.5g) are put into the flame-dried round-bottom flask equipped with nitrogen inlet. Add anhydrous DMF (23mL) and cover the round-bottom flask with foil, and at room temperature stir overnight. Dilute the reaction mixture with EtOAc (150mL) and wash the organic phase with water (3 × 50mL) and salt solution (1 × 50mL), use Na SO Dehydration, filter and vacuum concentrate to obtain the title compound (1.07g, 6.16mmol, 89%) in red liquid form.

[0567] 1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0568] Methyl 2-(methoxyimino)-3-(2-nitrobenzyl)-4-oxopentanoate (4.00 g, 23.1 mmol) was dissolved in MeOH (115 mL). 4-bromo-2-hydrazino-5-(isopropylthio)thiazole (6.19 g, 23.1 mmol) was added and then 12N HCl (7.70 mL, 92.4 mmol) was added dropwise to the reaction mixture. The reaction mixture was heated to reflux overnight. The crude product was concentrated in vacuo and purified by flash chromatography on silica gel (dry filling) using a solution of EtOAc in hexane (5 to 20% gradient) and flash chromatography on silica gel (dry filling) using a solution of DCM in hexane (10 to 50% gradient) to purify again and obtain the title compound (1.89 g, 5.02 mmol, 22%) as an orange oil.

[0569] 4-Bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0570] A 2M solution of bromine (3.32 mL, 6.64 mmol) in MeCN was added dropwise to a solution of 1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (500 mg, 1.33 mmol) in DCM / MeCN solution (7 mL, 1: 1). The reaction was stirred at room temperature for 5 hours. Na2SO3 solution was added and the aqueous layer was extracted with Et2O (3×). The combined organic layers were washed with brine, dehydrated over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel using a solution of DCM in hexane (20%) to give the title compound (421 mg, 0.93 mmol, 70%) as an orange solid.

[0571] 1-(4-(4-chloro-2-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl Methyl 1H-pyrazole-5-carboxylate

[0572] Degassed THF (2 mL) was added to a mixture of methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (100 mg, 0.220 mmol), 2-(4-chloro-2-(oxetan-3-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (137 mg, 0.220 mmol, 50% w / w), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (11 mg, 0.022 mmol), and potassium carbonate (152 mg, 1.10 mmol). The reaction mixture was heated at 90° C. for 18 hours. The mixture was mixed with silica and the solvent was evaporated to give the title compound (17 mg, 0.035 mmol, 16%) as a light yellow oil by flash chromatography on silica gel using ethyl acetate in hexanes (2 to 40%).

[0573] 1-(4-(4-chloro-2-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl 1H-pyrazole-5-carboxylic acid

[0574] Methyl 1-(4-(4-chloro-2-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (17 mg, 0.035 mmol) was diluted in a 1:1 solution of THF and MeOH (0.35 mL). 1 M NaOH (0.070 mL, 0.070 mmol) was added and the reaction was stirred at room temperature for 18 hours. 1 N HCl (1 mL) was added, followed by water (5 mL) and the mixture was extracted with EtOAc (3×5 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by semi-preparative HPLC-MS (column X-Bridge 30×50) using a solution of MeCN in water (containing 10 mM ammonium formate) (50 to 70%). The product was lyophilized to give the title compound (2 mg, 0.004 mmol, 12%) as a light yellow solid.

[0575] 1 H NMR (500MHz, DMSO) δ7.34(d,J=8.2Hz,1H),7.14(dd,J=8.1,1.9Hz,1H),6.83(d,J=1.9Hz,1H),6.64(s,1H),5.38–5.31(m,1H),4. 89(t,J=6.8Hz,2H),4.49(dd,J=7.3,5.1Hz,2H),3.21(d,J=6.6Hz,1H),2.25(s,3H),1.14(d,J=6.7Hz,6H); MS(m / z):466.1[M+1] + .

[0576] Compound 2: 1-(4-(4-chloro-3-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0577] 3-(5-bromo-2-chlorophenoxy)oxetane

[0578] Diisopropyl diazoformate (292 mg, 1.45 mmol) was added to a solution of 5-bromo-2-chlorophenol (200 mg, 0.964 mmol), oxetane-3-ol (89 mg, 1.2 mmol) and triphenylphosphine (379 mg, 1.45 mmol) in THF (4.2 mL). The reaction mixture was stirred at room temperature for 18 hours. Ethyl acetate was added and the mixture was washed with 1N NaOH (3 ×). The organic layer was dehydrated with sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using a solution of ethyl acetate in hexane (10%) to give the title compound (222 mg, 0.842 mmol, 87%).

[0579] 2-(4-chloro-3-(oxetan-3-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Cyclopentane

[0580] Degassed dioxane was added to a mixture of 3-(5-bromo-2-chlorophenoxy)oxetane (100 mg, 0.379 mmol), pinacol diborane (116 mg, 0.455 mmol), [1,1'-bis(diphenylphosphino)ferrocene] palladium(II) dichloride (28 mg, 0.038 mmol) and potassium acetate (112 mg, 1.14 mmol). The reaction mixture was heated at 85°C for 18 hours. The mixture was filtered over celite and the pad was washed with dioxane. The filtrate was evaporated to give the title compound (238 mg, 202%, 50% w / w, determined by NMR analysis) which was used as is.

[0581] 1-(4-(4-chloro-3-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl Methyl 1H-pyrazole-5-carboxylate

[0582] Degassed THF (2 mL) was added to a mixture of methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (100 mg, 0.220 mmol), 2-(4-chloro-3-(oxetan-3-yloxy)phenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (137 mg, 0.220 mmol, 50% w / w), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (11 mg, 0.022 mmol), and potassium carbonate (152 mg, 1.10 mmol) prepared in Example 27. The reaction mixture was heated at 90° C. for 18 hours. The mixture was mixed with silica and the solvent was evaporated to give the title compound (6.2 mg, 0.013 mmol, 66%) as a light orange oil by flash chromatography on silica gel using ethyl acetate in hexanes (2 to 40%).

[0583] 1-(4-(4-chloro-3-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl 1H-pyrazole-5-carboxylic acid

[0584] Methyl 1-(4-(4-chloro-3-(oxetan-3-yloxy)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (6.2 mg, 0.013 mmol) was diluted in a 1:1 solution of THF and MeOH (0.13 mL). 1 M NaOH (0.026 mL, 0.026 mmol) was added and the reaction was stirred at room temperature for 18 hours. 1 N HCl (1 mL) was added, followed by water (5 mL) and the mixture was extracted with EtOAc (3×5 mL). The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by semi-preparative HPLC-MS (column X-Bridge 30×50) using a solution of MeCN in water (containing 10 mM ammonium formate) (50 to 70%). The product was lyophilized to give the title compound (1.2 mg, 0.003 mmol, 20%) as a light yellow solid.

[0585] 1 H NMR (500MHz, DMSO) δ7.71–7.66(m,1H),7.57(d,J=8.3Hz,1H),7.36(d,J=1.8Hz,1H),6.71(s,1H),5.43–5.35(m,1H),5.04(t, J=6.8Hz,2H),4.62(dd,J=7.9,4.9Hz,2H),3.33(sept,J=6.7Hz,1H),2.27(s,3H),1.22(d,J=6.7Hz,6H); MS(m / z):466.1[M+1] +.

[0586] Compound 3: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0587] 4-Bromo-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiazole-2-yl 3-Methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0588] At room temperature, 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (100 mg, 0.220 mmol), (4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)boronic acid (38.1 mg, 0.187 mmol) and KCO (152 mg, 1.10 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a THF solution (2 mL) and the solution was then added to the microwave vial, followed by the addition of the catalyst Pd(dtbpf)Cl (14.3 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 90° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (0 to 50% gradient) to give the title compound (57.8 mg, 0.108 mmol, 49%) as a brown oil.

[0589] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiol Methyl 2-oxazol-2-yl-3-methyl-1H-pyrazole-5-carboxylate

[0590] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (57.8 mg, 0.108 mmol), 3-fluorophenylboronic acid (18.2 mg, 0.130 mmol) and Na2CO3 (57.3 mg, 0.541 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (12.5 mg, 0.011 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (5 to 40% gradient) to give the title compound (25.4 mg, 0.046 mmol, 43%) as a yellow solid.

[0591] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiophene oxazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0592] In a 25 mL round-bottom flask, 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (25.4 mg, 0.046 mmol) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (92.4 μL, 0.092 mmol) was added and the reaction was stirred at room temperature for 16 hours. The reaction mixture was acidified with 1 M HCl and the crude product was concentrated in vacuo. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 40-60% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 11 minutes) to give the title compound (3.99 mg, 0.007 mmol, 16%) as a white solid after lyophilization.

[0593] 1 H NMR(500MHz,DMSO)δ8.26(d,J=8.2Hz,2H),8.06(d,J=8.5Hz,2H),7.52–7.33(m,3H),7.12(s, 2H),3.37–3.24(m,1H),2.61(s,3H),2.30(s,3H),1.24(d,J=6.7Hz,6H); MS(m / z):536.1[M+1] + .

[0594] Compound 4: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0595] 4-Bromo-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H- Methyl pyrazole-5-carboxylate

[0596] At room temperature, 4- bromo -1- (4- bromo -5- (isopropylthio) thiazol-2-yl) -3- methyl -1H- pyrazole -5- carboxylic acid methyl ester (100 mg, 0.220 mmol), 4,4,5,5- tetramethyl -2- (4- methylcyclohex -1- ene -1- base) -1,3,2- dioxaborolane (41.5 mg, 0.187 mmol) and K CO (152 mg, 1.10 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream, and nitrogen and vacuum cycles (2 ×) were performed. Nitrogen was bubbled through a THF solution (2 mL) and the solution was then added to the microwave vial, followed by the addition of catalyst Pd (dtbpf) Cl (14.3 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 90 ° C for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (0 to 10% gradient) to give the title compound (45.6 mg, 0.097 mmol, 44%) as a yellow oil.

[0597] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3- Methyl-1H-pyrazole-5-carboxylate

[0598] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (44.6 mg, 0.085 mmol), 3-fluorophenylboronic acid (14.3 mg, 0.102 mmol) and Na2CO3 (45.2 mg, 0.427 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (9.86 mg, 0.009 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The crude product was purified by flash chromatography on silica gel (wet loading with DCM) using EtOAc in hexanes (1% isocratic elution) to give the title compound (40.0 mg, 0.082 mmol, 97%) as a yellow oil.

[0599] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3- Methyl-1H-pyrazole-5-carboxylic acid

[0600] In a round-bottom flask, 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylcyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (40.0 mg, 0.082 mmol) was diluted with THF / MeOH (2 mL, 1: 1). 1 M NaOH solution (165 μL, 0.165 mmol) was added and the reaction was stirred at room temperature for 16 hours. The reaction mixture was acidified with 1 M HCl and the crude product was concentrated in vacuo. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 60-80% MeCN / NH4CO2H 10 mM, pH 3.8 / flow 45 ml / min / 11 minutes) to give the title compound (2.55 mg, 0.005 mmol, 7%) as a yellow solid after lyophilization.

[0601] 1 H NMR(500MHz,DMSO)δ7.50(dd,J=14.9,7.8Hz,1H),7.35–7.27(m,2H),7.21(s,1H),6.35(s,1H),3.32–3.16(m,1H),2.57(s,1H),2.45–2.35(m,1H) ,2.32(s,1H),2.28(s,3H),1.86–1.74(m,2H),1.67(s,1H),1.33–1.26(m ,1H),1.24(d,J=6.6Hz,6H),0.98(d,J=6.6Hz,3H);MS(m / z):472.1[M+1] + .

[0602] Compound 5: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0603] 4-Bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methylthiophene Methyl 1H-pyrazole-5-carboxylate

[0604] At room temperature, in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (100 mg, 0.220 mmol), 4,4,5,5-tetramethyl-2-(4-(trifluoromethyl)cyclohex-1-en-1-yl)-1,3,2-dioxaborolane (51.6 mg, 0.187 mmol) and KCO (152 mg, 1.10 mmol) were placed and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a THF solution (2 mL) and the solution was then added to the microwave vial, followed by the addition of catalyst Pd(dtbpf)Cl (14.3 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 90° C. for 16 h. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry fill) using EtOAc in hexanes (0 to 10% gradient) to give the title compound (47.4 mg, 0.090 mmol, 41%) as a yellow oil.

[0605] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazole-2-yl 1H-pyrazole-5-carboxylic acid

[0606] At room temperature, 4-bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (47.4 mg, 0.090 mmol), 3-fluorophenylboronic acid (15.2 mg, 0.108 mmol) and Na2CO3 (47.9 mg, 0.452 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (10.4 mg, 0.009 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The reaction mixture was diluted with EtOAc and transferred to an extraction funnel. The layers were separated and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dehydrated over Na2SO4, filtered and concentrated in vacuo. THF / MeOH (2 mL, 1: 1) and 1 M NaOH (181 μL, 0.181 mmol) were added and the reaction was stirred at room temperature for 16 hours. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 55-75% MeCN / NH4CO2H 10 mM, pH 3.8 / flow 45 ml / min / 11 minutes) to give the title compound (12.8 mg, 0.024 mmol, 27%) as a yellow solid after lyophilization.

[0607] 1 H NMR (500MHz, DMSO) δ7.53–7.42(m,1H),7.30–7.23(m,2H),7.22–7.15(m,1H),6.41(s,1H),3.32–3.22(m,1H),2.74–2.60(m,1H),2.50 –2.33(m,3H),2.26(s,3H),2.23–2.15(m,1H),2.07–1.97(m,1H),1.57–1.46(m,1H),1.23(dd,J=6.7,3.4Hz,6H); MS(m / z):526.3[M+1] + .

[0608] Compound 6: 1-(4-(4,4-dimethylcyclohex-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0609] 4-Bromo-1-(4-(4,4-dimethylcyclohex-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl- 1H-pyrazole-5-carboxylic acid methyl ester

[0610] At room temperature, 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (100 mg, 0.220 mmol), 2-(4,4-dimethylcyclohex-2-ene-1-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (52 mg, 0.22 mmol), K2CO3 (152 mg, 1.10 mmol) and THF (2 mL) prepared as described above for compound 1 were placed in a 5 mL glass microwave vial equipped with a magnetic stirring bar and a nitrogen stream. Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of catalyst Pd(dtbpf)Cl2 (11 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 90°C for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using a 0 to 10% gradient of EtOAc / hexanes to give the title compound (57 mg, 0.12 mmol, 54%) as a yellow oil. MS (m / z): 484.0 [M+1] + .

[0611] 1-(4-(4,4-dimethylcyclohex-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorobenzene 1H-pyrazole-5-carboxylic acid

[0612] At room temperature, methyl 4-bromo-1-(4-(4,4-dimethylcyclohex-1-en-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (53 mg, 0.11 mmol), (3-fluorophenyl)boronic acid (18 mg, 0.13 mmol) and Na2CO3 (58 mg, 0.55 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (13 mg, 0.011 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (13 mg, 0.55 mmol) was added to the reaction mixture and stirred at 110°C for 15 minutes under microwave irradiation. The solvent was evaporated under vacuum and the product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 70-90% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (13 mg, 0.027 mmol, 24%) as a yellow solid after lyophilization.

[0613] 1H NMR (500MHz, DMSO) δ7.52–7.44(m,1H),7.35-7.27(m,2H),7.23-7.15(m,1H),6.33-6.27(m,1H),3.28-3.19(m,1 H),2.48-2.42(m,2H),2.28(s,3H),2.00-1.95(m,2H),1.43(t,J=6.4Hz,2H),1.23(d,J=6.7Hz,6H),0.94(s,6H). MS(m / z):486.1[M+1] + .

[0614] Compound 7: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0615] 4-Bromo-1-(5-(isopropylthio)-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)thiazol-2-yl)-3- Methyl-1H-pyrazole-5-carboxylate

[0616] At room temperature, 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (100 mg, 0.220 mmol), 4,4,5,5-tetramethyl-2-(1,4-dioxaspiro[4.5]dec-6-ene-8-yl)-1,3,2-dioxaborolane (59 mg, 0.22 mmol), K2CO3 (152 mg, 1.10 mmol) and THF (2 mL) prepared as described above for compound 1 were placed in a 5 mL glass microwave vial equipped with a magnetic stirring bar and a nitrogen flow. Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of catalyst Pd(dtbpf)Cl2 (11 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 90°C for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using a 0 to 20% gradient of EtOAc / hexanes to give the title compound (55 mg, 0.11 mmol, 49%) as a yellow oil. MS (m / z): 514.0 [M+1] + .

[0617] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)thiazole- 2-amino)-3-methyl-1H-pyrazole-5-carboxylic acid

[0618] At room temperature, 4-bromo-1-(5-(isopropylthio)-4-(1,4-dioxaspiro[4.5]dec-7-en-8-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (53 mg, 0.10 mmol), (3-fluorophenyl)boronic acid (17 mg, 0.12 mmol) and Na2CO3 (54 mg, 0.51 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and the solution was then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (12 mg, 0.010 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The reaction mixture was diluted with EtOAc, washed with water and brine. Dehydrated with MgSO4, filtered and concentrated in vacuo. The reaction mixture was dissolved in a 1 / 1 mixture of THF / MeOH (2 mL) and treated with 1N NaOH (102 μ L, 0.204 mmol). After 1 hour, 1N NaOH (102 μ L, 0.204 mmol) was added and stirred for 16 hours. The solvent was evaporated under vacuum and semi-preparative HPLC-MS (column X-Bridge 30 × 50, eluted with 55-75% MeCN / NH4CO2H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) was used to purify the product, and the title compound (14 mg, 0.027 mmol, 26%) was obtained as a yellow solid after lyophilization.

[0619] 1 H NMR (500MHz, DMSO) δ7.53-7.45(m,1H),7.34-7.27(m,2H),7.25-7.16(m,1H),6.34-6.28(m,1H),3.92(s,4H),3. 32–3.19(m,1H),2.67-2.60(m,2H),2.43–2.36(m,2H),2.28(s,3H),1.77(t,J=6.5Hz,2H),1.25(d,J=6.7Hz,6H). MS(m / z):516.1[M+1] + .

[0620] Compound 8: 1-(4-(4-chloro-3-(morpholine-4-carbonyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0621] 4-Bromo-1-(4-(4-chloro-3-(morpholine-4-carbonyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl- 1H-pyrazole-5-carboxylic acid methyl ester

[0622] Degassed THF (2 mL) was added to a mixture of methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (75.0 mg, 0.165 mmol), (4-chloro-3-(morpholine-4-carbonyl)phenyl)boronic acid (44 mg, 0.16 mmol), [1,1′-bis(di-tert-butylphosphino)ferrocene]dichloropalladium(II) (8.2 mg, 0.016 mmol), and potassium carbonate (114 mg, 0.824 mmol), prepared as described above for compound 1. The reaction mixture was heated at 90° C. for 18 hours. Water was added and the mixture was extracted with ethyl acetate (2×). The combined organic layers were dried over sodium sulfate, filtered, and evaporated. The crude product was purified by flash chromatography on silica gel using ethyl acetate in hexanes (2 to 10%) to give the title compound (47 mg, 0.078 mmol, 47%) as a light orange oil.

[0623] 1-(4-(4-chloro-3-(morpholine-4-carbonyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl) 1H-pyrazole-5-carboxylic acid

[0624] A solution of methyl 4-bromo-1-(4-(4-chloro-3-(morpholine-4-carbonyl)phenyl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (47 mg, 0.078 mmol), (3-fluorophenyl)boronic acid (13 mg, 0.094 mmol), Pd(PPh) (9 mg, 0.008 mmol), and NaCO (41 mg, 0.39 mmol) in degassed 1,4-dioxane and H2O (4:1, 1.6 mL) was heated at 85°C for 18 hours. LiOH hydrate (16 mg, 0.39 mmol) was added, and the reaction was heated at 95°C under microwave irradiation for 45 minutes. 1N HCl (1 mL) was added, followed by water (5 mL), and the mixture was extracted with EtOAc (3 x 5 mL). The combined organic layers were dried over sodium sulfate, filtered, and evaporated under reduced pressure. The crude product was purified by semi-preparative HPLC-MS (column X-Bridge 30×50) using a solution of MeCN in water (containing 10 mM ammonium formate) (45 to 65%). The product was lyophilized to afford the title compound (2 mg, 0.003 mmol, 4%) as an off-white solid.

[0625] 1H NMR (500 MHz, DMSO) δ 8.06 (d, J = 8.1 Hz, 1H), 7.99 (s, 1H), 7.65 (d, J = 8.5 Hz, 1H), 7.52–7.44 (m, 1H), 7.41–7.31 (m, 2H), 7.22–7.13 (m, 1H), 3.75–3.62 (m, 4H), 3.61–3.51 (m, 2H), 3.33 (1H, below water signal), 3.22–3.15 (m, 2H), 2.30 (s, 3H), 1.22 (d, J = 5.8 Hz, 6H); MS (m / z): 552.1 [M+1] + .

[0626] Compound 9: 4-(3,4-dichlorophenyl)-2-(4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazol-1-yl)-5-(isopropylthio)thiazole

[0627] 1-(4-(3,4-Dichlorophenyl)-5-(isopropylthio)thiazol-2-yl)-4-(2,6-dimethylpyridin-4-yl)-3-methyl-1H-pyrazole-5-carboxylic acid (38.0 mg, 0.071 mmol), copper chromite (12.0 mg, 0.085 mmol) and quinoline (0.6 ml) were heated under microwave irradiation at 230° C. for 15 minutes. The crude product was purified by reverse phase chromatography on a C-18 column using MeCN in water (containing 10 mM NH4CO2H) (55 to 80 to 100%) to give the title compound (24.7 mg, 0.050 mmol, 71%) as a beige solid after lyophilization.

[0628] 1 H NMR(500MHz,DMSO)δ9.05(s,1H),8.32(d,J=2.0Hz,1H),8.14(dd,J=8.4,2.1Hz,1H),7.79(d,J=8.5Hz,1H),7.34 (s,2H),3.38–3.32(m,J=13.4,6.7Hz,1H),3.29(s,3H),2.47(s,6H),1.23(d,J=6.7Hz,6H);MS(m / z):489.2[M+1] + .

[0629] Compound 10: 2-(4-(3-fluorophenyl)-3,5-dimethyl-1H-pyrazol-1-yl)-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0630] 4-iodo-3,5-dimethyl-1H-pyrazole

[0631] 3,5-Dimethyl-1H-pyrazole (100 mg, 1.04 mmol) was dissolved in 1.0 mL of TFA. N-iodosuccinimide (234 mg, 1.04 mmol) was added as a whole. The reaction was stirred at room temperature for 1 hour. LCMS showed complete reaction. Water and EtOAc were added and the phases were separated. The organic phase was washed with saturated aqueous sodium sulfite solution and dehydrated with sodium sulfate, filtered and concentrated. 230 mg of crude product (1.04 mmol, 99%) was obtained as a white solid.

[0632] 4-(3-Fluorophenyl)-3,5-dimethyl-1H-pyrazole

[0633] 4-iodo-3,5-dimethyl-1H-pyrazole (231 mg, 1.04 mmol), boric acid (281 mg, 2.01 mmol), sodium carbonate (551 mg, 5.20 mmol), dioxane (5.2 ml) and water (1.3 ml) were placed in a screw-cap tube. The mixture was degassed for 10 minutes and Pd(PPh 3 ) 4 (60 mg, 0.05 mmol) was added. The tube was sealed and the mixture was heated to 85° C. After 1 hour, there was no reaction. After 16 hours, the ratio of iodopyrazole: product was 1:6. The mixture was heated to 110° C. After 6 hours, no iodopyrazole starting material remained, so the mixture was cooled to room temperature and diluted with water and EtOAc. The phases were separated and the aqueous phase was washed with brine. SiO 2 was added to the organic phase and concentrated to dryness. The crude product on silica was purified using a hexane / EtOAc gradient on Isco. 144 mg (0.76 mmol, 73%) of the product were obtained as a colorless oil.

[0634] 2-Thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone

[0635] Potassium thiocyanate (9.55 g, 98.3 mmol) was added to a stirred solution of 2-bromo-1-(4-(trifluoromethyl)phenyl)ethanone (25.0 g, 93.6 mmol) in MeCN (178 mL) at room temperature. The reaction mixture was heated to reflux (90° C.) for 2 hours, then cooled to room temperature and diluted with water and EtOAc. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over MgSO , filtered, and concentrated in vacuo to afford the title compound (23.3 g, 94.9 mmol, 97%), which was used without further purification.

[0636] 2-Chloro-4-(4-(trifluoromethyl)phenyl)thiazole

[0637] A mixture of 2-thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone (23.3 g, 94.9 mmol) and 4M HCl in dioxane (142 mL, 569 mmol) in dioxane (95 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo and the residue was diluted with saturated aqueous NaHCO₃ and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford the title compound (25.0 g, 94.8 mmol, 100%) as a brown solid.

[0638] 2-Chloro-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0639] At -78 ° C, a 2.5M solution of n-BuLi / hexane (18.8mL, 40.3mmol) was added to a THF solution (107mL) of 2-chloro-4- (4- (trifluoromethyl) phenyl) thiazole (10.0g, 32.3mmol). The reaction mixture was stirred at the same temperature for 30 minutes. Diisopropyl disulfide (10.3mL, 64.5mmol) was added to the reactant and stirred at the same temperature for 2 hours. Water was added to quench the reaction and then Et2O was added. The reaction mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with Et2O (2×). The combined organic layers were dehydrated with Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry filling) using a solution of EtOAc in hexane (0 to 1% gradient) to give the title compound (3.05g, 9.03mmol, 28%) as a yellow oil.

[0640] 2-(4-(3-Fluorophenyl)-3,5-dimethyl-1H-pyrazol-1-yl)-5-(isopropylthio)-4-(4-(trifluoromethyl) 1-(2-amino)phenyl)thiazole

[0641] 4-(3-fluorophenyl)-3,5-dimethyl-1H-pyrazole (140 mg, 1.0 mmol), the thiazole prepared above (372 mg, 1.1 mmol), K2CO3 (690 mg, 5.0 mmol) and DMSO (3.3 ml) were placed in a 10 mL microwave vial. Nitrogen was bubbled through DMSO for 10 minutes. CuI (57 mg, 0.30 mmol) was then added. The resulting solution was capped and heated at 100 ° C for 3 hours using a microwave. LCMS showed 40% conversion (pyrazole: product ratio) and complete reaction. The mixture was heated in an oil bath for 3 hours. LCMS showed 74% conversion. Heating was continued for 16 hours. LCMS showed complete conversion. The mixture was diluted with EtOAc and water, the phases were separated and the organic phase was washed 3 times with water, followed by brine washing. Silicon dioxide was added to the organic phase and concentrated to dryness. The crude product on SiO2 was purified using a hexane / 10% DCM gradient on Isco. 151 mg (0.307 mmol, 31%) of a yellow oil was obtained. This mixture was repurified on a reverse phase Isco using a C18 column eluting with a 50-100% gradient of MeCN / water (10 mM ammonium formate, pH 3.8). The product-containing fractions were concentrated to remove most of the acetonitrile, water was added, and the flask was frozen and lyophilized. The product was obtained as a light yellow solid (99 mg, 0.201 mmol, 20% yield).

[0642] 1 H NMR (500MHz, DMSO) δ8.24(d,J=8.2Hz,2H),7.87(d,J=8.4Hz,2H),7.53(dd,J=14.2,7.9Hz,1H),7.29– 7.18(m,3H),3.39–3.33(m,1H),2.69(s,3H),2.25(s,3H),1.23(d,J=6.7Hz,6H); MS(m / z):492.3[M+1] + .

[0643] Compound 11: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0644] 4-Bromo-1-(5-(isopropylthio)-4-(piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid Methyl ester

[0645] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (100 mg, 0.220 mmol), XantPhos (12.7 mg, 0.022 mmol), and CsCO (358 mg, 1.10 mmol), and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane (2 mL) and piperidine (21.7 uL, 0.220 mmol), which was then added to the microwave vial, followed by the addition of the catalyst, RuPhos Palladacycle (17.9 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (1% isocratic elution) to give the title compound (41.0 mg, 0.089 mmol, 41%) as a yellow oil.

[0646] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrrolidone oxazole-5-carboxylic acid

[0647] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(5-(isopropylthio)-4-(piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (41.0 mg, 0.089 mmol), 3-fluorophenylboronic acid (15.0 mg, 0.108 mmol) and Na2CO3 (47.3 mg, 0.446 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (10.3 mg, 0.009 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (18.7 mg, 0.446 mmol) is added into the reaction mixture and stirred at 120 ° C for 10 minutes under microwave irradiation. The reaction mixture is diluted with EtOAc and 0.1M HCl. The aqueous layer is extracted with EtOAc (2 ×) and the combined organic layer is washed with brine, and the mixture is dehydrated, filtered and concentrated in vacuo. The product is purified using semi-preparative HPLC-MS (column X-Bridge 30 × 50, eluted with 55-75% MeCN / NH4CO2H 10mM, pH 3.8 / flow 45 ml / min / 11 minutes) to give the title compound (3.24 mg, 0.007 mmol, 8%) as a yellow solid after lyophilization.

[0648] 1 H NMR(500MHz,DMSO)δ7.55–7.40(m,1H),7.41–7.24(m,2H),7.23–7.05(m,1H),3.59–3.49(m,4 H),3.18–3.06(m,1H),2.27(s,3H),1.55(s,6H),1.23(d,J=6.7Hz,6H); MS(m / z):461.2[M+1] + .

[0649] Compound 12: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0650] 4-Bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3-methyl-1H- Methyl pyrazole-5-carboxylate

[0651] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (100 mg, 0.220 mmol), 4-(trifluoromethyl)piperidine (41.7 mg, 0.220 mmol), XantPhos (12.7 mg, 0.022 mmol), and CsCO (358 mg, 1.10 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through dioxane (2 mL) and then added to the microwave vial, followed by the addition of the catalyst RuPhos Palladacycle (17.9 mg, 0.022 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (1% isocratic elution) to give the title compound (52.0 mg, 0.099 mmol, 45%) as a yellow oil.

[0652] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3- Methyl-1H-pyrazole-5-carboxylic acid

[0653] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (52.0 mg, 0.099 mmol), 3-fluorophenylboronic acid (16.6 mg, 0.118 mmol) and Na2CO3 (52.3 mg, 0.493 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (11.4 mg, 0.010 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (42.0 mg, 0.493 mmol) is added into the reaction mixture and stirred at 120 ° C for 10 minutes under microwave irradiation. The reaction mixture is diluted with EtOAc and 0.1 M HCl. The aqueous layer is extracted with EtOAc (2 ×) and the combined organic layer is washed with brine, and the product is dehydrated, filtered and concentrated in vacuo. The product is purified using semi-preparative HPLC-MS (column X-Bridge 30 × 50, eluted with 55-75% MeCN / NH4CO2H 10 mM, pH 3.8 / flow 45 ml / min / 11 minutes) to give the title compound (3.41 mg, 0.007 mmol, 7%) as a yellow solid after lyophilization.

[0654] 1 H NMR (500MHz, DMSO) δ7.52–7.43(m,1H),7.36–7.26(m,2H),7.19(t,J=7.6Hz,1H),4.38(d,J=12.8Hz,2H),3.19–3.07(m,1H),2.95–2.86( m,2H),2.58–2.51(m,1H),2.28(s,3H),1.80(d,J=10.7Hz,2H),1.49(qd,J=12.6,4.1Hz,2H),1.24(d,J=6.7Hz,6H); MS(m / z):529.1[M+1] + .

[0655] Compound 13: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy-1H-pyrazole-5-carboxylic acid

[0656] 2-Thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone

[0657] Potassium thiocyanate (9.55 g, 98.3 mmol) was added to a stirred solution of 2-bromo-1-(4-(trifluoromethyl)phenyl)ethanone (25.0 g, 93.6 mmol) in MeCN (178 mL) at room temperature. The reaction mixture was heated to reflux (90° C.) for 2 hours, then cooled to room temperature and diluted with water and EtOAc. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over MgSO , filtered, and concentrated in vacuo to afford the title compound (23.3 g, 94.9 mmol, 97%), which was used without further purification.

[0658] 2-Chloro-4-(4-(trifluoromethyl)phenyl)thiazole

[0659] A mixture of 2-thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone (23.3 g, 94.9 mmol) and 4M HCl in dioxane (142 mL, 569 mmol) in dioxane (95 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo and the residue was diluted with saturated aqueous NaHCO₃ and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford the title compound (25.0 g, 94.8 mmol, 100%) as a brown solid.

[0660] 2-Chloro-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0661] At -78 ° C, a 2.5M solution of n-BuLi / hexane (18.8mL, 40.3mmol) was added to a THF solution (107mL) of 2-chloro-4- (4- (trifluoromethyl) phenyl) thiazole (10.0g, 32.3mmol). The reaction mixture was stirred at the same temperature for 30 minutes. Diisopropyl disulfide (10.3mL, 64.5mmol) was added to the reactant and stirred at the same temperature for 2 hours. Water was added to quench the reaction and then Et2O was added. The reaction mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with Et2O (2×). The combined organic layers were dehydrated with Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry filling) using a solution of EtOAc in hexane (0 to 1% gradient) to give the title compound (3.05g, 9.03mmol, 28%) as a yellow oil.

[0662] 2-Hydrazino-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0663] In a round-bottom flask, DIPEA (3.2 mL, 18.2 mmol) was added to a solution of hydrazine hydrochloride (1.2 g, 18.2 mmol) and 2-chloro-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole (3.1 g, 9.1 mmol) in NMP (18 mL). The flask was heated to 135 ° C in an oil bath for 2 hours. The reaction mixture was diluted with water and extracted with Et2O. The combined organic layers were washed with brine (3×), dehydrated over Na2SO4, filtered and concentrated in vacuo. The title compound (2.85 g, 8.55 mmol, 95%) was thus obtained as a blue oil.

[0664] 3-Hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid Methyl ester

[0665] A solution of 2-hydrazino-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole (1.9 g, 5.76 mmol) in toluene (5 mL) was slowly added to a solution of dimethyl 2,5-dioxohex-3-ynedioate (900 mg, 6.33 mmol) in toluene (3 mL) and AcOH (4 mL) at 0°C. The reaction was stirred at room temperature for 1 hour and refluxed for 4 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (5 to 30% gradient) to give the title compound (714 mg, 1.61 mmol, 28%) as a yellow oil.

[0666] 1-(5-(Isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy-1H-pyrazole-5-yl Methyl formate

[0667] At room temperature, a round-bottom flask equipped with a magnetic stir bar and a stream of nitrogen was placed in THF (7 mL) with ADDP (171 mg, 0.677 mmol) and tributylphosphine (205 mg, 1.02 mmol), followed by the addition of methyl 3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (150 mg, 0.338 mmol) and MeOH (20.6 μL, 0.507 mmol). The reaction mixture was heated to 80° C. for 3 hours. The reaction mixture was concentrated in vacuo and dissolved in Et2O to filter out tributylphosphine oxide. The filtrate was concentrated in vacuo and the crude product was purified by flash chromatography on silica gel (dry fill) using EtOAc in hexanes (10 to 30% gradient) to give the title compound (115 mg, 0.251 mmol, 74%) as a yellow oil.

[0668] 4-Bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0669] A 2M solution of bromine in acetonitrile (0.45 mL, 0.900 mmol) was added to a solution of methyl 1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy-1H-pyrazole-5-carboxylate (137 mg, 0.300 mmol) in MeCN / DCM (4 mL, 1:1 mL). The reaction was stirred at room temperature for 3 hours. Saturated aqueous Na2SO3 was added and the reaction mixture was extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel (dry packing) using a solution of EtOAc in hexane (2 to 10%) to give the title compound (98.0 mg, 0.183 mmol, 61%) as a yellow oil.

[0670] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy 1H-pyrazole-5-carboxylic acid

[0671] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methoxy-1H-pyrazole-5-carboxylate (98.0 mg, 0.183 mmol), 3-fluorophenylboronic acid (60.7 mg, 0.219 mmol) and Na2CO3 (96.8 mg, 0.914 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (21.1 mg, 0.018 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (38.3 mg, 0.914 mmol) is added into the reaction mixture and stirred at 120 ° C for 10 minutes under microwave irradiation. The reaction mixture is diluted with EtOAc and 0.1M HCl. The aqueous layer is extracted with EtOAc (2 ×) and the combined organic layer is washed with brine, and the organic layer is dehydrated, filtered and concentrated in vacuo. The product is purified using semi-preparative HPLC-MS (column X-Bridge 30 × 50, eluted with 40-60% MeCN / NH4CO2H 10mM, pH 3.8 / flow 45 ml / min / 11 minutes) to give the title compound (2.95 mg, 0.005 mmol, 3%) as a yellow solid after lyophilization.

[0672] 1H NMR(500MHz,MeOD)δ8.31(d,J=8.1Hz,2H),7.76(d,J=8.3Hz,2H),7.60–7.55(m,2H),7.40–7.34(m, 1H),7.02–6.97(m,1H),3.95(s,3H),3.29–3.21(m,1H),1.25(d,J=6.7Hz,6H);MS(m / z):538.2[M+1] + .

[0673] Compound 14: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-morpholinothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0674] Methyl 4-bromo-1-(5-(isopropylthio)-4-morpholinothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate

[0675] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (300 mg, 0.659 mmol), XantPhos (38.1 mg, 0.066 mmol), and CsCO (1.07 g, 3.30 mmol), and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane (3 mL) and morpholine (57.4 μL, 0.659 mmol) and then added to the microwave vial, followed by the addition of the catalyst RuPhos Palladacycle (53.8 mg, 0.066 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (5 to 20% gradient) to give the title compound (108 mg, 0.234 mmol, 36%) as a yellow oil.

[0676] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-morpholinothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate acid

[0677] At room temperature, 4-bromo-1-(5-(isopropylthio)-4-morpholinothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (108 mg, 0.234 mmol), 3-fluorophenylboronic acid (39.3 mg, 0.281 mmol) and Na2CO3 (124 mg, 1.17 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (27.0 mg, 0.023 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (49.1 mg, 1.17 mmol) was added to the reaction mixture and stirred at 110°C for 15 minutes under microwave irradiation. The reaction mixture was diluted with EtOAc and 0.1 M HCl. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated in vacuo. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 30-50% MeCN / NH4CO2H 10 mM, pH 3.8 / flow rate 45 ml / min / 11 minutes) to give the title compound (18.0 mg, 0.039 mmol, 16%) as a yellow solid after lyophilization.

[0678] 1 H NMR(500MHz,DMSO)δ7.46(dd,J=14.4,7.6Hz,1H),7.39–7.29(m,2H),3.70–3.63(m,4H),3.58–3.51 (m,4H),3.16–3.07(m,J=13.4,6.7Hz,1H),2.27(s,3H),1.24(d,J=6.7Hz,6H);MS(m / z):463.2[M+1] + .

[0679] Compound 15: 4-(3-Fluorophenyl)-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0680] 2-Thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone

[0681] Potassium thiocyanate (9.55 g, 98.3 mmol) was added to a stirred solution of 2-bromo-1-(4-(trifluoromethyl)phenyl)ethanone (25.0 g, 93.6 mmol) in MeCN (178 mL) at room temperature. The reaction mixture was heated to reflux (90° C.) for 2 hours, then cooled to room temperature and diluted with water and EtOAc. The aqueous layer was extracted with EtOAc (3×). The combined organic layers were washed with brine, dried over MgSO , filtered, and concentrated in vacuo to afford the title compound (23.3 g, 94.9 mmol, 97%), which was used without further purification.

[0682] 2-Chloro-4-(4-(trifluoromethyl)phenyl)thiazole

[0683] A mixture of 2-thiocyanato-1-(4-(trifluoromethyl)phenyl)ethanone (23.3 g, 94.9 mmol) and 4M HCl in dioxane (142 mL, 569 mmol) in dioxane (95 mL) was stirred at room temperature for 16 hours. The reaction mixture was concentrated in vacuo and the residue was diluted with saturated aqueous NaHCO₃ and extracted with EtOAc (2×). The combined organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated in vacuo to afford the title compound (25.0 g, 94.8 mmol, 100%) as a brown solid.

[0684] 2-Chloro-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0685] At -78 ° C, a 2.5M solution of n-BuLi / hexane (18.8mL, 40.3mmol) was added to a THF solution (107mL) of 2-chloro-4- (4- (trifluoromethyl) phenyl) thiazole (10.0g, 32.3mmol). The reaction mixture was stirred at the same temperature for 30 minutes. Diisopropyl disulfide (10.3mL, 64.5mmol) was added to the reactant and stirred at the same temperature for 2 hours. Water was added to quench the reaction and then Et2O was added. The reaction mixture was transferred to a separatory funnel and the layers were separated. The aqueous layer was extracted with Et2O (2×). The combined organic layers were dehydrated with Na2SO4 and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry filling) using a solution of EtOAc in hexane (0 to 1% gradient) to give the title compound (3.05g, 9.03mmol, 28%) as a yellow oil.

[0686] 2-Hydrazino-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole

[0687] In a round-bottom flask, diisopropylethylamine (3.2 mL, 18.2 mmol) was added to a solution of hydrazine hydrochloride (1.2 g, 18.2 mmol) and 2-chloro-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole (3.1 g, 9.1 mmol) in N-methylpyrrolidine ("NMP") (18 mL). The flask was heated to 135° C. in an oil bath for 2 hours. The reaction mixture was diluted with water and extracted with Et2O. The combined organic layers were washed with brine (3×), dried over Na2SO4, filtered, and concentrated in vacuo. This gave the title compound (2.85 g, 8.55 mmol, 95%) as a blue oil.

[0688] 3-Hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid Methyl ester

[0689] A solution of 2-hydrazino-5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazole (1.9 g, 5.76 mmol) in toluene (5 mL) was slowly added to a solution of dimethyl 2,5-dioxohex-3-ynedioate (900 mg, 6.33 mmol) in toluene (3 mL) and AcOH (4 mL) at 0°C. The reaction was stirred at room temperature for 1 hour and refluxed for 4 hours. The reaction mixture was concentrated in vacuo and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (5 to 30% gradient) to give the title compound (714 mg, 1.61 mmol, 28%) as a yellow oil.

[0690] 4-Bromo-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole- 5-Methyl formate

[0691] N-Bromosuccinimide (188 mg, 1.06 mmol) was added dropwise to a solution of methyl 3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (469 mg, 1.06 mmol) in MeCN / DCM (8 mL, 1:1). The reaction was stirred at room temperature for 5 minutes and then quenched with water and a few drops of Na2S2O3. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were dried over Na2SO4, filtered, and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry fill) using EtOAc in hexanes (0 to 30% gradient) to give the title compound (139 mg, 0.266 mmol, 25%) as a pink solid.

[0692] 3-acetoxy-4-bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H- Methyl pyrazole-5-carboxylate

[0693] Methyl 4-bromo-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (89 mg, 0.17 mmol) was placed in acetic anhydride (5.00 mL), followed by the addition of pyridine (2 drops). The reaction was stirred at room temperature for 1 hour and then evaporated to dryness. The crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (5% isocratic elution) to give the title compound (50 mg, 0.089 mmol, 52%) as a white solid.

[0694] 4-(3-Fluorophenyl)-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)- 1H-pyrazole-5-carboxylic acid methyl ester

[0695] At room temperature, in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, were placed methyl 3-acetoxy-4-bromo-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (30.0 mg, 0.053 mmol), 3-fluorophenylboronic acid (8.93 mg, 0.064 mmol) and KF (10.2 mg, 0.175 mmol), and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through THF (0.5 mL) and the solution was then added to the microwave vial, followed by the addition of catalyst Pd (P t To the mixture was added 4-[4-(4-[4-(4-(4-oxo-3-nitropropene)-1-yl)-1-nitropropene] ...

[0696] 4-(3-Fluorophenyl)-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)- 1H-Pyrazole-5-carboxylic acid

[0697] In a 10 mL round-bottom flask, methyl 4-(3-fluorophenyl)-3-hydroxy-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (4.00 mg, 0.007 mmol) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (15 μL, 0.015 mmol) was added and the reaction was stirred at room temperature overnight. The crude product was purified by reverse phase chromatography on a C-18 column using a solution of MeCN in water (containing 10 mM NH4CO2H) (35 to 65%) to give the title compound (0.548 mg, 0.001 mmol, 14%) as a light green powder after lyophilization.

[0698] 1H NMR(500MHz,MeOD)δ8.33–8.28(m,2H),7.74–7.70(m,2H),7.54–7.48(m,2H),7.29–7.20(m,1H),6.82–6.75(m,1H),4.57(br s,1H),3.25–3.17(m,1H),1.22(d,J=6.7Hz,6H); MS(m / z):524.2[M+1] + .

[0699] Compounds 16 and 17: 1-(5-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-3-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid and 1-(3-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-5-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0700] 3,4-Dichlorobenzohydrazide

[0701] Hydrazine hydrate (20.2ml, 324mmol) is added to methyl 3,4-dichlorobenzoate (4.52g, 21.6mmol) dissolved in EtOH (108ml). The reactant is refluxed for 1.5 hours. LCMS indicates that the reaction is complete. Most of the ethanol is evaporated and the product is wet-ground in water. After drying under high vacuum, the product (4.42g, 21.6mmol) is obtained as a white solid.

[0702] N-(5-(3,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl)nitramide

[0703] Nitroguanidine (3.04g, 29.3mmol) is suspended in 1N NaOH (19.5ml, 19.5mmol). 3,4-dichlorobenzohydrazide (2.00g, 9.75mmol) is added (it stays on the surface but enters the solution when heated). The reaction is heated at 75°C for 3 hours. 1N HCl (20mL) is added to acidify the mixture (product precipitation). The mixture is filtered and washed with water. LCMS shows that the product is the main substance. The product (2.36g, 6.80mmol, 70%) is obtained as an off-white solid after drying under high vacuum.

[0704] 5-(3,4-dichlorophenyl)-3-hydrazino-1H-1,2,4-triazole

[0705] To a flask containing N-(5-(3,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl)nitramide (250 mg, 0.91 mmol) was added acetic acid (4.56 mL). The stirred suspension was brought to 10°C and a suspension of zinc powder (298 mg, 4.56 mmol) in water (4.56 mL) was added. After 16 hours, the mixture was cooled to 0°C and 8M aqueous sodium hydroxide solution (15 mL) was added, and the pH was checked to be alkaline (pH>10). The mixture was used in the next step.

[0706] tert-Butyl 2-(5-(3,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl)hydrazinecarboxylate

[0707] THF (9 mL) was added to a flask containing a crude solution of 5-(3,4-dichlorophenyl)-3-hydrazino-1H-1,2,4-triazole in water (pH <10, the aqueous phase from the previous step, the theoretical amount is 223 mg, 0.91 mmol). Di-tert-butyl dicarbonate (499 mg, 2.28 mmol) was added. After 16 hours, LCMS showed no starting material and a lot of products. The mixture was transferred to a separatory funnel with EtOAc and the phases were separated. The aqueous phase was extracted with EtOAc. The combined organic phase was washed with brine and dehydrated with sodium sulfate, filtered and concentrated. A mixture of Boc-product and Boc-impurity was obtained as a light brown oil. It was used directly in the next step.

[0708] 1-(5-(3,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0709] In the flask containing the material (theoretical amount 314mg, 0.91mmol) of the crude Boc protection of the previous step, MeOH (9.1mL) is added. Keto-oxime (332mg, 1.92mmol) is added, followed by the concentrated HCl aqueous solution (0.33ml, 4.0mmol) of 37%. In an oil bath, the mixture is heated to 80°C and after 1 hour and 3 hours, LCMS shows only trace products. 37% concentrated HCl aqueous solution (0.33mL, 4.0mmol) is added again and after heating for 4 hours, without starting material. EtOAc is used to transfer the mixture into a separating funnel and use a saturated sodium bicarbonate solution, followed by salt water washing of the organic phase. The organic phase is dehydrated through sodium sulfate, filtered and concentrated. The crude product is purified on Isco using the C18 post loaded with DMSO, eluted with MeCN / water (containing 10mM ammonium formate, pH 3.8) of 35-55% gradient. The product-containing fractions were lyophilized to afford the product as an off-white solid (72 mg, 0.20 mmol, 22%).

[0710] 1-(5-(3,4-dichlorophenyl)-1H-1,2,4-triazol-3-yl)-4-iodo-3-methyl-1H-pyrazole-5-carboxylic acid ester

[0711] In the flask containing the triazolyl pyrazole (72mg, 0.20mmol) of the previous step, TFA (1mL) was added. N-iodosuccinimide (115mg, 0.51mmol) was added and stirred for 16 hours. LCMS showed that there was no starting material and pure product. The mixture was transferred to a separatory funnel using EtOAc and washed with water, followed by a saturated sodium bicarbonate solution and then a brine wash organic phase. The organic phase was dehydrated over sodium sulfate, filtered and concentrated. The crude product (98mg, 0.20mmol, 100%) was obtained as a light yellow oil and used in the next step as is.

[0712] 1-(3-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-5-yl)-4-iodo-3-methyl-1H-pyrazole- 5-Methyl formate and 1-(5-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-3-yl)-4-iodo-3-methyl-1H- Methyl pyrazole-5-carboxylate

[0713] In the flask containing the product (98mg, 0.205mmol) of the previous step, cesium carbonate (200mg, 0.61mmol), DMF (2mL) were added, followed by isobutyl iodide (189uL, 302mg, 1.64mmol). After 16 hours, the ratio of the pyrazole-free starting material and the product was 77:13 products. The mixture was added to a C18 column and eluted with a 65-100% gradient of MeCN / water (containing 10mM ammonium formate, pH 3.8). The eluted fractions containing the product were combined and lyophilized to give a mixture of the product ester as an off-white solid (110mg, 0.205mmol, 100%).

[0714] 1-(5-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-3-yl)-4-(3-fluorophenyl)-3-methyl- 1H-pyrazole-5-carboxylic acid and 1-(3-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-5-yl)-4-(3-fluorophenyl)- 1H-pyrazole-5-carboxylic acid

[0715] The mixture of the previous step (5: 1 ratio, 110 mg, 0.21 mmol), boric acid (58 mg, 0.41 mmol), sodium carbonate (109 mg, 1.03 mmol), dioxane (2.1 ml) and water (0.5 mL) were loaded into a screw cap tube. The mixture was degassed for 10 minutes and Pd (PPh ) (24 mg, 0.021 mmol) was added. The tube was sealed and the mixture was heated to 85 ° C. After 16 hours, LCMS showed no product, so boric acid (58 mg, 0.41 mmol), sodium carbonate (109 mg, 1.03 mmol) and degassed water (0.5 mL) were added. The mixture was degassed for 10 minutes and Pd (PPh ) (24 mg, 0.021 mmol) was added. After 4 hours, LCMS showed no iodine-substituted pyrazole starting material, so the mixture was cooled to room temperature, neutralized with 2 mL of 1 M HCl aqueous solution and added to a C18 column with DMSO. The mixture was purified on Isco using a 25-100% gradient of MeCN / water (containing 10 mM ammonium formate, pH 3.8).The ester fractions were lyophilized to give the ester mixture as an off-white solid (38 mg, 0.076 mmol, 37%).

[0716] 1-(5-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-3-yl)-4-(3-fluorophenyl)-3-methyl- 1H-pyrazole-5-carboxylic acid and 1-(3-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-5-yl)-4-(3-fluorophenyl)- 1H-pyrazole-5-carboxylic acid

[0717] In a microwave vial containing the ester mixture from the previous step (1:3 ratio of isomers, 35 mg, 70 umol), dioxane (0.70 mL), methanol (70 uL) and a 1 M NaOH solution in water (0.70 mL, 0.70 mmol) were added. The mixture was heated to 100 ° C in a microwave reactor for 20 minutes. LCMS showed complete reaction. A 1 M HCl solution in water (0.70 mL, 0.70 mmol) was added and the mixture was purified on a reverse phase Isco using a C18 column eluting with a 30-70% gradient of MeCN / water (10 mM ammonium formate, pH 3.8). The pure fractions containing the first eluted product were combined, concentrated to remove most of the acetonitrile, frozen and lyophilized. 1-(5-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-3-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (5 mg, 0.010 mmol, 15% yield) was obtained as an off-white solid. The pure fractions containing the second eluting product were combined, concentrated to remove most of the acetonitrile, frozen, and lyophilized. 1-(3-(3,4-dichlorophenyl)-1-isobutyl-1H-1,2,4-triazol-5-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (8 mg, 0.016 mmol, 24% yield) was obtained as a white solid.

[0718] 1 H NMR (500 MHz, CDCl3) δ 7.75 (s, 1H), 7.58 (d, J = 8.2 Hz, 1H), 7.47 (d, J = 7.1 Hz, 1H), 7.33 (dd, J = 14.1, 7.7 Hz, 1H), 7.08 (d, J = 7.4 Hz, 1H), 7.06–6.98 (m, 2H), 4.03 (d, J = 7.2 Hz, 2H), 2.38–2.31 (m, 1H), 2.28 (s, 3H), 0.87 (d, J = 6.6 Hz, 6H). The formic acid OH signal was not detected or was hidden under the water signal (br s, 3.7–2.5 ppm); MS (m / z): 488.12 [M+1] + .

[0719] 1 H NMR (500MHz, CDCl3) δ8.07(d,J=2.0Hz,1H),7.77(dd,J=8.4,2.0Hz,1H),7.42(d,J=8.4Hz,1H),7.32(td,J=8.0,6.0Hz,1H ),7.06–6.92(m,3H),4.03(d,J=7.3Hz,2H),2.31–2.22(m,1H),2.20(s,3H),0.88(d,J=6.7Hz,6H); MS(m / z):488.12[M+1] + .

[0720] Compound 18: 1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0721] 4-Bromo-1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0722] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed with methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (300 mg, 0.659 mmol), 4,4-difluoropiperidine (104 mg, 0.659 mmol), XantPhos (38.1 mg, 0.066 mmol) and CsCO (1.07 g, 3.30 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through dioxane (3 mL) and then added to the microwave vial, followed by the addition of the catalyst RuPhos Palladacycle (53.8 mg, 0.066 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using hexanes (100% isocratic elution) to give the title compound (173 mg, 0.350 mmol, 53%) as a yellow oil.

[0723] 1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl Methyl 1H-pyrazole-5-carboxylate

[0724] At room temperature, 4-bromo-1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (173 mg, 0.349 mmol), 3-fluorophenylboronic acid (58.6 mg, 0.419 mmol) and Na2CO3 (185 mg, 1.75 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (40.4 mg, 0.035 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The reaction mixture was diluted with EtOAc. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry fill) using EtOAc in hexanes (0 to 1% gradient) to give the title compound (150 mg, 0.294 mmol, 84%) as a yellow oil.

[0725] 1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl 1H-pyrazole-5-carboxylic acid

[0726] In a 25 mL round-bottom flask, 1-(4-(4,4-difluoropiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (150 mg, 0.294 mmol) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (588 uL, 0.588 mmol) was added and the reaction was stirred at room temperature for 16 hours. 1 M HCl solution (588 uL, 0.588 mmol) and water (2 mL) were added. The reaction mixture was directly purified by reverse phase chromatography on a C-18 column using a solution of MeCN in water (containing 10 mM NH4CO2H) (40 to 70%) to give the title compound (31.5 mg, 0.064 mmol, 22%) as a yellow powder after lyophilization.

[0727] 1 H NMR(500MHz,DMSO)δ7.50(dd,J=14.6,7.9Hz,1H),7.34–7.27(m,2H),7.25–7.18(m,1H),3.74–3.66(m ,4H),3.22–3.13(m,1H),2.28(s,3H),2.07–1.95(m,4H),1.25(d,J=6.7Hz,6H);MS(m / z):497.1[M+1] + .

[0728] Compound 19: Methyl 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (enantiomerically pure - unknown stereochemistry)

[0729] In a 25 mL round bottom flask, methyl 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (prepared as described above and resolved to enantiomerically pure form (12.7 mg, 0.024 mmol)) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (235 uL, 0.235 mmol) was added and the reaction was stirred at 60° C. for 16 hours. 1 M NaOH was added. To the mixture was added HCl solution (235 uL, 0.235 mmol) and water (10 mL). The reaction mixture was diluted with EtOAc and transferred to an extraction funnel. The layers were separated and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to give the title compound (9.00 mg, 0.017 mmol, 73%) as a yellow solid after lyophilization.

[0730] 1 H NMR(500MHz,MeOD)δ7.49–7.42(m,1H),7.28–7.23(m,1H),7.22–7.17(m,1H),7.15–7.09(m,1H),6.53–6.44(m,1H),3.30–3.21(m,1H),2.80 (d,J=18.1Hz,1H),2.59–2.40(m,3H),2.31(s,3H),2.18–2.10(m,1H),1.71–1.56(m,2H),1.30(dd,J=6.7,1.9Hz,6H); MS(m / z):526.1[M+1] + .

[0731] Compound 19: Methyl 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (enantiomerically pure - unknown stereochemistry)

[0732] In a 25 mL round-bottom flask, enantiopure 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(trifluoromethyl)cyclohex-1-en-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (30.7 mg, 0.057 mmol) (prepared and resolved as described above) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (569 uL, 0.569 mmol) was added and the reaction was stirred at 60 ° C for 16 hours. 1 M HCl solution (569 uL, 0.569 mmol) and water (10 mL) were added. The reaction mixture was diluted with EtOAc and transferred to an extraction funnel. The layers were separated and the aqueous layer was extracted with EtOAc (3×). The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo to afford the title compound (20.0 mg, 0.038 mmol, 67%) as a yellow solid after lyophilization.

[0733] 1H NMR(500MHz,MeOD)δ7.36(td,J=8.0,6.0Hz,1H),7.18–7.13(m,1H),7.11–7.07(m,1H),7.05–6.99(m,1H),6.41–6.34(m,1H),3.21–3.11(m,1H), 2.70(d,J=18.3Hz,1H),2.50–2.30(m,3H),2.21(s,3H),2.08–1.99(m,1 H),1.59–1.42(m,2H),1.20(dd,J=6.7,1.9Hz,6H);MS(m / z):526.1[M+1] + .

[0734] Compound 20: 4-(3-Fluorophenyl)-3-methyl-1-(4-(4-(trifluoromethyl)cyclohexyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0735] In a 10mL glass vial equipped with a magnetic stir bar, compound 5 (20.0mg, 0.037mmol) was dissolved in acetic acid (4mL). Pd / activated carbon (3.94mg, 0.004mmol) was added and the reaction mixture was stirred at 80°C under a hydrogen atmosphere for 16 hours. The crude product was purified by reverse phase chromatography on a C-18 column using a solution of MeCN in water (containing 10mM NH4CO2H) (35 to 65%) to give the title compound (3.00mg, 0.007mmol, 18%) as a white powder after lyophilization.

[0736] 1 H NMR(500MHz,MeOD)δ7.47–7.40(m,1H),7.30–7.25(m,1H),7.24–7.18(m,1H),7.13–7.06(m,2H),3.09–3.01(m,1H),2.36–2.28(m,4H),2. 27–2.16(m,1H),2.05(d,J=11.6Hz,1H),1.89–1.72(m,3H),1.67–1.56(m,2H),1.54–1.41(m,1H),1.35–1.20(m,1H); MS(m / z):454.1[M+1] + .

[0737] Compound 22: 4-(3-Fluorophenyl)-1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0738] Methyl 1-(5-iodo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate

[0739] Methyl 3-methyl-1-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (100 mg, 0.272 mmol), prepared substantially as above for the butylthio analog, was dissolved in TFA (1.4 ml) and N-iodosuccinimide (73 mg, 0.33 mmol) was added. The reaction mixture was stirred at room temperature for 45 minutes. The reaction mixture was poured into water and extracted with EtOAc. The organic layer was washed sequentially with saturated aqueous NaHCO3, 10% aqueous Na2S2O3, and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated. The product was purified by flash chromatography on silica gel (dry pack) using a gradient of 0 to 10% EtOAc / hexanes to give the title compound (79 mg, 0.16 mmol, 59%) as a pink solid. MS (m / z): 493.9 [M+1] + .

[0740] 3-Methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0741] At room temperature, 1-(5-iodo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (200 mg, 0.405 mmol), (2-methylprop-1-ene-1-yl)boronic acid (49 mg, 0.49 mmol), K2CO3 (280 mg, 2.03 mmol) and THF (3 mL) were placed in a 5 mL glass microwave vial equipped with a magnetic stirring bar and a nitrogen stream. Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of catalyst Pd (dtbpf) (26 mg, 0.041 mmol). The vial was capped and placed in an oil bath at 90 ° C for 16 hours. The product was purified by flash chromatography (dry filling) on ​​silica gel using a 0 to 10% gradient of EtOAc / hexane to give the title compound (64 mg, 0.059 mmol, 38%) as a yellow oil. MS (m / z): 422.3 [M+1] + .

[0742] Methyl 1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate

[0743] 3-Methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (64 mg, 0.15 mmol) was dissolved in MeOH / AcOH (3 ml) and 20% Pd(OH)2 / C (16 mg) was added. The reaction mixture was purged and stirred under a hydrogen atmosphere for 16 hours. The reaction mixture was heated to 40 ℃ and then dried over 30 ℃. Filter through a pad of Celite® and concentrate in vacuo. The crude reaction mixture was re-subjected to reaction conditions for two more cycles and evaporated to afford the title compound (36 mg, 0.084 mmol, 55%) as a light yellow solid. MS (m / z): 424.2 [M+1] + .

[0744] 4-Bromo-1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid Methyl ester

[0745] 1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (36 mg, 0.084 mmol) was dissolved in MeCN / DCM (1 mL) and a 2M solution of bromine in MeCN (210 μL, 0.420 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 16 hours and quenched with a 10% aqueous solution of Na2S2O3. The reaction mixture was diluted with EtOAc, washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and concentrated to give the title compound (36 mg, 0.072 mmol, 85%) as a yellow solid. MS (m / z): 502.0 [M+1] + .

[0746] 4-(3-Fluorophenyl)-1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrrolidone oxazole-5-carboxylic acid

[0747] At room temperature, methyl 4-bromo-1-(5-isobutyl-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (36 mg, 0.072 mmol), (3-fluorophenyl)boronic acid (12 mg, 0.086 mmol) and NaCO (38 mg, 0.36 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (8.3 mg, 0.0072 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (8.5 mg, 0.36 mmol) was added to the reaction mixture and stirred at 110°C for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 60-80% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (7.5 mg, 0.015 mmol, 21%) as a white solid after lyophilization.

[0748] 1H NMR(500MHz,DMSO)δ7.83(s,4H),7.53-7.47(m,1H),7.34-7.28(m,2H),7.25-7.18( m,1H),2.89(d,J=7.2Hz,2H),2.30(s,3H),1.96–1.83(m,1H),0.93(d,J=6.6Hz,6H). MS(m / z):504.0[M+1] + .

[0749] Compound 23: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0750] tert-Butyl 4-(2,2,2-trifluoroethyl)piperazine-1-carboxylate

[0751] Trifluoroiodoethane (0.794 mL, 8.05 mmol) was added to a stirred solution of boc-piperazine (1.25 g, 6.71 mmol), DIPEA (6.25 mL, 33.6 mmol) and DMF (7 mL). The reaction mixture was stirred at room temperature for 72 hours. The reactants were filtered and the filtrate was evaporated. The crude product was purified by flash chromatography on silica gel (dry packing) using a solution of EtOAc in hexane (20 to 100% gradient) to give the title compound (253 mg, 0.943 mmol, 14%) as a yellow solid.

[0752] 1-(2,2,2-Trifluoroethyl)piperazine hydrochloride

[0753] Tert-Butyl 4-(2,2,2-trifluoroethyl)piperazine-1-carboxylate (253 mg, 0.94 mmol) was dissolved in DCM (9 mL) and a 4M solution of HCl in dioxane (4.72 mL, 18.9 mmol) was added. The reaction was stirred at room temperature for 3 hours. The product was then concentrated in vacuo and co-evaporated with DCM three times to give the title compound (200 mg, 0.977 mmol, 100%) as a beige solid.

[0754] 4-Bromo-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazol-2-yl)-3-methyl Methyl 1H-pyrazole-5-carboxylate

[0755] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed with methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (300 mg, 0.659 mmol), 1-(2,2,2-trifluoroethyl)piperazine hydrochloride (135 mg, 0.659 mmol), XantPhos (38.1 mg, 0.066 mmol), and CsCO (1.07 g, 3.30 mmol). Nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through dioxane (3 mL) and then added to the microwave vial, followed by the addition of the catalyst RuPhos Palladacycle (53.8 mg, 0.066 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (10 to 30% gradient) to give the title compound (123 mg, 0.227 mmol, 34%) as a yellow oil.

[0756] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazole-2-yl 3-Methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0757] At room temperature, 4-bromo-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (123 mg, 0.227 mmol), 3-fluorophenylboronic acid (38.1 mg, 0.272 mmol) and Na2CO3 (120 mg, 1.13 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (26.2 mg, 0.023 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The reaction mixture was diluted with EtOAc. The aqueous layer was extracted with EtOAc (2×) and the combined organic layers were washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (0 to 15% gradient) to give the title compound (41.3 mg, 0.074 mmol, 33%) as a yellow oil.

[0758] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazole-2-yl 1H-pyrazole-5-carboxylic acid

[0759] In a 25 mL round-bottom flask, methyl 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2,2,2-trifluoroethyl)piperazin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (41.3 mg, 0.076 mmol) was diluted with THF / MeOH (2 mL, 1:1). 1 M NaOH solution (381 uL, 0.381 mmol) was added and the reaction was stirred at room temperature for 16 hours. 1 M HCl solution (381 uL, 0.381 mmol) and water (2 mL) were added. The reaction mixture was directly purified by reverse phase chromatography on a C-18 column using a solution of MeCN in water (containing 10 mM NH4CO2H) (40 to 70%) to give the title compound (32.0 mg, 0.059 mmol, 77%) as a yellow powder after lyophilization.

[0760] 1 H NMR (500MHz, DMSO) δ7.56–7.46(m,J=14.4,8.0Hz,1H),7.28(d,J=8.4Hz,2H),7.26–7.19(m,J=9.0Hz,1H),3.59–3.53(m,4H),3.21(dd ,J=20.5,10.2Hz,2H),3.17–3.07(m,J=13.4,6.7Hz,1H),2.73–2.66(m,4H),2.28(s,3H),1.24(d,J=6.7Hz,6H); MS(m / z):544.1[M+1] + .

[0761] Compound 24: 1-(4-(4-cyanopiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0762] 4-Bromo-1-(4-(4-cyanopiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole- 5-Methyl formate

[0763] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (150 mg, 0.330 mmol), piperidine-4-carbonitrile (36 mg, 0.33 mmol), CsCO (537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol), and dioxane (3 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhosPd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 70-90% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to afford the title compound (29 mg, 0.059 mmol, 18%) as a yellow solid after evaporation. MS (m / z): 484.0 [M+1] + .

[0764] 1-(4-(4-cyanopiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl- 1H-Pyrazole-5-carboxylic acid

[0765] At room temperature, methyl 4-bromo-1-(4-(4-cyanopiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (29 mg, 0.059 mmol), (3-fluorophenyl)boronic acid (9.9 mg, 0.071 mmol) and NaCO (31 mg, 0.29 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (6.8 mg, 0.0059 mmol). The vial was capped and placed in an oil bath at 85° C. for 16 hours. LiOH (7.0 mg, 0.29 mmol) was added to the reaction mixture and stirred at 110° C. for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 50-70% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (2.3 mg, 0.0047 mmol, 8%) as a light yellow solid after lyophilization.

[0766] 1H NMR(500MHz,MeOD)δ7.41(td,J=8.0,6.1Hz,1H),7.37-7.34(m,1H),7.33–7.28(m,1H),7.07–7.01(m,1H),4.02-3.95(m,2H),3. 54-3.47(m,2H),3.22-3.10(m,1H),3.01-2.91(m,1H),2.32(s,3H),2.09–1.98(m,2H),1.93–1.80(m,2H),1.30(d,J=6.7Hz,6H). MS(m / z):486.1[M+1] + .

[0767] Compound 25: 1-(4-(4-cyclopropylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0768] 4-Bromo-1-(4-(4-cyclopropylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0769] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (150 mg, 0.330 mmol), 1-cyclopropylpiperazine (42 mg, 0.33 mmol), CsCO (537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol), and dioxane (3 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhos Pd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The product was purified by flash chromatography on silica gel (dry pack) using a 0 to 10% gradient of EtOAc / hexanes to give the title compound as a yellow oil (28 mg, 0.055 mmol, 17%). MS (m / z): 500.0 [M+1] + .

[0770] 1-(4-(4-cyclopropylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl 1H-pyrazole-5-carboxylic acid

[0771] At room temperature, methyl 4-bromo-1-(4-(4-cyclopropylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (28 mg, 0.055 mmol), (3-fluorophenyl)boronic acid (9.2 mg, 0.066 mmol) and NaCO (29 mg, 0.28 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (6.3 mg, 0.0055 mmol). The vial was capped and placed in an oil bath at 85° C. for 16 hours. LiOH (6.6 mg, 0.28 mmol) was added to the reaction mixture and stirred at 110° C. for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 35-55% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 min, and then eluted with 35-55% MeCN / NH 4 CO 3 H 10 mM, pH 10 / flow rate 45 ml / min / 10 min) to give the title compound (3.0 mg, 0.0060 mmol, 11%) as a yellow solid after lyophilization.

[0772] 1 H NMR(500MHz,MeOD)δ7.46–7.40(m,1H),7.39-7.35(m,1H),7.35–7.31(m,1H),7.09-7.03(m,1H),3.93-3.75(m,4H ),3.40-3.32(m,4H),3.26-3.15(m,1H),2.76-2.60(m,1H),2.34(s,3H),1.31(d,J=6.7Hz,6H),0.95-0.81(s,4H). MS(m / z):502.1[M+1] + .

[0773] Compound 26: 1-(4-(4-ethylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0774] 4-Bromo-1-(4-(4-ethylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole- 5-Methyl formate

[0775] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (150 mg, 0.330 mmol), 1-ethylpiperazine (38 mg, 0.33 mmol), CsCO (537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol), and dioxane (3 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhosPd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 50-70% MeCN / NH4CO2H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to afford the title compound (49 mg, 0.10 mmol, 31%) as a yellow solid after evaporation. MS (m / z): 488.0 [M+1] + .

[0776] 1-(4-(4-ethylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl- 1H-Pyrazole-5-carboxylic acid

[0777] At room temperature, methyl 4-bromo-1-(4-(4-ethylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (49 mg, 0.10 mmol), (3-fluorophenyl)boronic acid (17 mg, 0.12 mmol) and NaCO (53 mg, 0.50 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (12 mg, 0.010 mmol). The vial was capped and placed in an oil bath at 85° C. for 16 hours. LiOH (12 mg, 0.50 mmol) was added to the reaction mixture and stirred at 110° C. for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 35-55% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (1.1 mg, 0.0022 mmol, 2%) as a white solid after lyophilization.

[0778] 1H NMR (500 MHz, MeOD) δ 8.49 (s, 1H), 7.43 (td, J = 7.9, 6.0 Hz, 1H), 7.40–7.32 (m, 2H), 7.09–7.02 (m, 1H), 4.06–3.63 (m, 4H), 3.40–3.27 (m, 4H), 3.27–3.12 (m, 3H), 2.34 (s, 3H), 1.36 (t, J = 7.3 Hz, 3H), 1.31 (d, J = 6.7 Hz, 6H). Ammonium formate salt. MS (m / z): 490.1 [M+1] + .

[0779] Compound 27: 1-(4-(4-acetylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0780] 1-(4-(4-acetylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-bromo-3-methyl-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0781] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (150 mg, 0.330 mmol), 1-(piperazin-1-yl)ethanone (42 mg, 0.33 mmol), CsCO (537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol), and dioxane (3 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhos Pd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 65-85% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give after evaporation the title compound as a yellow oil (30 mg, 0.059 mmol, 18%).

[0782] MS (m / z): 502.0 [M+1] + .

[0783] 1-(4-(4-acetylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl 1H-pyrazole-5-carboxylic acid

[0784] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream was placed methyl 1-(4-(4-acetylpiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-bromo-3-methyl-1H-pyrazole-5-carboxylate (30 mg, 0.059 mmol), (3-fluorophenyl)boronic acid (10 mg, 0.071 mmol) and Na2CO3 (31 mg, 0.30 mmol). Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (12 mg, 0.010 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (7.1 mg, 0.30 mmol) was added to the reaction mixture and stirred at 110°C for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 40-60% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (4.1 mg, 0.0081 mmol, 14%) as a yellow solid after lyophilization.

[0785] 1 H NMR(500MHz,MeOD)δ7.43(td,J=8.0,6.1Hz,1H),7.36-7.32(m,1H),7.31–7.27(m,1H),7.09-7.0 3(m,1H),3.74-3.60(m,8H),3.26-3.13(m,1H),2.34(s,3H),2.14(s,3H),1.31(d,J=6.7Hz,6H). MS(m / z):504.1[M+1] + .

[0786] Compound 28: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylpiperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0787] 4-Bromo-1-(5-(isopropylthio)-4-(4-methylpiperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole- 5-Methyl formate

[0788] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (150 mg, 0.330 mmol), 4-methylpiperidine (33 mg, 0.33 mmol), CsCO (537 mg, 1.65 mmol), XantPhos (19 mg, 0.033 mmol), and dioxane (3 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhosPd G1 (27 mg, 0.033 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 80-100% MeCN / NH4CO2H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to afford the title compound (9.5 mg, 0.020 mmol, 6%) as a yellow oil after evaporation. MS (m / z): 473.1 [M+1] + .

[0789] 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylpiperidin-1-yl)thiazol-2-yl)-3-methyl- 1H-Pyrazole-5-carboxylic acid

[0790] At room temperature, methyl 4-bromo-1-(5-(isopropylthio)-4-(4-methylpiperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (9.5 mg, 0.020 mmol), (3-fluorophenyl)boronic acid (3.4 mg, 0.024 mmol) and Na2CO3 (11 mg, 0.10 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (2.3 mg, 0.0020 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (2.4 mg, 0.10 mmol) was added to the reaction mixture and stirred at 110°C for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted once with 65-85% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (1.6 mg, 0.0034 mmol, 17%) as a yellow solid after lyophilization.

[0791] 1H NMR(500MHz,MeOD)δ7.45–7.39(m,1H),7.35-7.31(m,1H),7.31-7.26(m,1H),7.010-7.03(m,1H),4.43-4.34(m,2H),3.23-3.10(m,1H) ,2.95-2.86(m,2H),2.32(s,3H),1.74-1.62(m,2H),1.61-1.49(m,1H),1.38-1.19(m,2H)1.29(d,J=6.7Hz,6H),0.98(d,J=6.6Hz,3H). MS(m / z):475.2[M+1] + .

[0792] Compound 29: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methylpiperazin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0793] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR(500MHz,MeOD)δ7.43(td,J=7.9,6.1Hz,1H),7.40–7.37(m,1H),7.37–7.32(m,1H),7.09–7.03(m,1H), 4.43-3.50(m,4H),3.42-3.31(m,4H),3.29-3.14(m,1H),2.91(s,3H),2.35(s,3H),1.31(d,J=6.7Hz,6H). MS(m / z):476.1[M+1] +

[0794] Compound 30: 4-(3-Fluorophenyl)-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0795] 5-(4-(Trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-amine

[0796] Thiosemicarbazide (480 mg, 5.26 mmol) and 4-(trifluoromethyl)benzoic acid (1.00 g, 5.26 mmol) were suspended in phosphorus oxychloride (1.40 mL) and heated at 75 ° C for 30 minutes. After cooling to room temperature, water (5.5 mL) was added and the reaction mixture was refluxed for 4 hours. The reaction mixture was cooled to room temperature and basified to pH 8 by dropwise addition of 6N NaOH solution under stirring. The precipitate was filtered and washed with water to give the title compound (1.09 g, 4.44 mmol, 85%) as a white solid.

[0797] 2-Chloro-5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazole

[0798] A stirred suspension of 5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazole-2-amine (700mg, 2.85mmol) and copper (18mg, 0.29mmol) in concentrated hydrochloric acid (2.8mL) and acetic acid (14mL) was cooled to 0°C. A solution of sodium nitrite (206mg, 2.99mmol) in water (0.94mL) was added portionwise to the suspension and the reaction mixture was then stirred at room temperature for 16 hours. After cooling to 0°C, a solution of sodium nitrite (41mg, 0.59mmol) in water (0.20mL) was added and stirring was continued at room temperature for 3 hours. The reaction mixture was added dropwise to a cold water solution (150mL) and the precipitate was filtered to give the title compound (627mg, 2.37mmol, 83%) as a yellow solid.

[0799] 2-Hydrazino-5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazole

[0800] 2-Chloro-5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazole (425 mg, 1.61 mmol) and hydrazine hydrate (176 mg, 1.93 mmol) were stirred in dioxane at 82 ° C. After 3 hours, hydrazine hydrate (65 mg, 0.71 mmol) was added and stirring was continued at 82 ° C for 16 hours. Hydrazine hydrate (60 mg, 0.66 mmol) was added to the suspension and another 4 hours were required to complete the reaction. The yellow precipitate was filtered and rinsed with Et2O to give the title compound (346 mg, 1.33 mmol, 83%) as a yellow solid.

[0801] 3-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester

[0802] 2-(methoxyimino)-4-oxopentanoic acid methyl ester (127mg, 0.734mmol) is dissolved in MeOH (4mL) and 2-hydrazino-5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazole (191mg, 0.734mmol) is added, followed by dropwise addition of 12NHCl (245 μL, 2.94mmol). The reaction mixture is heated to reflux for 5 hours. The reaction mixture is concentrated. The residual starting material is removed by wet grinding in DCM. The filtrate is concentrated and the crude product is purified by flash chromatography on silica gel using a solution of ethyl acetate in hexane (0 to 50% gradient) to give the title compound (55.6mg, 0.151mmol, 21%) as a yellow oil.

[0803] 4-Bromo-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylic acid Methyl ester

[0804] 3-Methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (88 mg, 0.24 mmol) was dissolved in TFA (1.2 ml) and N-bromosuccinimide (47 mg, 0.26 mmol) was added. The reaction mixture was stirred at room temperature for 2 hours, followed by the addition of N-bromosuccinimide (12 mg, 0.067 mmol) and continued stirring for 16 hours. N-bromosuccinimide (12 mg, 0.067 mmol) was added and continued stirring for another 16 hours. The reaction mixture was slowly added to ice water and the solid was filtered, washed with water and dried to give the title compound (84 mg, 0.19 mmol, 78%) as a yellow solid.

[0805] 4-(3-Fluorophenyl)-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrrolidone oxazole-5-carboxylic acid

[0806] At room temperature, methyl 4-bromo-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-1,3,4-thiadiazol-2-yl)-1H-pyrazole-5-carboxylate (42 mg, 0.094 mmol), (3-fluorophenyl)boronic acid (16 mg, 0.11 mmol) and NaCO (50 mg, 0.47 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream. Nitrogen was bubbled through a solution of dioxane / water (1.2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (11 mg, 0.00095 mmol). The vial was capped and placed in an oil bath at 85° C. for 16 hours. LiOH (11 mg, 0.47 mmol) was added to the reaction mixture and stirred at 115° C. for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 40-60% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (6.4 mg, 0.014 mmol, 15%) as a white solid after lyophilization.

[0807] 1 H NMR (500MHz, DMSO) δ8.23(d,J=8.2Hz,2H),7.95(d,J=8.2Hz,2H),7.48-7.36(m,3H),7.18–7.09(m,1H),2.32(s,3H); MS(m / z):448.9[M+1] +

[0808] Compound 31: 4-(3-Fluorophenyl)-1-(5-((2-methoxyethyl)(methyl)amino)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0809] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0810] 2-(Methoxyimino)-4-oxopentanoic acid methyl ester (1.00 g, 5.77 mmol) was dissolved in MeOH (60 mL) and 4-(3,4-dichlorophenyl)-2-hydrazinylthiazole (1.52 g, 5.77 mmol) prepared as described was added, followed by dropwise addition of 12N HCl (1.82 mL, 23.1 mmol). The reaction mixture was heated to reflux overnight. The reaction mixture was diluted with EtOAc and transferred to an extraction funnel. The layers were separated and the aqueous layer was extracted with EtOAc (3 ×). The combined organic layers were dehydrated over Na2SO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography on silica gel (dry filling) using a solution of 1:2:18 EtOAc / DCM / hexane in 1:9 DCM / hexane (0 to 100% gradient) to give the title compound (1.23 g, 2.19 mmol, 38%) as a yellow solid.

[0811] 1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0812] 1-(4-(3,4-dichlorophenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (500 mg, 1.36 mmol) was dissolved in MeCN / DCE (4 mL, 1: 1). SelectFluor (577 mg, 1.63 mmol) was added and the reaction was stirred at 80 ° C for 18 hours. The crude product was concentrated in vacuo and flash chromatography on silica gel (wet loading with DCM) was used to purify the title compound (190 mg, 0.492 mmol, 36%) using a solution of EtOAc in hexane (5 to 20% gradient) to give a white solid.

[0813] 4-Bromo-1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0814] Bromine (0.126 mL, 2.46 mmol) was added to a solution of methyl 1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (190 mg, 0.492 mmol) in MeCN / DCM (5 mL, 1:1 mL). The reaction was stirred at room temperature for 5 hours. Saturated aqueous Na2SO3 was added and the reaction mixture was extracted with EtOAc (3×). The combined organic layers were dried over sodium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel (dry fill) using a solution of DCM in hexane (10 to 40%) to give the title compound (42.6 mg, 0.092 mmol, 19%) as a white solid.

[0815] 1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0816] At room temperature, 4-bromo-1-(4-(3,4-dichlorophenyl)-5-fluorothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (42.6 mg, 0.092 mmol), 3-fluorophenylboronic acid (15.4 mg, 0.110 mmol) and Na2CO3 (48.5 mg, 0.458 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and a nitrogen stream, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (10.6 mg, 0.009 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. LiOH (19.2 mg, 0.458 mmol) was added to the reaction mixture and stirred at 120°C for 10 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 55-75% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 11 minutes) to give the title compound (8.93 mg, 0.019 mmol, 21%) as a white solid after lyophilization.

[0817] 1 H NMR (500 MHz, DMSO) δ 7.92 (t, J = 1.1 Hz, 1H), 7.76 (d, J = 1.1 Hz, 2H), 7.48 (dd, J = 14.4, 8.0 Hz, 1H), 7.41–7.30 (m, J = 15.4, 9.1 Hz, 2H), 7.19 (t, J = 7.6 Hz, 1H), 3.33 (1H, below the water signal), 2.29 (s, 3H); MS (m / z): 466.9 [M+1] + .

[0818] 4-(3-Fluorophenyl)-1-(5-((2-methoxyethyl)(methyl)amino)-4-(4-(trifluoromethyl)phenyl)thiol oxazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0819] In a 5 mL glass microwave vial equipped with a magnetic stir bar was placed 1-(5-fluoro-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid (10 mg, 0.021 mmol) and (2-methoxyethyl)methylamine (246 mg, 2.75 mmol). The vial was capped and placed in an 80 ° C oil bath for 16 hours. The reaction mixture was warmed to 90 ° C and stirred for another 3 days. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 55-75% MeCN / NH4CO2H 10 mM, pH 3.8 / flow 45 ml / min / 10 minutes) to give the title compound (3.3 mg, 0.0062 mmol, 29%) as a light yellow solid after lyophilization.

[0820] 1 H NMR(500MHz,MeOD)δ8.38(d,J=8.3Hz,2H),7.68(d,J=8.3Hz,2H),7.50-7.44(m,1H),7.33-7.29(m,1H),7.28–7.23(m,1H),7 .16-7.09(m,1H),3.56(t,J=5.3Hz,2H),3.28(s,3H),3.20(t,J=5.3Hz,2H),2.89(s,3H),2.35(s,3H); MS(m / z):535.1[M+1] +

[0821] Compound 32: 1-(4-(4,4-dimethylpiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0822] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR(500MHz,DMSO)δ7.47-7.46(m,1H),7.34-7.30(m,2H),7.17(bs,1H),3.59-3.53(m,4H) ,3.11(q,J=5.0Hz,1H),2.27(s,3H),1.38-1.34(m,4H),1.23(d,J=6.7Hz,6H),0.95(s,6H). MS(m / z):489.2[M+1] + .

[0823] Compound 33: 1-(4-(4-(tert-Butoxycarbonyl)piperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0824] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR(500MHz,DMSO)δ7.53-7.48(m,1H),7.30-7.28(m,2H),7.24-7.21(m,1H),3.53-3.51( m,4H),3.40(bs,4H),3.19-3.14(m,1H),2.28(s,3H),1.41(s,9H),1.24(d,J=6.7Hz,6H). MS(m / z):562.2[M+1] + .

[0825] Compound 34: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(3-(trifluoromethyl)pyrrolidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0826] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR (500MHz, DMSO) δ7.53-7.49(m,1H),7.30-7.27(m,2H),7.25-7.21(m,1H),3.82-3.70(m,3H),3.64-3. 59(m,1H),3.06-3.01(m,1H),2.28(s,3H),2.25-2.18(m,1H),2.06-1.99(m,1H),1.22(d,J=6.7,Hz,6H). MS(m / z):515.1[M+1] + . .

[0827] Compound 35: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(piperazin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid hydrochloride

[0828] The title compound was prepared in an analogous manner to compound 12 as described above. 1H NMR(500MHz,MeOD)δ8.45(bs,1H),7.44-7.39(m,1H),7.37-7.31(m,2H),7.06-7.03(m,1H), 3.85-3.83(m,4H),3.28-3.26(m,4H),3.23-3.17(m,1H),2.33(s,3H),1.29(d,J=6.7Hz,6H). MS(m / z):462.1[M+1] + .

[0829] Compound 36: 4-(3-Fluorophenyl)-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0830] 4-iodo-1-(5-iodo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0831] Methyl 3-methyl-1-(4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (1.86 g, 5.06 mmol), prepared as described above, was dissolved in TFA (25 ml) and N-iodosuccinimide (2.39 g, 10.6 mmol) was added. The reaction mixture was stirred at room temperature for 1 hour and 30 minutes, followed by the addition of N-iodosuccinimide (190 mg, 0.844 mmol) and continued stirring for 4 hours. The reaction mixture was slowly added to ice water and the solid was filtered, washed with water, and dried to give the title compound (2.45 g, 3.96 mmol, 78%) as a pink solid.

[0832] 4-iodo-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)- 1H-pyrazole-5-carboxylic acid methyl ester

[0833] At room temperature, 4-iodo-1-(5-iodo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-formic acid methyl ester (800mg, 1.29mmol), (2-methylprop-1-ene-1-yl)boric acid (129mg, 1.29mmol) and KCO (893mg, 6.46mmol) were placed in a glass microwave vial equipped with a magnetic stirring bar and a nitrogen stream, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a THF solution (13mL) and the solution was then added to a microwave vial, followed by the addition of catalyst Pd(dtbpf)Cl (84.2mg, 0.129mmol). The vial was capped and placed in an oil bath at 90°C for 16 hours. The reaction mixture was diluted with EtOAc, washed with water and brine. The organic layer was dehydrated with magnesium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by flash chromatography on silica gel using ethyl acetate in hexanes (0 to 10% gradient) to give the title compound (172 mg, 0.314 mmol, 24%) as a yellow solid.

[0834] 4-(3-Fluorophenyl)-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiol Methyl 2-oxazol-2-yl-1H-pyrazole-5-carboxylate

[0835] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-iodo-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (172 mg, 0.314 mmol), 3-fluorophenylboronic acid (52.8 mg, 0.377 mmol) and Na2CO3 (167 mg, 1.57 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (3 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (36.3 mg, 0.0314 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The crude product was purified by flash chromatography on silica gel using EtOAc in hexanes (0 to 10% gradient) to give the title compound (111 mg, 0.215 mmol, 69%) as a yellow solid.

[0836] 4-(3-Fluorophenyl)-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiol oxazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0837] 4-(3-Fluorophenyl)-3-methyl-1-(5-(2-methylprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (20 mg, 0.039 mmol) and LiOH (4.6 mg, 0.19 mmol) were placed in a 5 mL glass microwave vial. Dioxane / water solution (2 mL, 4: 1) was added. Under microwave irradiation, the vial was heated to 110 ° C for 15 minutes. The crude product was purified using semi-preparative HPLC-MC (X-Bridge 30×50, eluted with 60-80% MeCN / AmForm 10 mM, pH 3.8 / flow 45 ml / min / 10 minutes) to give the title compound (8.2 mg, 0.016 mmol, 42%) as a yellow solid after lyophilization.

[0838] 1 H NMR (500MHz, DMSO) δ7.89(d,J=8.3Hz,2H),7.81(d,J=8.3Hz,2H),7.51-7.44(m,1H),7.39-7.30(m,2H ),7.22-7.14(m,1H),6.41–6.36(m,1H),2.30(s,3H),1.95(s,3H),1.90(s,3H); MS(m / z):502.0[M+1] + .

[0839] Compound 37: 4-(3-Fluorophenyl)-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0840] 4-Bromo-1-(4,5-dibromothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0841] To a solution of methyl 1-(4-bromo-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (27.9 g, 74.07 mmol) in MeCN (570 mL) prepared as described above for compound 1 at 0°C was added a solution of Br2 (21 mL) in MeCN (170 mL). The reaction mixture was allowed to warm to room temperature and stirred for 2.5 hours. The reaction mixture was filtered and the mother liquor was transferred to an extraction funnel. The layers were separated and the aqueous layer was extracted with DCM (3×). The combined organic layers were dried over MgSO4, filtered and concentrated in vacuo to give the title compound product (8.76 g, 19.0 mmol, 26%) as a yellow solid.

[0842] Methyl 4-bromo-1-(4-bromo-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate

[0843] At room temperature, 4-bromo-1-(4,5-dibromothiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (1.50 g, 3.26 mmol), (4-(trifluoromethyl)phenyl)boronic acid (619 mg, 3.26 mmol) and KCO (2.25 g, 16.3 mmol) were placed in a 20 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a THF solution (11 mL) and the solution was then added to the microwave vial, followed by the addition of catalyst Pd(dtbpf)Cl (212 mg, 0.326 mmol). The vial was capped and placed in an oil bath at 90° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (1 to 5% gradient) and then repurified by reverse phase chromatography on a C-18 column using MeCN in water (containing 10 mM NH4CO2H) (60 to 100%) to give the title compound (490 mg, 0.933 mmol, 29%) as a white powder after lyophilization.

[0844] 4-Bromo-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)- 1H-pyrazole-5-carboxylic acid methyl ester

[0845] At room temperature, 4-bromo-1-(4-bromo-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (200 mg, 0.381 mmol), (2-methylprop-1-en-1-yl)boronic acid (38.0 mg, 0.381 mmol) and KCO (263 mg, 1.90 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow, and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a THF solution (2 mL) and then the solution was added to the microwave vial, followed by the addition of catalyst Pd(dtbpf)Cl (24.8 mg, 0.0381 mmol). The vial was capped and placed in an oil bath at 90° C. for 16 hours. The solvent was evaporated under vacuum and the crude product was purified by flash chromatography on silica gel (dry pack) using EtOAc in hexanes (0 to 5% gradient) to give the title compound (62.0 mg, 0.124 mmol, 33%) as a white solid.

[0846] 4-(3-Fluorophenyl)-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiol Methyl 2-oxazol-2-yl-1H-pyrazole-5-carboxylate

[0847] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was charged with methyl 4-bromo-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (62.0 mg, 0.124 mmol), 3-fluorophenylboronic acid (20.8 mg, 0.149 mmol) and Na2CO3 (65.7 mg, 0.620 mmol) and nitrogen and vacuum cycles (2×) were performed. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh3)4 (13.8 mg, 0.012 mmol). The vial was capped and placed in an oil bath at 85°C for 16 hours. The crude product was purified by flash chromatography on silica gel using EtOAc in hexanes (1% isocratic elution) to give the title compound (27.0 mg, 0.052 mmol, 42%) as a colorless oil.

[0848] 4-(3-Fluorophenyl)-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiol oxazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0849] In a 25mL round-bottom flask, 4-(3-fluorophenyl)-3-methyl-1-(4-(2-methylprop-1-en-1-yl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (27.0 mg, 0.052 mmol) was diluted with THF / MeOH (2mL, 1:1). 1M NaOH solution (262 μL, 0.262 mmol) was added and the reaction was stirred at room temperature for 16 hours. 1M HCl solution (262 μL, 0.262 mmol) and water (2mL) were added. The reaction mixture was directly purified by reverse phase chromatography on a C-18 column using a solution of MeCN in water (containing 10mM NH4CO2H) (35 to 75%) to give the title compound (3.00 mg, 0.006 mmol, 11%) as a white powder after lyophilization.

[0850] 1 H NMR(500MHz,MeOD)δ7.75(d,J=8.3Hz,2H),7.69(d,J=8.2Hz,2H),7.43–7.30(m,3H),7.06–6.99(m,1H ),6.14–6.09(m,1H),2.33(s,3H),2.14(d,J=1.0Hz,3H),1.88(d,J=1.1Hz,3H); MS(m / z):502.1[M+1] + .

[0851] Compound 38: 1-(4,5-bis(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0852] The title compound was prepared in an analogous manner to compound 37 as described above. 1 H NMR (500MHz, DMSO) δ7.82(d,J=8.2Hz,2H),7.73(d,J=8.4Hz,2H),7.65(dd,J=8.1, 3.6Hz,4H),7.53–7.46(m,1H),7.40–7.33(m,2H),7.23–7.17(m,1H),2.32(s,3H). MS(m / z):592.2[M+1] + .

[0853] Compound 39: 2-(4-(3-fluorophenyl)-3-methyl-1H-pyrazol-1-yl)-4,5-bis(4-(trifluoromethyl)phenyl)thiazole

[0854] The title compound was prepared in an analogous manner to compound 37 as described above. 1 H NMR (500MHz, DMSO) δ8.94(s,1H),7.82(d,J=8.3Hz,2H),7.78(d,J=8.3Hz,2H),7.73(d, J=8.2Hz,2H),7.66(d,J=8.0Hz,2H),7.54–7.48(m,3H),7.22–7.15(m,1H),2.48(s,3H). MS(m / z):548.2[M+1] + .

[0855] Compound 40: 1-(4-(4-(tert-Butyl)piperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0856] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR (500MHz, DMSO) δ7.53-7.48(m,1H),7.29-7.21(m,3H),4.37(d,J=12.9Hz,2H),3.15-3.10(m,1H),2.76 (t,J=11.6Hz,2H),2.28(s,3H),1.66(d,J=12.6Hz,2H),1.27-1.20(m,8H),1.18-1.14(m,1H),0.85(s,9H). MS(m / z):517.2[M+1] + .

[0857] Compound 41: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(6-azaspiro[2.5]octan-6-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0858] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR(500MHz,DMSO)δ7.47(bs,1H),7.31(bs,2H),7.18(bs,1H),3.62-3.60(m,4H),3. 16-3.11(m,1H),2.27(s,3H),1.40-1.38(m,4H),1.24(d,J=6.7Hz,6H),0.32(s,4H). MS(m / z):487.2[M+1] + .

[0859] Compound 42: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-methoxy-4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0860] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR (500MHz, DMSO) δ7.50-7.46(m,1H),7.32-7.29(m,2H),7.21-7.18(m,1H),4.24(d,J=13.1Hz,2H),3.39(s,3H),3.18-3. 13(m,1H),3.05(t,J=11.9Hz,2H),2.28(s,3H),1.91(d,J=12.6Hz,2H),1.76(td,J=13.5,4.4Hz,2H),1.24(d,J=6.7Hz,6H). MS(m / z):559.1[M+1] + .

[0861] Compound 43: 4-(3-Fluorophenyl)-1-(4-(4-methoxyphenyl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0862] The title compound was prepared in an analogous manner to compound 37 as described above. 1H NMR (500MHz, DMSO) δ7.79(d,J=8.2Hz,2H),7.64(d,J=8.2Hz,2H),7.54-7.46(m,1H),7.41–7. 36(m,2H),7.36-7.31(m,2H),7.26-7.17(m,1H),6.95–6.90(m,2H),3.77(s,3H),2.32(s,3H). MS(m / z):554.0[M+1] + .

[0863] Compound 44: 1-(4,5-bis(4-methoxyphenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0864] The title compound was prepared in an analogous manner to compound 37 as described above. 1 H NMR(500MHz,DMSO)δ7.56–7.46(m,1H),7.43–7.29(m,6H),7.27-7.14(m,1H), 7.03–6.97(m,2H),6.92-6.85(m,2H),3.80(s,3H),3.75(s,3H),2.30(s,3H). MS(m / z):516.4[M+1] + .

[0865] Compound 45: 4-(3-Fluorophenyl)-1-(5-(4-methoxyphenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0866] The title compound was prepared in an analogous manner to compound 37 as described above. 1 H NMR(500MHz,DMSO)δ7.70(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),7.54-7.47(m,1H), 7.340-7.30(m,4H),7.27-7.18(m,1H),7.05-7.00(m,2H),3.81(s,3H),2.32(s,3H). MS(m / z):553.9[M+1] + .

[0867] Compound 46: 1-(4-(4-(tert-butyl)-3-oxopiperazin-1-yl)-5-(isopropylthio)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0868] The title compound was prepared in an analogous manner to compound 12 as described above.1 H NMR(500MHz,DMSO)δ7.44-7.40(m,2H),7.36-7.34(m,1H),7.12-7.09(m,1H),4.19(s,2H),3.77-3 .75(m,2H),3.46-3.44(m,2H),3.12-3.07(m,1H),2.26(s,3H),1.38(s,9H),1.23(d,J=6.7Hz,6H). MS(m / z):532.1[M+1] + .

[0869] Compound 47: 4-(3-Fluorophenyl)-3-methyl-1-(5-(3-(methylamino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0870] 1-(5-(3-(tert-Butoxy)-3-oxoprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazole-2- (4-Iodo-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0871] At room temperature, 4-iodo-1-(5-iodo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-formic acid methyl ester (500 mg, 0.807 mmol), tert-butyl acrylate (113 μL, 0.888 mmol), K CO (558 mg, 4.035 mmol) and catalyst Pd (dtbpf) Cl (53 mg, 0.0807 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stirring bar. THF (8.1 mL, 0.1 M) was added to the microwave tube and a stream of nitrogen was bubbled through the brown mixture for 5 minutes. The vial was capped and stirred in an oil bath at 90° C. for 16 hours. After 16 hours, the reactant was purified using a mobile phase of 0-5% EtOAc / hexane on a silica gel column. The product-containing fractions were evaporated under reduced pressure to give the title compound (215 mg, 0.347 mmol, 43%) as an off-white foam.

[0872] 1-(5-(3-(tert-Butoxy)-3-oxoprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazole-2- 4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0873] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar was placed with 1-(5-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-iodo-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (105 mg, 0.169 mmol), (3-fluorophenyl)boronic acid (24 mg, 0.169 mmol), Na2CO3 (90 mg, 0.845 mmol) and catalyst Pd(PPh3)4 (20 mg, 0.0169 mmol). THF:water (1.7 mL, 4:1, 0.1 M) deoxygenated with a nitrogen stream for 5 minutes was added to the microwave tube. The vial was capped and stirred in an oil bath at 90°C for 16 hours. After 16 hours, the reaction was purified on a silica gel column using a mobile phase of 0-5% EtOAc / hexane. The product-containing fractions were evaporated under reduced pressure to give the title compound (69 mg, 0.117 mmol, 70%) as a colorless oil.

[0874] 1-(5-(3-(tert-Butoxy)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluoro phenyl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester

[0875] At room temperature, 1-(5-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid methyl ester (68 mg, 0.115 mmol), catalyst Pd(OH)2 (15 mg) and MeOH:AcOH (1 mL, 1:1, 0.1 M) were placed in a 10 mL round-bottom flask equipped with a magnetic stir bar. The flask was equipped with a hydrogen balloon. The reactants were purged with hydrogen and vacuum three times. Under a hydrogen atmosphere, the reaction was stirred at room temperature for 16 hours. After 16 hours, the reactants were filtered through celite and the filter cake was washed with methanol. The reactants were purified on a silica gel column using a mobile phase of 0-5% EtOAc / hexane. The eluted fraction containing the product was evaporated under reduced pressure to give the title compound (50 mg, 0.0848 mmol, 75%) as a yellow oil.

[0876] 3-(2-(4-(3-fluorophenyl)-5-(methoxycarbonyl)-3-methyl-1H-pyrazol-1-yl)-4-(4-(trifluoromethyl) 5-(4-Yl)phenyl)thiazol-5-yl)propanoic acid

[0877] At room temperature, a 10 mL round-bottom flask equipped with a magnetic stir bar was charged with methyl 1-(5-(3-(tert-butoxy)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylate (50 mg, 0.0848 mmol), CeCl 7H O (47 mg, 0.127 mmol), NaI (16 mg, 0.110 mmol), and MeCN (0.7 mL, 0.1 M). The reaction was heated under reflux for 2 hours. After 2 hours, the reaction was diluted with EtOAc and treated with 0.5 M HCl. The compound was extracted three times with EtOAc. The combined organic layers were dried over Na SO , filtered, and evaporated under reduced pressure to give the title compound (38 mg, 0.0729 mmol, 86%) as an orange solid.

[0878] 4-(3-Fluorophenyl)-3-methyl-1-(5-(3-(methylamino)-3-oxopropyl)-4-(4-(trifluoromethyl)benzene 1H-pyrazole-5-carboxylic acid

[0879] In a 10 mL round-bottom flask equipped with a magnetic stir bar was placed a solution of 3-(2-(4-(3-fluorophenyl)-5-(methoxycarbonyl)-3-methyl-1H-pyrazol-1-yl)-4-(4-(trifluoromethyl)phenyl)thiazol-5-yl)propanoic acid (48 mg, 0.0899 mmol), HATU (51 mg, 0.134 mmol), MeNH2 (67 μL, 0.134 mmol) and Hunig's base (39 μL, 0.224 mmol) in DMF (0.9 mL, 0.1 M) at room temperature. The orange solution turned light yellow within 5 minutes. After 5 minutes, analysis of the reaction mixture by HPLC-MS indicated that the reaction was complete. The compound was evaporated to dryness. The light yellow residue was transferred to a microwave vial, to which was added LiOH (21 mg, 0.899 mmol) and THF:water (4:1, 2 mL, 0.04 M). The microwave vial was capped and heated under microwave irradiation at 110° C. for 15 minutes. The reaction was filtered and the crude product was purified using semi-preparative HPLC-MC (X-Bridge 30×50, eluting with 40-60% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 mL / min / 11 minutes) to give the title compound (8 mg, 0.015 mmol, 17%) as a white solid after lyophilization.

[0880] 1H NMR(500MHz,DMSO)δ7.93-7.87(m,3H),7.83-7.81(m,2H),7.46-7.39(m,2H),7.36-7.34(m,1H),7.13-7.10 (m,1H),3.19(t,J=7.2Hz,2H),2.58(d,J=4.6Hz,3H),2.53-2.51(m,2H),2.28(s,3H);MS(m / z):533.0[M+1] + .

[0881] Compound 48: 4-(3-Fluorophenyl)-1-(5-(isopropylthio)-4-(4-(2-methoxyethoxy)-4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0882] The title compound was prepared in an analogous manner to compound 11 as described above. 1 H NMR (500MHz, DMSO) δ14.16(s,1H),7.54–7.47(m,1H),7.28(d,J=7.7Hz,2H),7.24(t,J=8.1Hz,1H),4.22(d,J=13.2Hz,2H),3.72–3.67(m,2H) ,3.53–3.48(m,2H),3.28(s,3H),3.20–3.08(m,3H),2.29(s,3H),1.93 (d, J=12.8Hz, 2H), 1.77 (td, J=13.4, 4.4Hz, 2H), 1.24 (d, J=6.7Hz, 6H). MS(m / z):603.3[M+1] + .

[0883] Compound 49: 4-(3-Fluorophenyl)-1-(5-(4-((2-methoxyethyl)carbamoyl)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0884] The title compound was prepared in an analogous manner to compound 36 as described above. 1HNMR(500MHz,DMSO)δ8.56(t,J=5.3Hz,1H),7.87–7.81(m,2H),7.65(d,J=8.3Hz,2H),7.58(d,J=8.3Hz,2 H),7.49-7.40(m,3H),7.33-7.25(m,2H),7.19-7.10(m,1H),3.42–3.34(m,4H),3.21(s,3H),2.26(s,3H). MS(m / z):625.2[M+1] + .

[0885] Compound 50: 4-(3-Fluorophenyl)-1-(5-(4-((2-methoxyethyl)(methyl)carbamoyl)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0886] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR(500MHz,DMSO)δ7.75–7.62(m,4H),7.54-7.42(m,5H),7.41-7.32(m,2H), 7.26-7.16(m,1H),3.69-3.35(m,4H),3.17(s,3H),2.98(s,3H),2.32(s,3H). MS(m / z):639.2[M+1] + .

[0887] Compound 51: 4-(3-Fluorophenyl)-1-(5-(4-(2-methoxyacetamido)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0888] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR(500MHz,DMSO)δ9.92(s,1H),7.72–7.66(m,2H),7.66-7.57(m,4H),7.44–7.36( m,1H),7.36–7.27(m,4H),7.13-7.05(m,1H),3.96(s,2H),3.32(s,3H),2.24(s,3H). MS(m / z):611.2[M+1]

[0889] Compound 52: 4-(3-Fluorophenyl)-1-(5-(4-(2-(2-methoxyethoxy)acetamido)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0890] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR(500MHz,DMSO)δ9.87(s,1H),7.77–7.65(m,6H),7.49–7.36(m,5H),7.17-7.07( m,1H),4.11(s,2H),3.72–3.65(m,2H),3.57–3.51(m,2H),3.31(s,3H),2.31(s,3H). MS(m / z):655.1[M+1] +

[0891] Compound 53: 4-(3-Fluorophenyl)-1-(5-(3-((2-methoxyethyl)amino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0892] The title compound was prepared in an analogous manner to compound 47 as described above. 1 H NMR(500MHz,DMSO)δ8.49(bs,1H),7.97-7.95(m,2H),7.73-7.71(m,2H),7.42-7.30(m,3H),7.04-7 .00(m,1H),3.44-3.42(m,2H),3.38-3.32(m,4H),3.32(s,3H),2.64(t,J=7.4Hz,2H),2.33(s,3H). MS(m / z):577.1[M+1] + .

[0893] Compound 54: 4-(3-Fluorophenyl)-1-(5-(3-((2-methoxyethyl)(methyl)amino)-3-oxopropyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0894] The title compound was prepared in an analogous manner to compound 47 as described above. 1H NMR(500MHz,MeOD)δ7.91-7.90(m,2H),7.75-7.74(m,2H),7.47-7.42(m,1H),7.29-7.27(m,1H),7.24-7.22(m,1H),7.12-7.08(m,1H),3.58 -3.49(m,4H),3.35-3.32(m,2H),3.33-3.29(m,3H),3.07-2.96(m,3H),2.91(t,J=7.1Hz,1H),2.85(t,J=7.0Hz,1H),2.32(d,J=1.3Hz,3H). MS(m / z):591.1[M+1] + .

[0895] Compound 55: 4-(3-Fluorophenyl)-1-(5-(4-(2-methoxy-N-methylacetamido)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0896] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR (500MHz, DMSO) δ7.73-7.64(m,4H),7.52-7.32(m,7H),7.22-7.15(m,1H),4.02-3.86(m,2H),3.23(s,3H),3.22(s,3H),2.33(s,3H). MS(m / z):625.2[M+1] +

[0897] Compound 56: 4-(3-Fluorophenyl)-1-(5-(4-(2-(2-methoxyethoxy)-N-methylacetamido)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0898] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR(500MHz,DMSO)δ7.72-7.63(m,4H),7.51–7.33(m,7H),7.21-7.13(m,1H),4.08-3.9 1(m,2H),3.55-3.44(m,2H),3.42-3.35(m,2H),3.22(s,3H),3.20(s,3H),2.31(s,3H). MS(m / z):669.4[M+1] +

[0899] Compound 57: 4-(3-Fluorophenyl)-1-(5-(methoxymethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0900] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR (500MHz, DMSO) δ7.90–7.81(m,4H),7.56–7.46(m,1H),7.36–7.28(m,2H),7.25–7.18(m,1H),4.77(s,2H),3.42(s,3H),2.31(s,3H). MS(m / z):492.0[M+1] +

[0901] Compound 58: 1-(5-(4-(2-(2-ethoxyethoxy)ethoxy)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-4-(3-fluorophenyl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0902] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR (500MHz, DMSO) δ7.66-7.56(m,4H),7.48-7.41(m,1H),7.32-7.24(m,4H),7.20-7.11(m,1H),7.00–6.94(m,2H),4.08(dd,J=5.4,3.8Hz,2H), 3.69(dd,J=5.4,3.8Hz,2H), 3.52(dd,J=5.8,3.8Hz,2H), 3.43(dd,J=5.8,3.9Hz,2H), 3.37(q,J=7.0Hz,2H), 2.25(s,3H), 1.03(t,J=7.0Hz,3H). MS(m / z):656.3[M+1] +

[0903] Compound 59: 4-(3-fluorophenyl)-1-(5-(3-fluorophenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0904] The title compound was prepared in an analogous manner to compound 36 as described above. 1H NMR (500MHz, DMSO) δ7.70(d,J=8.4Hz,2H),7.65(d,J=8.4Hz,2H),7.54-7.45(m,2H),7. 41-7.34(m,2H),7.33-7.28(m,2H),7.27-7.24(m,1H),7.23-7.17(m,1H),2.32(s,3H). MS(m / z):542.0[M+1] +

[0905] Compound 60: 4-(3-Fluorophenyl)-1-(5-(hydroxymethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0906] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR (500MHz, DMSO) δ7.91–7.80(m,4H),7.57–7.45(m,1H),7.36–7.27(m,2H),7.26–7.16(m,1H),6.13(s,1H),4.85(d,J=4.0Hz,2H),2.31(s,3H). MS(m / z):478.1[M+1] +

[0907] Compound 61: 4-(3-Fluorophenyl)-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0908] 4-Bromo-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazole-2- 1H-pyrazole-5-carboxylic acid methyl ester

[0909] At room temperature, a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow was placed methyl 4-bromo-1-(4-bromo-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylate (131 mg, 0.249 mmol), 4-(trifluoromethyl)piperidine (47.3 mg, 0.249 mmol), CsCO (406 mg, 1.25 mmol), XantPhos (14 mg, 0.025 mmol), and dioxane (2.5 mL). Nitrogen was bubbled through the solvent for 10 minutes, followed by the addition of the catalyst, RuPhos Pd G1 (20 mg, 0.025 mmol). The vial was capped and placed in an oil bath at 105° C. for 16 hours. The crude product was purified by flash chromatography on silica gel using ethyl acetate in hexanes (0 to 10% gradient) to give the title compound (74 mg, 0.12 mmol, 50%) as a yellow oil.

[0910] 4-(3-Fluorophenyl)-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-4-(4-(trifluoromethyl)piperidin-1-yl) Thiazol-2-yl)-1H-pyrazole-5-carboxylic acid

[0911] At room temperature, methyl 4-bromo-3-methyl-1-(5-(4-(trifluoromethyl)phenyl)-4-(4-(trifluoromethyl)piperidin-1-yl)thiazol-2-yl)-1H-pyrazole-5-carboxylate (74 mg, 0.12 mmol), (3-fluorophenyl)boronic acid (21 mg, 0.15 mmol) and NaCO (66 mg, 0.62 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar and nitrogen flow. Nitrogen was bubbled through a solution of dioxane / water (2 mL, 4:1) and then added to the microwave vial, followed by the addition of catalyst Pd(PPh) (14 mg, 0.012 mmol). The vial was capped and placed in an oil bath at 85° C. for 16 hours. LiOH (15 mg, 0.62 mmol) was added to the reaction mixture and stirred at 115° C. for 15 minutes under microwave irradiation. The product was purified using semi-preparative HPLC-MS (column X-Bridge 30×50, eluted with 60-80% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 ml / min / 10 minutes) to give the title compound (4.2 mg, 0.0070 mmol, 6%) as a light yellow solid after lyophilization.

[0912] 1H NMR(500MHz,MeOD)δ7.91(d,J=8.2Hz,2H),7.74(d,J=8.2Hz,2H),7.50–7.43(m,1H),7.38–7.32(m,1H),7.32–7.27(m, 1H),7.15-7.08(m,1H),3.59-3.50(m,2H),3.00-2.91(m,2H),2.36(s,3H),2.39-2.25(m,1H),1.95-1.88(m,2H),1.81 -1.68(m,2H);MS(m / z):599.1[M+1] +

[0913] Compound 62: 4-(3-fluorophenyl)-1-(4-(3-fluorophenyl)-5-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0914] The title compound was prepared in an analogous manner to compound 36 as described above. 1 H NMR(500MHz,MeOD)δ7.76(d,J=8.2Hz,2H),7.66(d,J=8.2Hz,2H),7.51–7.45( m,1H),7.38–7.28(m,5H),7.15-7.10(m,1H),7.09-7.04(m,1H),2.38(s,3H). MS(m / z):542.1[M+1] +

[0915] Compound 63: 4-(3-Fluorophenyl)-1-(5-(1-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0916] The title compound was prepared in an analogous manner to compound 64 as described below. 1 H NMR(500MHz,MeOD)δ8.52(bs,1H),7.96(d,J=8.1Hz,2H),7.72(d,J=8.0Hz,2H),7.43-7. 31(m,3H),7.05-7.01(m,1H),5.30(q,J=6.2Hz,1H),2.34(s,3H),1.61(d,J=6.3Hz,3H). MS(m / z):492.1[M+1] + .

[0917] Compound 64: 4-(3-Fluorophenyl)-1-(5-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0918] 4-Bromo-3-methyl-1-(4-(4-(trifluoromethyl)phenyl)-5-vinylthiazol-2-yl)-1H-pyrazole-5-carboxylic acid Methyl ester

[0919] At room temperature, 4-bromo-1-(5-bromo-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-formic acid methyl ester (200 mg, 0.380 mmol), potassium vinyl trifluoroborate (51 mg, 0.380 mmol), K CO (158 mg, 1.14 mmol) and catalyst Pd (dtbpf) Cl (25 mg, 0.0380 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stirring bar. THF (1.9 mL, 0.2 M) was added to the microwave tube and a stream of nitrogen was bubbled through the brown mixture for 5 minutes. The vial was capped and stirred in an oil bath at 90° C. for 16 hours. After 16 hours, the reactant was purified using mobile phase 0-5% EtOAc / hexane on a silica gel column. The product-containing fractions were evaporated under reduced pressure to give the title compound (104 mg, 0.220 mmol, 58%) as an off-white solid.

[0920] 4-(3-Fluorophenyl)-3-methyl-1-(4-(4-(trifluoromethyl)phenyl)-5-vinylthiazol-2-yl)-1H-pyrrolidone Methyl oxadiazole-5-carboxylate

[0921] At room temperature, 4-bromo-3-methyl-1-(4-(4-(trifluoromethyl)phenyl)-5-vinylthiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (101 mg, 0.213 mmol), (3-fluorophenyl)boronic acid (30 mg, 0.213 mmol), Na2CO3 (68 mg, 0.639 mmol) and catalyst Pd(PPh3)4 (25 mg, 0.0213 mmol) were placed in a 5 mL glass microwave vial equipped with a magnetic stir bar. THF:water (2.1 mL, 4:1, 0.1 M) deoxygenated with a nitrogen stream for 5 minutes was added to the microwave tube. The vial was capped and stirred in an oil bath at 90°C for 16 hours. After 16 hours, the reactants were purified on a silica gel column using a mobile phase of 0-5% EtOAc / hexane. The product-containing fractions were evaporated under reduced pressure to give the title compound (77 mg, 0.159 mmol, 75%) as a white solid.

[0922] 4-(3-Fluorophenyl)-1-(5-(2-hydroxyethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl- 1H-Pyrazole-5-carboxylic acid

[0923] At room temperature, 4-(3-fluorophenyl)-3-methyl-1-(4-(4-(trifluoromethyl)phenyl)-5-vinylthiazol-2-yl)-1H-pyrazole-5-carboxylic acid methyl ester (22 mg, 0.0451 mmol) dissolved in anhydrous THF (0.5 mL, 0.1 M) was placed in a 10 mL round-bottom flask equipped with a magnetic stirring bar. The solution was cooled to 0 ° C and borane DMS (225 μ L, 0.451 mmol) was added dropwise. The reactants were allowed to warm to room temperature and stirred under a nitrogen atmosphere for 16 hours. After 16 hours, 30% aqueous solution of hydrogen peroxide (250 μ L) and NaOH (18 mg, 0.451 mmol) dissolved in water (250 μ L) at 0 ° C were added. The reaction was stirred at room temperature for 16 hours. The reactants were extracted three times with EtOAc. The combined organic layers were dehydrated through Na SO , filtered and evaporated. The white solid was transferred to a microwave vial to which LiOH (11 mg, 0.451 mmol) and THF:water (1.5 mL; 4:1, 0.03 M) were added. The microwave vial was capped and heated at 110 ° C for 15 minutes under microwave irradiation. The reaction was filtered and the crude product was purified using semi-preparative HPLC-MC (X-Bridge 30×50, eluted with 40-60% MeCN / NH 4 CO 2 H 10 mM, pH 3.8 / flow rate 45 mL / min / 11 minutes) to give the title compound (1 mg, 0.002 mmol, 5%) as a white solid after lyophilization.

[0924] 1 H NMR(500MHz,MeOD)δ7.96(d,J=8.1Hz,2H),7.71(d,J=7.7Hz,2H),7.42-7.30(m,3H),7.05-7 .01(m,1H),3.86(t,J=6.2Hz,2H),3.20(t,J=6.2Hz,2H),2.33(s,3H); MS(m / z):492.1[M+1] + .

[0925] Compound 65: 4-(3-Fluorophenyl)-1-(5-(4-(2-methoxyethoxy)phenyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0926] The title compound was prepared in an analogous manner to compound 36 as described above. 1H NMR(500MHz,DMSO)δ7.71-7.63(m,4H),7.53–7.46(m,1H),7.39-7.32(m,4H),7.24-7.16( m,1H),7.06–7.00(m,2H),4.16–4.12(m,2H),3.70–3.66(m,2H),3.32(s,3H),2.31(s,3H). MS(m / z):598.2[M+1] + .

[0927] Compound 66: 4-(3-Fluorophenyl)-1-(5-(1-methoxyethyl)-4-(4-(trifluoromethyl)phenyl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0928] The title compound was prepared in an analogous manner to compound 64 as described above. 1 H NMR(500MHz,MeOD)δ7.88(d,J=7.9Hz,2H),7.74(d,J=8.1Hz,2H),7.44-7.39(m,1H),7.36-7.34(m,1H),7 .31-7.29(m,1H),7.07-7.03(m,1H),4.89-4.87(m,1H),3.26(s,3H),2.34(s,3H),1.63(d,J=6.3Hz,3H). MS(m / z):506.1[M+1] + .

[0929] Compound 67: 4-(3-Fluorophenyl)-1-(4-(4-isopropylpiperidin-1-yl)-5-(isopropylthio)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0930] The title compound was prepared in an analogous manner to compound 12 as described above. 1 H NMR(500MHz,MeOD)δ7.44-7.40(m,1H),7.29(d,J=7.6Hz,1H),7.24(d,J=9.7H z,1H),7.08-7.05(m,1H),4.41(d,J=12.8Hz,2H),3.17-3.12(m,1H),2.82(t, J=12.3Hz,2H),2.30(s,3H),1.71(d,J=12.2Hz,2H),1.48-1.40(m,1H),1.37- 1.31(m,2H),1.28(d,J=6.7Hz,6H),1.23–1.18(m,1H),0.91(d,J=6.7Hz,6H). MS (m / z): 503.3 [M+1]+ .

[0931] Compound 68: 4-(3-fluorophenyl)-1-(5-(isopropylthio)-4-(3-methoxy-3-(trifluoromethyl)-8-azabicyclo[3.2.1]octan-8-yl)thiazol-2-yl)-3-methyl-1H-pyrazole-5-carboxylic acid

[0932] The title compound was prepared in an analogous manner to compound 47 as described above. 1 H NMR(500MHz,DMSO)δ7.50–7.41(m,1H),7.38–7.27(m,2H),7.24–7.08(m,1H),4.77(s,2H ), 3.37 (s, 3H), 3.16–3.07 (m, 1H), 2.28 (s, 3H), 2.09–1.82 (m, 8H), 1.23 (d, J = 6.7Hz, 6H). MS(m / z):585.1[M+1] + .

[0933] BJAB data

[0934] BJAB cells (DSMZ) were maintained in RPMI 1640 growth medium + 10% FBS at 37°C / 5% CO2 and used before passage 34. Cells were seeded at 2500 cells / well in 50 μL of culture medium in a white Corning Costar 96-well assay plate. Serial dilutions of the test compounds were prepared in cell culture medium / FBS + 0.2% DMSO and transferred to the assay plate in a volume of 50 μL (final DMSO concentration was 0.1%). The plates were maintained at 37°C for approximately 72 hours. The effects of the compounds on cell proliferation were evaluated using Cell Titer Glo reagent (Promega) according to the manufacturer's instructions. Briefly, 100 μL of reagent was added to each well, and after a 10-minute incubation, luminescence values ​​were measured on a plate reader (Tecan F200PRO). The percentage of luminescence signal relative to the untreated control was calculated at each compound concentration, and the EC values ​​were determined from the dose-response data using Prism (GraphPad) by nonlinear regression analysis. 50 Values. The data are shown in the compound table above. The mTor inhibitor Torin1 (Liu et al. (2010) Journal of Medicinal Chemistry (J. Med. Chem.) 53, 7146.) was used as a control. The data are summarized in the compound table provided above.

[0935] Further studies with various test compounds indicated that cell viability was reduced in a dose-dependent manner and that the test compounds induced cell death in a dose-dependent manner 48 hours after treatment.

[0936] Biological Examples

[0937] The present inventors have determined that, although initial data suggest that they inhibit translation initiation of RNA, as described by the data provided herein, an important biological effect caused by the compounds as described herein is the inhibition of cell cycle progression. While not intending to be bound by theory, the present inventors speculate that the compounds disclosed herein disrupt the G0 / G1 phase of the cell cycle, thereby preventing further proliferation of cancer cells.

[0938] The following examples provide insights into the compounds of the present disclosure, particularly those within the broad scope of the compounds described herein and IC 50 Four measurements of activity were made for test compounds with values ​​in the "A" range. Test compounds were considered representative of active compounds as described herein. The first measurement was the overall sensitivity of the tumor cell line to the test compound. The second was the role of KRAS genotype in the sensitivity of the cells to the test compound. The third was the effect of the test compound on the key cellular metabolite glutathione. And the fourth was the effect of the test compound on the cell cycle.

[0939] Example 1: Anticancer Activity

[0940] A panel of 96 tumor and 3 normal cell lines were tested for sensitivity to the test compounds. These cell lines were cultured in standard culture medium and pipetted into 96-well plates at the desired plating density. Prior to compound testing, the cells were allowed to acclimate for 24 hours. 20 mM stock solutions of the compounds in DMSO were prepared. To prepare a dose-response curve, the compounds were serially diluted in DMSO and dispensed into each well of the plate using a Tecan D300e digital dispenser. The final DMSO concentration was 0.15%. After 72 hours of incubation, the cells were diluted using the CellTiter- Cell number was determined using the ELISA (Promega) protocol. In this assay, ATP was measured as a surrogate for cell number. Compound activity was determined by comparing untreated cells with treated cells and calculating the percentage of signal retained. Compound activity was expressed as the EC at the maximal efficacy level. 50 These two values ​​are measured and used to calculate the activity area curve.

[0941] Of the 96 tumor cell lines, 39 tumors (40%) showed significant responses to the test compound (as estimated by IC 50The ability of the compound to inhibit the tumour response was determined by the ability of the compound to inhibit the tumour response (Table 1). Hematopoietic tumours showed a significant enrichment of responses. More than 89% of all hematopoietic tumours responded to the compound, while 28.5% of solid tumours showed a substantial response.

[0942] Table 1. Overview of tumor reactivity

[0943]

[0944] Data for various cell lines are provided in Table 2 below:

[0945] Table 2. Specific tumor responses

[0946]

[0947]

[0948]

[0949] Example 2: Effect of KRAS on activity

[0950] Next, the KRAS alleles in the solid tumor lines were genotyped. Using the COSMIC database, the KRAS genotype and zygosity (homozygous or heterozygous) of 74 of the 77 solid tumor cell lines could be determined (Table 3).

[0951] Table 3. Tumor responsiveness according to KRAS genotype

[0952]

[0953] Only 20% of the cell types with wild-type KRAS alleles responded to the test compounds. In contrast, 65% of the cell types with mutations in the KRAS alleles responded to the test compounds. When the analysis was extended to whether the KRAS allele was homozygous or heterozygous, the results were significantly different (Table 4). KRAS Cell lines carrying heterozygous mutations in one allele showed the greatest responsiveness.

[0954] Table 4. Tumor Reactivity with Respect to KRAS Zygosity

[0955]

[0956]

[0957] The final analysis of the role of KRAS in the response to the test compounds used was pooled based on the area of ​​compound activity. The responses of all cell lines were included in the analysis using Tukey's All Pairs HSD test. Data are in Figure 1 The activity area is plotted as a function of KRAS genotype and KRAS zygosity. The average reactivity of the test compound in cell lines containing heterozygous KRAS mutant genotypes is significantly higher than that in the corresponding wild-type cell lines.

[0958] Example 3: Cellular metabolism and activity

[0959] Measurement of glutathione levels after treatment with three cell lines: BJAB, HCT116, and normal human lung fibroblasts (NHLF) were maintained in RPMI medium (Wisent), McCoy medium (Wisent), or FGM-2 medium (Lonza), respectively. To measure total glutathione, 5,000 cells / well (BJAB or HCT116) or 10,000 cells / well (NHLF) were transferred to a clear-bottom 96-well assay plate (Thermo Fisher) in a volume of 50 μL. The plates were incubated overnight at 37°C in 5% CO2 in an unsealed plastic bag containing moistened paper. Test compounds were serially diluted in culture medium plus 0.4% DMSO, and 50 μL of each dilution was transferred to the assay plate per well. The assay plates were incubated at 37°C in 5% CO2 in an unsealed plastic bag containing moistened paper for the indicated times. To measure total glutathione, fluorescein-NT (1:100), glutathione S-transferase (1:100), and DTT (1 mM final concentration) were diluted to GSH-Glo TM GSH-Glo was prepared in reaction buffer TM Reagent (Promega) was added to the assay plate at 100 μL, followed by incubation at room temperature for 30 minutes, and then 100 μL of luciferin detection reagent was added. The plate was kept in the dark at room temperature for 10 minutes. Luminescence was measured using a Tecan Infinite 200 Pro.

[0960] Figure 2 Figure 5 shows data from a typical experiment showing that the test compounds reduce cellular glutathione levels in a dose-dependent manner. Cell lines sensitive to the test compounds (BJAB and HCT116) showed a dose-dependent decrease in cellular glutathione levels, while the insensitive cell line (NHLF) showed no change.

[0961] To evaluate proliferation (in parallel with glutathione level measurement), 50 μL of cells per well in the culture medium described above were added to a transparent 96-well plate (TPP). At the specified time, the cells were fixed by adding 50 μL of cold 50% trichloroacetic acid (TCASigma) and incubated at 4°C for at least 45 minutes, followed by rinsing with distilled water. 1% acetic acid containing 0.4% (w / v) sulforhodamine B (Sulforhodamine B, SRB; Sigma) per well was added to each well to determine total protein content. The plate was rinsed several times in a large amount of 1% acetic acid to remove excess dye, and then the total protein was dissolved in 200 μL of 10 mM unbuffered Tris base and stirred for 30 minutes. On a Tecan Infinite 200Pro, absorbance was measured at 560 nm.

[0962] Effect on glutathione levels: BJAB and HCT116 cells were maintained in RPMI medium (Wisent) or McCoy medium (Wisent), respectively. 5000 cells / well were transferred to a clear-bottom 96-well assay plate (Thermo Fisher) in a 50 μL volume. The plates were incubated overnight at 37°C in 5% CO2 in an unsealed plastic bag containing moistened paper. Menadione (Sigma) was dissolved in DMSO and diluted to 20 μM and 5 μM (each at 0.2% DMSO) in 10% heat-inactivated FBS plus culture medium. The culture medium was gently aspirated from the cells and replaced with 50 μL of diluted menadione or 0.2% DMSO as a control. The test compound was diluted to 80 μM (0.2% DMSO) in 10% heat-inactivated FBS plus culture medium, followed by further dilutions to 5 μM, 1 μM, 0.5 μM, and 0.05 μM (in 0.2% DMSO). 50 μL of the test compound solution was added to each well with or without menadione. Where indicated, 1 μL of a 100 mM solution of N-acetylcysteine ​​(Sigma) in water was added. The assay plates were incubated at 37°C and 5% CO2 in an open plastic bag containing moistened paper for the indicated times. Total glutathione levels were determined according to the procedure described above.

[0963] Inclusion of N-acetylcysteine ​​in the culture medium prevents the reduction of glutathione caused by menadione. Figure 3 The upper graph shows the test compound-mediated reduction of glutathione levels in HCT116 cells. There was no difference in glutathione levels in the presence or absence of N-acetylcysteine. Figure 3The figure below demonstrates menadione-mediated reduction of glutathione levels in HCT116 cells. This data suggests that the test compound reduces cellular glutathione in a manner distinct from agents that affect mitochondrial function and induce cellular ROS. Without being bound by a particular theory, since N-acetylcysteine ​​is unable to restore glutathione levels, it is believed that the lack of glutathione levels in treated cells is caused by an inability to synthesize glutathione following treatment with the test compound.

[0964] Example 3: Cell cycle analysis of compound-treated cells

[0965] HCT116 cells (3 × 10 5 Cells were plated in 6-well plates and allowed to adhere overnight. Duplicate samples were prepared by treating cells with serum starvation (0% FBS), 5 μM test compound, or DMSO vehicle control for 24 hours. Two hours before collection, replicated DNA was labeled with 10 μM 5-ethynyl-2'-deoxyuridine (EdU, Thermo Fisher). Adherent and floating cells were collected and fixed in a solution of 4% paraformaldehyde in PBS and kept at room temperature for 15 minutes. Next, cells were permeabilized in a 0.25% v / v triton X-100 / 0.5% BSA / PBS solution at room temperature for 20 minutes. A click reaction with OG488-azide was then performed to detect EdU incorporation as follows: cells were incubated for 30 minutes in a reaction mixture containing 100 mM Tris-HCl pH 7.6, 4 mM CuSO4, 10 μM OG488-azide, and 100 mM ascorbic acid. Excess reagents were removed by repeated washing in 0.5% BSA / PBS wash buffer. Cells were resuspended in 500 μL DAPI staining solution (PBS containing 1 μg / mL DAPI and 50 μg / mL RNase A).

[0966] Flow cytometric analysis was performed in an LSRII flow cytometer (BD Biosciences) equipped with blue (488 nm), red (633 nm), and violet (405 nm) lasers. OG488 analysis was performed using 488 nm excitation and detection with a 505LP mirror and a 530 / 30BP filter. DAPI analysis was performed using 405 nm excitation and detection with a 442 / 16BP filter. Voltage settings were: FSC = 324, SSC = 276, OG488 = 215, DAPI = 351. Cell cycle analysis was performed using a linear axis scale and DAPI. A logarithmic scale was used for EdU. Data analysis was performed using FCS Express version 6 software (DeNovo Software).

[0967] Figure 4A Presents flow cytometry data collected from a representative cell cycle experiment performed in HCT116 cells after treatment with test compounds. Data are presented as dot plots of cell marker data, with each channel gated for detection and quantification. Figure 4B It is expressed as the percentage of cells in each phase of the cell cycle Figure 4A The data clearly show that serum starvation affects cells by arresting them in the G0 / G1 phase. The test compound showed a similar distribution of cells in G1, S, and G2 / M, indicating that the test compound arrested cells in the G0 / G1 phase.

[0968] This application specifically relates to the following implementation plans:

[0969] 1. A compound having any one of structural formulas (Ia) to (Ie),

[0970]

[0971]

[0972] The compound is optionally in the form of a pharmaceutically acceptable salt or N-oxide, and / or solvate or hydrate, wherein

[0973] L 1 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6 -and-NR 6 S(O) 1-2 -;

[0974] R 1 Selected from the group consisting of:

[0975] hydrogen,

[0976] C1-C8 alkyl, C1-C8 alkenyl and C1-C8 alkynyl, each of which is unsubstituted or fluorinated,

[0977] Cycloalkyl and heterocycloalkyl, each of which is optionally substituted by 1-2 R 1E Replace, and

[0978] Phenyl and monocyclic heteroaryl, each of which is optionally substituted by 1-5 R 1E replace,

[0979] in

[0980] Each R 1E Independently selected from oxo; optionally substituted C1-C4 alkyl; C1-C4 fluoroalkyl; halogen; -CN; SF5; -N3; ​​-C(O)R 1F ;-SR 1F ;-S(O) 1-2 R 1F ;-OR 1F ;-(OCH2CH2O) n -R 1G , wherein n is 1-4; -N(R 1G )C(O)CH2-O-(CH2CH2O) n R 1G , wherein n is 0-3; -C(O)NR 1G (CH2CH2O) n R 1G ;-NR 1G R 1F ; and -C(O)R 1F ;

[0981] Each R 1F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[0982] Each R 1G Independently selected from H and C1-C3 alkyl;

[0983] L 2 selected from the group consisting of: a chemical bond, -CH2-, -CH(CH3)-, or -CH2CH2-;

[0984] Q is selected from the group consisting of: H, -CH2OH, -C(O)OH, -C(O)OR 2A 、-C(O)NR 2B R 2A 、-C(O)NR 2B S(O)2R 2A 、-C(O)NR 2B S(O)2NR 2B R 2A 、-C(O)R 2A, -S(O)2OH, -P(O)(OH)2, -C(OH)(CF3)2, S(O)2R 2A 、-N(R 2B )S(O)2R 2A 、-S(O)2NR 2B R 2A , -C(O)NHOH, -C(O)NH-O(C1-C3 alkyl) and -CO(NH)CN, wherein

[0985] Each R 2A are independently selected from H and C1-C3 alkyl, and

[0986] Each R 2B Independently selected from H and C1-C3 alkyl;

[0987] L 3 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2-, -CH(CH3)(OH)- or -CH(OH)-;

[0988] R 3 is aryl or heteroaryl, each of which (i) is optionally substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1-5 R 3E replace,

[0989] in

[0990] Each L 3C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O-, or -NR 3G -;

[0991] Each R 3D independently selected from oxo optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and -NR 3G S(O) 1-2 R 3F ;

[0992] Each R 3E independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F 、-NR 3G S(O) 1-2 R 3F ;

[0993] Each R 3F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[0994] Each R 3G Independently selected from H and C1-C3 alkyl, C1-C3 fluoroalkyl;

[0995] L 4 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6 -and-NR 6 S(O) 1-2 -;

[0996] R 4 selected from the group consisting of hydrogen, optionally substituted C1-C8 alkyl, optionally substituted C1-C8 alkenyl, and optionally substituted C1-C8 alkynyl;

[0997] L 5 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -, -CH2CH2-, -CH=CH-, -C≡C-, -CH2-, -CH(CH3)(OH)-, or -CH(OH)-; and

[0998] R 5 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each of which (i) is optionally substituted with a single substituent selected from: -L 5C -(optionally replaced by 1-5 R 5D substituted phenyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heteroaryl) and -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic cycloalkyl), -L 5C -(optionally replaced by 1-5 R 5D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1-5 R 5E replace,

[0999] in

[1000] Each L 5C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O-, or -NR 3G -;

[1001] Each R 5D independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, SF5, -N3, -C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O)1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and -NR 3G S(O) 1-2 R 3F ;

[1002] Each R 5E independently selected from oxo, optionally substituted C1-C4 alkyl, C1-C4 fluoroalkyl, halogen, -CN, -SF5, -N3, -C(O)R 5F 、-SR 5F 、-S(O) 1-2 R 5F 、-OR 5F 、-NR 5G R 5F 、-C(O)R 5F 、-C(O)NR 5G R 5F 、-NR 5G C(O)R 5F 、-C(S)NR 5G R 5F 、-NR 1G C(S)R 5F 、-C(O)OR 5F 、-OC(O)R 5F 、-C(O)SR 5F 、-SC(O)R 5F 、-C(S)OR 5F 、-OC(S)R 5F 、-C(S)SR 5F 、-SC(S)R 5F 、-S(O) 1-2 OR 5F 、-OS(O) 1-2 R 5F 、-S(O) 1-2 NR 5G R 5F and -NR 5G S(O) 1-2 R 5F ; Each R 5F are independently selected from H, C1-C3 alkyl and C1-C3 fluoroalkyl, and

[1003] Each R 5G Independently selected from H and C1-C3 alkyl;

[1004] in

[1005] Each R 6Selected from the group consisting of: hydrogen, C1-C3 alkyl and -C(O)(C1-C3 alkyl);

[1006] Each optionally substituted alkyl, alkenyl, and alkynyl group is unsubstituted, fluorinated, or substituted with one or two hydroxy groups;

[1007] each cycloalkyl group has 3-10 ring carbons and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each fused ring having 3-8 ring members;

[1008] each heterocycloalkyl group has 3-10 ring members and 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each having 3-8 ring members;

[1009] each aryl is phenyl or naphthyl, and optionally comprises one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members;

[1010] Each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, and optionally contains one or two fused...

Claims

1. A compound having any one of the structural formulas (Ia) to (Ie), The compound is optionally in the form of a pharmaceutically acceptable salt or N-oxide, and / or solvate or hydrate, wherein L 1 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6 -and-NR 6 S(O) 1-2 -; R 1 Selected from the group consisting of: hydrogen, C 1 -C 8 Alkyl, C 1 -C 8 Alkenyl and C 1 -C 8 Alkynyl, each of which is unsubstituted or fluorinated, cycloalkyl and heterocycloalkyl, each of which is optionally substituted with 1-2 R 1E Replace, and phenyl and monocyclic heteroaryl, each of which is optionally substituted by 1 to 5 R 1E replace, in Each R 1E independently selected from oxo; optionally substituted C 1 -C 4 Alkyl; C 1 -C 4 Fluoroalkyl; Halogen; -CN; SF 5 ;-N 3 ;-C(O)R 1F ;-SR 1F ; -S(O) 1-2 R 1F ;-OR 1F ;-(OCH 2 CH 2 O) n -R 1G , where n is 1-4; -N(R 1G )C(O)CH 2 -O-(CH 2 CH 2 O) n R 1G , wherein n is 0-3; -C(O)NR 1G (CH 2 CH 2 O) n R 1G ;-NR 1G R 1F ; and -C(O)R 1F ; Each R 1F Independently selected from H, C 1 -C 3 Alkyl and C 1 -C 3 fluoroalkyl, and Each R 1G Independently selected from H and C 1 -C 3 alkyl; L 2 Selected from the group consisting of: chemical bonds, -CH 2 -、-CH(CH 3 )-or-CH 2 CH 2 -; Q is selected from the group consisting of: H, -CH 2 OH, -C(O)OH, -C(O)OR 2A 、-C(O)NR 2B R 2A 、-C(O)NR 2B S(O) 2 R 2A 、-C(O)NR 2B S(O) 2 NR 2B R 2A 、-C(O)R 2A 、-S(O) 2 OH, -P(O)(OH) 2 、-C(OH)(CF 3 ) 2 、S(O) 2 R 2A 、-N(R 2B )S(O) 2 R 2A 、-S(O) 2 NR 2B R 2A 、-C(O)NHOH、-C(O)NH-O(C 1 -C 3 alkyl) and -CO(NH)CN, where Each R 2A Independently selected from H and C 1 -C 3 Alkyl, and Each R 2B Independently selected from H and C 1 -C 3 alkyl; L 3 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-CH 2 -、-CH(CH 3 )(OH)- or -CH(OH)-; R 3 is aryl or heteroaryl, each of which (i) is optionally substituted with a single substituent selected from: -L 3C -(optionally replaced by 1-5 R 3D substituted aryl), -L 3C -(optionally replaced by 1-5 R 3D substituted heteroaryl), -L 3C -(optionally replaced by 1-5 R 3D Substituted cycloalkyl), -L 3C -(optionally replaced by 1-5 R 3D substituted heterocycloalkyl) and (ii) optionally substituted by 1 to 5 R 3E replace, in Each L 3C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O- or -NR 3G -; Each R 3D independently selected from oxo optionally substituted C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, halogen, -CN, SF 5 、-N 3 、-C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and-NR 3G S(O) 1-2 R 3F ; Each R 3E are independently selected from oxo, optionally substituted C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, halogen, -CN, SF 5 、-N 3 、-C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F 、-NR 3G S(O) 1-2 R 3F ; Each R 3F Independently selected from H, C 1 -C 3 Alkyl and C 1 -C 3 fluoroalkyl, and Each R 3G Independently selected from H and C 1 -C 3 Alkyl, C 1 -C 3 Fluoroalkyl; L 4 Selected from the group consisting of: chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-C(O)NR 6 -、-NR 6 C(O)-、-C(S)NR 6 -、-NR 6 C(S)-, -C(O)O-, -OC(O)-, -C(O)S-, -SC(O)-, -C(S)O-, -OC(S)-, -C(S)S-, -SC(S)-, -S(O) 1-2 O-、-OS(O) 1-2 -、-S(O) 1-2 NR 6 -and-NR 6 S(O) 1-2 -; R 4 Selected from the group consisting of: hydrogen, optionally substituted C 1 -C 8 Alkyl, optionally substituted C 1 -C 8 Alkenyl and optionally substituted C 1 -C 8 Alkynyl; L 5 It is a chemical bond, -C(O)-, -S-, -S(O) 1-2 -、-O-、-NR 6 -、-CH 2 CH 2 -、-CH=CH-、-C≡C-、-CH 2 -、-CH(CH 3 )(OH)- or -CH(OH)-; and R 5 is aryl, heteroaryl, cycloalkyl or heterocycloalkyl, each of which (i) is optionally substituted with a single substituent selected from: -L 5C -(optionally 1-5 R 5D Substituted phenyl), -L 5C -(optionally 1-5 R 5D substituted monocyclic heteroaryl) and -L 5C -(optionally 1-5 R 5D substituted monocyclic cycloalkyl), -L 5C -(optionally 1-5 R 5D substituted monocyclic heterocycloalkyl) and (ii) optionally substituted by 1 to 5 R 5E replace, in Each L 5C It is a chemical bond, methylene, ethylene, -C(O)-, -S-, -S(O) 1-2 -, -O- or -NR 3G -; Each R 5D are independently selected from oxo, optionally substituted C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, halogen, -CN, SF 5 、-N 3 、-C(O)R 3F 、-SR 3F 、-S(O) 1-2 R 3F 、-OR 3F 、-NR 3G R 3F 、-C(O)R 3F 、-C(O)NR 3G R 3F 、-NR 3G C(O)R 3F 、-C(S)NR 3G R 3F 、-NR 3G C(S)R 3F 、-C(O)OR 3F 、-OC(O)R 3F 、-C(O)SR 3F 、-SC(O)R 3F 、-C(S)OR 3F 、-OC(S)R 3F 、-C(S)SR 3F 、-SC(S)R 3F 、-S(O) 1-2 OR 3F 、-OS(O) 1-2 R 3F 、-S(O) 1-2 NR 3G R 3F and-NR 3G S(O) 1-2 R 3F ; Each R 5E are independently selected from oxo, optionally substituted C 1 -C 4 Alkyl, C 1 -C 4 Fluoroalkyl, halogen, -CN, -SF 5 、-N 3 、-C(O)R 5F 、-SR 5F 、-S(O) 1-2 R 5F 、-OR 5F 、-NR 5G R 5F 、-C(O)R 5F 、-C(O)NR 5G R 5F 、-NR 5G C(O)R 5F 、-C(S)NR 5G R 5F 、-NR 1G C(S)R 5F 、-C(O)OR 5F 、-OC(O)R 5F 、-C(O)SR 5F 、-SC(O)R 5F 、-C(S)OR 5F 、-OC(S)R 5F 、-C(S)SR 5F 、-SC(S)R 5F 、-S(O) 1-2 OR 5F 、-OS(O) 1-2 R 5F 、-S(O) 1-2 NR 5G R 5F and-NR 5G S(O) 1-2 R 5F ; Each R 5F Independently selected from H, C 1 -C 3 Alkyl and C 1 -C 3 fluoroalkyl, and Each R 5G Independently selected from H and C 1 -C 3 alkyl; in Each R 6 Selected from the group consisting of: hydrogen, C 1 -C 3 Alkyl and -C(O)(C 1 -C 3 alkyl); Each optionally substituted alkyl, alkenyl, and alkynyl group is unsubstituted, fluorinated, or substituted with one or two hydroxy groups; Each cycloalkyl has 3-10 ring carbons and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each fused ring having 3-8 ring members; each heterocycloalkyl has 3-10 ring members and 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur and is unsaturated or partially unsaturated, and optionally contains one or two fused cycloalkyl rings, each having 3-8 ring members; each aryl is phenyl or naphthyl, and optionally comprises one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members; Each heteroaryl is a 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8-10 membered bicyclic heteroaryl having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, and optionally contains one or two fused cycloalkyl or heterocycloalkyl rings, each fused cycloalkyl or heterocycloalkyl ring having 4-8 ring members.

2. The compound according to claim 1, wherein the compound has structural formula (Ia).

3. The compound according to claim 1, wherein the compound has structural formula (Ib).

4. The compound according to claim 1, wherein the compound has structural formula (Ic).

5. The compound of claim 1, wherein the compound has structural formula (Id).

6. The compound according to claim 1, wherein the compound has structural formula (Ie).

7. A compound according to any one of claims 1 to 6, wherein R 1 Selected from the group consisting of: hydrogen, optionally substituted C 1 -C 8 Alkyl and cycloalkyl, which are optionally substituted by 1 to 5 R 1E replace.

8. A compound according to any one of claims 1 to 6, wherein R 1 It's hydrogen.

9. A compound according to any one of claims 1 to 6, wherein R 1 is an optionally substituted C 1 -C 8 alkyl.

10. A compound according to any one of claims 1 to 6, wherein R 1 is the unsubstituted C 1 -C 8 Alkyl or fluorinated C 1 -C 8 alkyl.